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Abstract  
 
Hypothesis and Aim:  
This thesis aims to assess current ultrasound tools and protocols for the diagnosis and 
management of ovarian tumours. I hypothesized that the IOTA (International Ovarian 
Tumour Analysis) tools would have less diagnostic accuracy when performed by a less 
experienced operator and that the IOTA LR models would therefore not be useful as a 
triage tool but that while the ‘simple rules’ (SR) model may be useful as a triage tool as 
it is most similar to pattern recognition. I also hypothesized that the SR modified 
protocol would offer fewer operations to women with benign disease as compared with 
Royal College of Obstetricians and Gynaecologists [RCOG] protocol using the risk of 
malignancy index [RMI]. 
 
Objectives: 
The aim of this thesis was to investigate and explore recently developed and currently 
utilised ultrasound based tools as methods of evaluation and means of determining the 
management of adnexal tumours.  
 
The novel approach was to investigate the use of these tools when performed by an 
average (level II) ultrasound operator as compared with the experts who developed 
them and to determine the management for asymptomatic postmenopausal women with 
incidentally detected adnexal tumours.  
 
Studies: Determining the accuracy of LR1/LR2 and ‘Simple Rules’ (SR) by an average 
operator compared with pattern recognition and evaluating the performance 
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of LR1/LR2 and SR using two reference standards, (histology and follow-up ultrasound 
scans) as a triage tool. Performing a meta-analysis of the SR model. Comparing the 
performance of two management protocols (Royal College of Obstetricians and 
Gynaecologists [RCOG] using the risk of malignancy index [RMI] and an SR-based 
protocol) for the likely intervention rates in asymptomatic postmenopausal women, and 
conducting a randomised controlled trial to compare the performance of those two 
management protocols (the RMI/RCOG guidance and the SR-based protocol) for the 
actual intervention rates in asymptomatic postmenopausal women. 
 
Findings: 
LR2 (average operator) had a similar sensitivity but the specificity was significantly 
lower, LR1/LR2 showed higher sensitivities and significantly lower specificities 
compared to the experts and pattern recognition and LR1/LR2 can be used as a triage 
tool once you accept the greater false positive rate. SR (average operator) showed 
similar sensitivity but a poorer specificity. When indeterminate tumours were assumed 
to be malignant there was a significantly increased sensitivity, decreased specificity and 
decreased diagnostic accuracy versus when pattern recognition was used, the sensitivity 
and diagnostic accuracy were maintained with increased specificity. SR performed well 
for the diagnosis of malignancy (meta-analysis) and SR works well as a triage tool, 
With the RMI/RCOG protocol, the likely intervention rate was 6 x more compared with 
SR and the RMI/RCOG protocol offered women surgery 9 x more often than SR and 
the actual surgical rate was 2.6 x more than SR (RCT). 
 
Conclusions:  
The IOTA LR1/LR2 models performed fairly well when used pre-operatively or as a 
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triage test by a less experienced operator. Comparatively, the SR model worked very 
well when the rules were applicable but this leaves the problem of deciding what to do 
with the 25% of women for whose ovarian tumours, the rules are not applicable. This 
thesis confirmed that the SRMP protocol had fewer indeterminately defined tumours 
and therefore offered surgery to fewer women with benign tumours when compared 
with the RCOG/RMI protocol. 
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Part I – Introduction 
 
Adnexal tumours can arise from the ovary, fallopian tube or para-ovarian / para-tubal 
structures. There are many tools used to assess these adnexal tumours.  
 
Pavlik et al found the prevalence of ovarian cysts in premenopausal woman to be higher 
than in postmenopausal women (35% versus 17% respectively). The incidence of new 
cyst formation was also significantly higher for premenopausal women (15.3% 
premenopausal; 8.2% postmenopausal, P<0.001). (Pavlik, 2013) Nezhat found amongst 
1101 women, only 0.4% of the tumours in women under the age of 55 years were 
malignant while 80% were functional or endometriomas. (Nezhat, 1992) Another study 
with women at or below the age of 45 found a 1.4% incidence of malignancy. (Mecke, 
1992) 
 
In a cohort study of 31,834 women in whom 6,807 had an ultrasound scan abnormality, 
63% of these had complete resolution of their cysts. (Pavlik, 2013) In a cohort of 15,106 
asymptomatic postmenopausal women, a similar percentage (69%) was found to resolve 
spontaneously. (Modesitt, 2003) 
 
When a woman is found to have an ovarian cyst or an adnexal mass, the nature of this 
mass and the symptoms she experiences determine the management of this tumour. The 
most important determination is whether the tumour is benign or malignant. Benign 
lesions can be managed expectantly if a woman is asymptomatic. Alternatively benign 
lesions can be managed by conservative surgery with laparoscopic excision. Minimally 
invasive surgery requires shorter hospitalization, affords the patient a faster 
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recovery and allows a speedier return to work. Laparoscopic surgery is also more 
aesthetically pleasing to women with smaller incision scars. Malignant lesions on the 
other hand will need to be managed by an oncology team in a tertiary unit. This has 
been found to provide the best outcome for these women. These lesions often require a 
staging laparotomy and debulking surgery. Women managed and operated on by a 
gynaecological oncologist have better operative staging, more complete debulking with 
less residual tissue and better survival rates and should therefore be referred pre-
operatively. (Elattar, 2011) 
 
Non-invasive diagnosis has therefore become even more relevant and important. It is 
imperative that all efforts are made to determine the nature of a tumour before 
embarking on empirical surgical management.  
 
The tool with the most widespread use in the United Kingdom is the risk of malignancy 
index (RMI). (Jacobs, 1990) It combines features of the tumour on ultrasound scan with 
the absolute value of a tumour marker CA 125 (U/ml).  The tumour marker CA 125 
though, is not specific for the diagnosis of ovarian cancer. It can be raised in many 
benign conditions or non-ovarian malignancies while it may be normal in borderline, 
early stage epithelial and non-epithelial ovarian malignancies.  
 
A number of newer models have been developed since then. Artificial neural networks 
are computer-based learning statistical algorithms, which are modelled after the brain. 
(Timmerman, 1999a; Tailor, 1999) They have not though shown to work consistently. 
There are logistic regression models such as Tailor’s, the IOTA LR1 and LR2, which 
require complex calculations. (Tailor, 1997; Timmerman, 2005) 
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There are ultrasound only based models such as the simple rules method, which is 
simple indeed but requires a greater degree of skill and assessment than the RMI. There 
is a recent model called the risk of malignancy algorithm (ROMA), which involves a 
score for the patient’s menopausal status and the laboratory value of two tumour 
markers (CA 125 and HE4). Moore et al found that combining the two tumour markers 
gave a sensitivity of 76.4% and a specificity of 95%. (Moore, 2008) Moore et al went 
on to describe the ROMA algorithm, which classified 93.8% of epithelial ovarian 
carcinomas as high risk. (Moore, 2009) 
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Part II – Ovarian / Adnexal Tumours 
 
2.1 Ultrasound Scan Appearance and Histology of the Normal Ovary 
and Adnexa 
 
2.1.1 Normal Ovary 
 
2.2.1.1. The Normal Ovarian Embryology 
 
The ovaries begin to develop from the 3rd week after fertilization. Primordial germ cells 
migrate from endoderm located at the hindgut-yolk sac interface and migrate to the 
gonadal ridge. The indifferent gonad develops at a crown-rump length of 5.5mm and 
becomes ovarian around day 42 at a crown-rump length of 17mm. Pre-granulosa cells 
(some of which are derived from the surface epithelium) surround the germ cells, which 
form the primordial follicles. The germ cells proliferate during early pregnancy to reach 
6 million in the 6-month-old fetus. At birth the ovary is primarily made up of follicles 
with scant stroma and most stromal development occurs during the first year of life. 
(Robboy, 2008) 
 
2.2.1.2. The Normal Ovarian Anatomy and Histology 
 
A single layer of cells called the serosa or the surface epithelium, which is white on 
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examination, covers the surface of the ovary. Beneath the surface epithelium is the 
cortex, which contains primordial and developing follicles with the interstitial lutein and 
theca cells. Beneath this layer is the medulla where the blood vessels run from the 
ovarian hilum. This layer is pauci-cellular. The cortex and medulla appear pinkish grey. 
 
2.2.1.3. The Normal Ovary on Ultrasound Scan 
 
The ovaries in a normal woman are located in the pelvis and can vary in size and scan 
appearance. In the pre-pubertal female the ovaries are small and smooth. In the post-
pubertal female they are larger (30 x 20 x 10 mm on average) and they vary in 
appearance throughout the hormonal cycle with follicular development, ovulation and 
the development and then regression of the corpus luteum. During the early follicular 
phase of the menstrual cycle the normal ovary contains 3-11 follicles of ≤10mm, which 
appear as anechoic structures within the ovary. One follicle usually becomes dominant 
and enlarges to 18-20mm before ovulation occurs around day 14 (of a 28 day cycle). 
The dominant follicle becomes a corpus luteum after ovulation, which can appear cystic 
or solid on ultrasound scan with a circumferential increased vascular pattern. In the 
post-menopausal female the ovary are often smaller and contain no follicles. 
 
2.1.2 Normal Fallopian Tube and other Adnexal Organs 
 
2.2.2.1. Embryology 
 
Fallopian tubes are derivatives of the unfused cephalic aspect of the Müllerian 
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(paramesonephric) ducts. This occurs during the 5th to 8th week after fertilisation.  
Caudal to this is the aspect of the Müllerian ducts, which fuse and cannulate to form the 
halves of the upper uterine corpus. Medial to the Müllerian ducts are the Wolffian 
(mesonephric) ducts, which regress, in female embryos.  
 
2.2.2.2. Anatomy and Histology 
 
The 9-12 cm long fallopian tubes have 4 segments, which, from medial to lateral, are 
the interstitial portion, the isthmus, the ampulla and the infundibulum.  (Robboy, 2008) 
The wall of the interstitial aspect of the tube is the most muscular and is continuous 
with the myometrium. Lateral to this is the narrow but also muscular isthmus, which is 
2-3 cm in length. The ampulla is the longest segment of the tube (half its length) and 
runs a meandering course. The most lateral aspect of the tube is the funnel-shaped 
infundibulum, which is 1cm in length and diameter and has a number of irregular, 
tongue-like extensions, the fimbriae.  
 
The tubes have 3 layers, which are the mucosa, the muscle and the outer serosa. The 
mucosa contains 4 cell types, which are the ciliated cells, secretory cells, intercalary (or 
peg) cells, and reserve basal (or undifferentiated) cells. The ciliated cells have tongue 
like cilia, which protrude into the lumen and waft the contents along. This is important 
for the function of the tubes to fertilization and movement of the fertilized embryo to 
the uterine cavity. 
 
Remnants of the Wolffian ducts may persist, forming cysts from the fimbria, along the 
mesosalpinx and in the broad ligament. 
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2.2.2.3. Ultrasound Scan 
 
Apart from the interstitial portions, the fallopian tubes are not easily visible on 
ultrasound scan when no pathology or surrounding fluid is present. In transverse view, 
when sweeping the ultrasound probe towards the fundus, the interstitial portions are 
seen. From here, if the probe is moved laterally, the tube can be followed to the fimbria. 
If there is a trace of retrograde menstruation within the tube or surrounding free fluid in 
the pelvis, this makes visualisation more apparent. Wolffian duct remnants, which form 
cysts or masses, will be seen in the adnexa but will be separate from the ovary and 
uterus.  
 
2.2 Ovarian Tumours: Ultrasound Scan Appearance, Histology, 
Demographics and Treatment 
 
All tumours within this thesis were assigned a tumour histological type according to the 
World Health Organisation (WHO) tumour classification and borderline and primary 
invasive malignancies were further grouped according to the International Federation of 
Gynecology and Obstetrics’ staging. (WHO, 1973; FIGO, 1971; Shepherd, 1989) 
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2.2.1 Physiological Cysts 
 
2.3.1.1. Follicular Cysts 
 
Follicular cysts are thin walled unilocular cysts, which are due to persistence of the 
normal Graafian follicle. Unluteinised follicular cysts produce estradiol and result from 
overstimulation of the ovary by follicle-stimulating hormone (FSH) or ovulation 
inducing drugs. Granulosa lutein cysts result from failure of rupture of the dominant 
follicle for release of the ovum. A layer of luteinised granulosa cells lines them with 
uniform round or oval nuclei and little cytoplasm. The fluid within is usually serous but 
it may also be haemorrhagic. They produce progesterone. Theca-lutein cysts 
predominantly produce androstendione and due to prolonged ovarian exposure to 
luteinizing hormone (LH) or beta-human chorionic gonadotropin (β-hCG). They contain 
luteinised theca interna cells. 
 
On ultrasound, these cysts appear to be simple thin-walled, unilocular cysts with 
anechoic or haemorrhagic (web-like) fluid. They are predominantly 2-5cm in size but 
they can be larger and they often resolve on their own. They can be multiple or bilateral 
and they are poorly vascular. These are often found incidentally as they are usually 
asymptomatic unless haemorrhage has occurred. A repeat ultrasound scan can be done 
to confirm resolution in the early follicular phase of the woman’s next menstrual cycle.  
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2.3.1.2. Corpus Luteal Cysts 
 
A corpus luteum develops after ovulation. A cystic corpus luteum contains the same 
layers as the follicular cysts. The luteinized granulosa cells are intermixed with blood 
and macrophages laden with hemosiderin. Unlike those from follicular cysts, these cells 
are large, polyhedral in shape with a low nuclear: cytoplasmic ratio. There is often 
central haemorrhage 
 
Corpus luteal cysts often appear as thick-walled haemorrhagic cysts with the classical 
“ring of fire” vascularity on Doppler interrogation. 
 
2.2.2 Epithelial Tumours 
 
Tumours that arise from the surface epithelium of the ovary comprise 60-75% of all 
ovarian tumours and 90% of primary ovarian cancers.  
 
2.3.2.1. Serous Tumours 
 
Benign serous cystadenomas are thin walled cysts with watery or thin mucinous fluid 
within. The inner wall can be smooth or can have polypoid projections, which may be 
firm if fibrous or soft if edematous.  The external wall can also be smooth or it can be 
exophytic with external projections. They average 10 cms and are bilateral in 10-20% 
cases. A single layer of ciliated or non-ciliated epithelium usually lines the inner cyst 
wall and the papillae usually consist mostly of stroma. These cells secrete mucin and 
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mitoses are unusual. 
 
2.3.2.2. Mucinous Tumours 
 
These tumours are usually thick-walled cysts with a smooth capsule and with thick 
mucinous fluid within them. They are usually up to 50 cm in size though much larger 
ones have been documented. They are usually multilocular while mucinous 
cystadenofibromas are rare. Histologically, the walls may be collagenous and 
paucicellular with calcification present and they are be lined with columnar cells with 
high mucin content and small basal nuclei. Daughter cysts may arise from the cyst wall. 
Mitoses are unusual. On ultrasound these cysts are uni- or multilocular with smooth 
walls and low-level echogenic fluid with positive acoustic streaming.  
 
2.3.2.3. Endometrioid Tumours 
 
These tumours may arise de novo, on the surface epithelium, without the presence of 
endometriosis, while 20-30% of cases have endometriosis on the same ovary or 
elsewhere. This is a rare tumour and occurs primarily as a cystadenofibroma in women 
with an average age of 57years. Ultrasound appearance is believed to be the same as 
other benign cystadenomas/cystadenofibromas. 
 
2.3.2.4. Müllerian Mesenchymal (stromal) Tumours 
 
These occur uncommonly in the ovary but more often occur in the uterus. They 
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contain stromal of mesenchymal cells with varying degrees of proliferation. 
 
2.3.2.5. Clear Cell Tumours 
 
Benign clear cell cystadenomas/cystadenofibromas are rare tumours occurring at the 
mean age of 45 years. Microscopically they contain large polyhedral clear cells thus 
their name.  
 
2.3.2.6. Transitional Cell (Brenner) Tumours 
 
These are autochthonous tumours that arise from metaplasia of the surface epithelium 
into urothelial-like cells. Polyhedral or elongated cells are seen with grooved long 
‘coffee-bean’ nuclei. Alternatively cells can be mucinous, endocervical or 
pseudostratified and ciliated. Brenner tumours are usually benign and account for 2% of 
primary ovarian tumours. They are usually unilateral and occur in women in their 4th to 
8th decades. These are primary solid tumours < 2cm with a bosselated surface.  
 
2.2.3 Germ Cell Tumours 
 
These tumours account for 20% of all ovarian neoplasms. 
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2.3.3.1. Dysgerminoma 
 
These tumours originate from pluripotential premeiotic oocytes. They account for 1% of 
all primary ovarian malignant tumours, about 1-2% of all ovarian germ cell tumours, 
and something over 25% of malignant ovarian germ cell tumours. (Robboy, 2008) 
These tumours are more commonly seen in adolescence and early adult life while it is 
rare in pre-pubertal children and postmenopausal women. Women with a Y 
chromosome and abnormal gonads due to gonadal dysgenesis and androgen 
insensitivity syndrome have a high risk of developing these tumours in the form of a 
gonadoblastoma. 
 
Bilateral tumours are found in 15-20% cases and in half of those cases the second 
tumour is microscopic. Tumours are solid and highly vascular and are made up of sheets 
of pale uniform cells with a large central nucleus. Focal calcification is often seen in 
gonadoblastomas. Elevated serum lactate dehydrogenase (LDH) is a feature of these 
tumours. 
 
2.3.3.2. Yolk Sac Tumours (Endodermal Sinus Tumours) 
 
Pure yolk sac tumours are rare and are half as common as dysgerminomas. Most occur 
in women under the age of 30 years. Patients often present with abdominal distension 
and pain. Serum alpha-fetoprotein (α-FP) is often raised. 
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2.3.3.3. Teratomas 
 
Teratomas are composed of mature or immature tissues deriving from the three 
pluripotential germ cell layers found in an embryo: ectoderm (skin or epidermal 
derivates and neural tissue), mesoderm (fat, bone, cartilage, connective tissue, muscle) 
and endoderm (epithelium of the gastrointestinal tract and the bronchial tree, thyroid 
tissue). (Saba, 2009; Robboy, 2008)  
 
Mature Teratoma 
 
Mature cystic teratomas of the ovary are more commonly seen in premenopausal 
women, predominantly in the third to forth decades though they are seen in all age 
groups. (Westhoff, 1988) They are the most common type of germ cell tumour seen and 
account for approximately 12% of all ovarian tumours. One series found that 42% of 
their tumours were dermoids. (Ayhan, 1991) They are bilateral in 10-14% cases. 
(Ayhan, 1991; Papadias, 2005) Complications that may occur include torsion (8%), 
rupture (4%), infection 2% and malignant transformation which is reported in 0.3-5% of 
cases. (Ayhan, 1991; Papadias, 2005) 
 
Mature ovarian cystic teratomas are often called dermoids because of their 
preponderance to contain epidermal tissue. They are generally unilocular but can be 
multilocular. They usually contain sebaceous fluid with sebum and keratin with 
dispersed hair and other tissue such as adipose tissue, thyroid tissue, bone or cartilage. 
Fat is found in 93% of dermoids. (Saba, 2009; Caspi, 1996) This contributes to its 
pathognomonic appearance on ultrasound and MRI scan.  
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On ultrasound the following features are seen in dermoid cysts: 1) predominantly cystic 
(18%) 2) Uniformly or predominantly dense echogenicity (33%) which represents 
adipose tissue or floating fat or ball of hair 3) Presence of echogenic thin band-like 
echoes which represent the dispersed hair 4) presence of a discrete highly echogenic 
focus with posterior acoustic shadowing (Rokitansky protuberance) 5) Presence of a fat 
fluid level (Caspi, 1996; Cohen, 1993; Hutton, 1979) 
 
Dermoids cysts have been found to grow by 1.7-1.8mm/year. (Hoo, 2010; Caspi, 1997) 
Hoo et al found 5 factors, which increased the risk of surgical intervention. These were 
lower age, greater parity (≥ 2), past history of an ovarian cyst, bilateral cysts and larger 
cyst size. (Hoo, 2010) Alternatively expectant management has been found to be 
successful in up to 77% patients after 1 year. (Hoo, 2010) 
 
Struma Ovarii 
 
Struma ovarii is a teratoma where thyroid tissue is the only or major component 
(>50%). These primarily unilateral tumours account for 5% of mature teratomas but 
only 50-60% of strumas occur within a mature teratoma. The remainder are pure or are 
associated with a carcinoid tumour or a mucinous adenocarcinoma. These customarily 
occur in the 2nd to 5th decades and are incidental findings or present with vague 
symptoms. Less than 5% demonstrate hyperthyroidism while 33% may have ascites. 
Some patients have a pleural effusion and present with Meigs syndrome. These 
predominantly unilateral tumours are mostly benign and are solid and vascular with a 
smooth surface when pure. Cystic tumours also occur. Histologically it is identical to 
thyroid tissue and extraovarian spread is needed to confirm malignancy.  Treatment 
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is oopherectomy when benign and pelvic clearance for malignant tumours. 
 
Carcinoid and Strumal Carcinoid 
 
Primary carcinoid tumours (< 5% of ovarian teratomas) are four times as prevalent as 
carcinoids metastatic to the ovaries. Types include insular (50% cases), trabecular 
(33%), strumal (17%) and mucinous. In the ovary, insular carcinoids are analogous to 
midgut carcinoids whereas trabecular carcinoids are analogous to foregut or hindgut 
carcinoids biochemically, histochemically and morphologically. Patients could be of 
any age but are usually peri- or post-menopausal. These tumours are usually unilateral 
but a 15% have a dermoid or a mucinous tumour in the contralateral ovary. Most 
primary ovarian carcinoids (60%) occur within dermoids or mucinous tumours. 
Metastatic carcinoids are usually bilateral and insular in type.  
 
2.3.3.4. Mixed Germ Cell and Sex Chord-Stromal Tumours 
 
These tumours have 2-3 cell type components.  
 
Gonadoblastoma 
 
An excess of 80% of these tumours occur in phenotypic females while the rest occur in 
males with cryptorchidism. The phenotypical females though have a high incidence 
(95%) of abnormal sex chromosomal combinations such as 46, XY (50%) and 45 
X/46,XY (25%). Age at presentation is from birth up to the 4th decade. These 
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tumours are unilateral in 67% cases and are usually solid. These tumours can progress 
to be overgrown by a dysgerminoma, which can become malignant.  
 
2.2.4 Sex cord-Stromal Tumours 
 
This group of tumours account for 8% all ovarian tumours. 
 
2.3.4.1. Granulosa Cell Tumours (GCT) 
 
These tumours are classified by having ≥ 10% cells that resemble granulosa cells which 
are small cells with scanty cytoplasm and alongside theco-fibroma tumours they 
account for 70% of sex cord – stromal tumours. These predominently occur in peri-
menopausal women (45-55 years of age) and present with vague abdominal symptoms 
(20%) or with endocrinological disruption.(50%) or both (30%). In 5% of cases there is 
a separate histological identity called jeuvenille GCT, which is more commonly seen in 
young girls and women. Meig’s syndrome (benign ovarian tumour, ascites and pleural 
effusion) may occur. Raised serum estrogen is often found which is associated with 
irregular bleeding in premenopausal women or postmenopausal bleeding for those after 
the menopause. Half have associated endometrial hyperplasia and 10% with an 
endometrial cancer. Virilization is an alternative presentation and these tumours may 
occur in dysgenetic gonads. Serum inhibin is raised. These tumours are usually 
unilateral, solid-cystic and range in size from subclinical to the size of a term gestation. 
GCTs are treated as low-grade malignancies. 
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2.3.4.2. Thecoma-Fibroma Tumours 
 
These tumours include the more frequently occuring fibromas (6% primary ovarian 
tumours) and the rarer thecomas as well as a range of tumours with features of a mix of 
them. These all arise from ovarian stroma and occur in a range of sizes. (Robboy, 2008) 
 
Thecomas occur at any age but more commonly after the 4th decade with 75% in 
postmenopausal women. Thes tumour often present with estrogenic symptoms as with 
GCTs while androgenic thecomas are rare. Meigs syndrome an occur. These tumours 
are solid, well-circumscribed and usually unilateral. Other appearances have been 
described including calcification and posterior acoustic shadowing. (Athey,1987) 
 
The theca cells are spindle shaped and have small pale round nuclei and mitoses are 
rare. These tumours are almost exclusively benign and may exibit cystic degeneration. 
 
Thecafibromas are less likely to have estrogenic effects and look like fibromas on scan 
and macroscopically. Fibromas accound for 65% of the sex stromal tumours and over 
90% occur in women over age 30. Ascites occurs in 10% of cases and in 40% of those 
with tumours>10cm. Also unilateral solid tumours, fibromas have a bosselated surface 
and often exibit cystic degeneration. Tumours may be edematous and may be confused 
with ovarian edema which tends to occur in polycystic ovaries. These tumours are 
hormonally inactive. 
 
Sclerosing stromal tumours occur predominantly in the young (80% <30 years). They 
arise from peri-follicular myoid stromal cells and they are hormonally active secreting 
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estrogens, progestogens or androgens. These unilateral, solid, lobulated, well 
circumscribed tumours are 3-5cm in diameter and are all benign. 
 
2.3.4.3. Sertoli-Leydig Cell Tumours (Androblastomas) 
 
These tumours are rare (1% sex cord stromal and 0.1-0.5% primary ovarian tumours). 
Diagnosis is made due to the presence of Sertoli cells, Leydig cells or fibroblastic cells 
and are characterised by the finding of Reinke crystals. These are primarily found in the 
2nd and 3rd decades and unilateral in 98% cases. These encapsulated and lobulated 
tumours are solid with small cystic areas and usually <10cms. They may be associated 
with raised alpha-fetoprotein levels but not as high as is seen in yolk sac tumours. They 
may be estrogen- or androgen- producing but are often hormonally inert. Well-
differentiated Sertoli cell tumours are seen with testicular feminization syndrome (XY 
females). 
 
2.2.5 Other 
 
2.3.5.1. Endometriomas 
 
Endometriosis occurs when ectopic endometrial glands and stroma are found outside of 
the endometrial cavity. There is an environment supporting growth due to the presence 
of growth factors. This endometriosis commonly occurs in the pelvis such as the pelvic 
sidewalls, the pouch of Douglas and any pelvic peritoneal surfaces. When this tissue is 
found on the ovaries, this is where the classic endometriomas develop. The 
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ovarian ectopic endometrium bleeds each month at the same time the normally located 
endometrium sheds (menses) causing the cyst to accumulate this old blood. There are 2 
theories for the cause of endometriosis. The first is due to receptive pelvic peritoneum, 
which allows implantation of endometrium, which makes its way to the pelvic 
peritoneal cavity via retrograde menstruation. The second is thought to be due to 
metaplastic change in the tissue which is present premenstrually and which activates 
later in life. 
 
On ultrasound scan endometriomas are typically described as thick walled well-
circumscribed cysts. Within them homogenous low-level fluid is seen which is 
classically described as “ground glass” is this is due to the presence of old blood. Cysts 
are usually unilocular but up to 30% can be multilocular. (Van Holsbeke, 2010b; 
Kupfer, 1992) Papillary projections have been described in up to 20% of 
endometriomas. (Patel, 1999) Hyperechoic cyst wall foci are also described. (Kinkel, 
2006; Patel, 1999) Acoustic streaming is absent in up to 91% of endometriomas. (Van 
Holsbeke, 2010a) A carpet like debris is often seen in the dependant part o the cyst. 
(Fried, 1993; Kupfer, 1992) Kupfer et al saw this in 82% of their endometriomas. These 
cysts are usually poorly vascular but vascularity can be seen around the cyst in the 
normal ovarian tissue near the ovarian hilum. 
 
During pregnancy endometriomas and deposits of endometriosis often undergo 
decidualization including within cutaneous endometriosis. (Tazegül, 2013) There is 1 
reported case of cutaneous decidualized endometriosis in a non-pregnant woman. 
(DeClerck, 210) The cysts can be misdiagnosed as malignancies at this time as the 
appearance changes. The fluid become anechoic or less echogenic, the papillary 
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projections become larger, more prominent or appear where there were none before, and 
with the typical pregnancy–induced increase in vascularity, these cysts become more 
vascular.  
 
Management of endometriomas involves medical and surgical options (gold standard of 
laparoscopic excision or alternatively laparotomy for clearance). Treatment often 
depends on symptoms and fertility requirements rather that the sonographic appearance 
of the disease as these may not correlate to symptoms. 
 
 
2.2.6 Borderline Ovarian Tumours 
 
 
The International Federation of Gynecology and Obstetrics (FIGO) classify borderline 
tumours (BOT) (previously called carcinomas of low malignant potential) separately 
from primary invasive ovarian tumours since 1971. (FIGO, 1971) Both borderline and 
primary invasive tumours are classified into 1 of 4 stages with further classification into 
subsections. (Shepherd, 1989) 
 
BOTs have varying ultrasound appearances. They tend to be tumours that get quite 
large despite having a slower growth rate compared to invasive malignancies. They are 
usually well-circumscribed tumours with no evidence of invasion or ascites and they are 
often multilocular with papillary projections. (Valentin, 2006) Normal surrounding 
ovarian tissue “crescent sign” is usually seen. (Yazbek, 2007a) 
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Borderline ovarian tumours (BOT) are tumours, which have proliferating cells and 
nuclear atypia with mitotic activity but with no infiltrative destructive growth or stromal 
invasion whereas primary invasive tumours do. BOTs account for 10-15% of all ovarian 
tumours. (Tinelli, 2009) BOTs are more commonly found in pre-menopausal women as 
compared to primary invasive tumours. (Gotlieb, 2005) BOTs peak in the 5th decade 
versus primary invasive tumours which peak in the 6th and 7th decades. (Heintz, 2006; 
Cancer Research UK, 2013) These women are more likely to be diagnosed in early 
stages (82% stage 1), have a lower relapse rate (7.8%) and have an overall better 
prognosis. (du Bois, 2013; Heintz, 2006). They have a better 5-year survival 87.3% 
versus 49.7% when compared to that of primary invasive tumours but it is suggested 
that this is heavily influenced by the fact that BOTs usually present at stage 1 whereas 
invasive tumours are often diagnosed at later stages. (Heintz, 2006)  
Treatment of BOTs tends to be more conservative and minimally invasive with fertility 
sparing surgery for those who wish to maintain their reproductive function. (Maneo, 
2004; Tinelli, 2009; Seracchioli, 2001) Surgery may be a laparoscopic salpingo-
oopherectomy for unilateral disease or an ovarian cystectomy for 1 of the ovaries when 
bilateral disease exists. Fertility and pregnancy outcomes appear to be good and 
ultrasound surveillance is possible for recurrence. (Seracchioli, 2001) Further 
appropriate laparoscopic procedures include appendicectomy for mucinous tumours, 
total laparoscopic hysterectomy and bilateral salpingo-oopherectomy, peritoneal 
biopsies, omentectomy and pelvic and paraaortic lymphadenectomy.  
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2.3.6.1. Epithelial tumours 
 
Serous BOTs (SBOTs) are bilateral in 35-40% cases. These tumours tend to have 
multiple papillary projections as do endocervical-type BOTs. (Yazbek, 2007a) 
 
Mucinous BOTs (MBOTs) tend to be more multilocular when compared to their benign 
counterparts. Classic honeycomb nodules (multilocular nodules) are seen in MBOTs of 
gastrointestinal type on ultrasound scans. (Yazbek, 2007a)  
 
Patients with endometriod BOTs have a mean age of 55-60 years and the tumour may 
be associated with synchronous or metachronous endometrial hyperplasia or an 
adenocarcinoma. (Robboy, 2008) 
 
Transitional cell (Brenner) BOTs behave like benign tumours though they get much 
larger (up to 23cm) and primarily only have symptoms of mass effect. There are highly 
multilocular tumours and are rarely associated with a synchronous or metachronous 
bladder transitional cell carcinoma. 
 
Stage 1 invasive tumours have a 5 year survival of 83-90% while serous BOTs stage Ia 
and Ib have a near 100% 5 year survival. (Silverberg, 2004) Serous BOTs are just over 
twice as common as mucinous BOTs while invasive serous tumours are 4 times as 
common as mucinous invasive tumours. (du Bois, 2013; Heintz, 2006). Of all the 
histological types at stage IV, clear cell was found to have the worse prognosis/ 5 year 
survival rate (12.9%) followed closely by mixed epithelial (13.2%) and mucinous 
(17.3%).  
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2.3.6.2. Germ cell Tumours 
 
Germ cell tumours provide a number of diagnostic challenges to pathologists because of 
the varying cell line components. The literature does not describe a distinct subclass of 
borderline germ cell tumours. 
 
2.3.6.3. Sex cord-Stromal Tumours 
 
Granulosa cell tumours are treated as tumours of low malignant potential. Diagnosis is 
usually at an early stage and recurrence is often very late (30-50% at 20 years). (See 
above) 
 
2.2.7 Primary Malignant Ovarian Tumours 
 
2.3.7.1. Epithelial tumours 
Epithelial primary invasive malignancies are usually multilocular-solid tumours which 
are highly vascular, fairly large with irregular borders and which begin to invade 
surrounding structures. For primary invasive ovarian malignancies, the principle of 
treatment is debulking followed by adjuvant chemotherapy.  
Primary undifferentiated and serous carcinomas are commonly bilateral whereas 
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endometrioid and mucinous are often unilateral. Mucinous carcinomas are usually 15-
30cm and multilocular or multilocular-solid and rarely they may be almost entirely solid 
with a soft mucoid surface.  
 
Endometroid carcinoma is the second commonest ovarian epithelial malignancy and is 
associated with endometriosis in 30% of cases and with endometrial carcinoma in 25-
30% of cases. They are bilateral in 28% cases and confined to the pelvis in 70% cases. 
Those that occur within endometriomas are often in younger women but generally these 
occur in the 4th and 5th decades of life. While up to 30% of cases have a synchronous 
endometrial cancer, in 15-25% it is histologically similar which raises the suspicion of 
metastases. These though are usually considered as a separate independent tumour. 
Primary tumours are more likely to be cystic-solid, unilateral and larger than the 
metastatic versions, which are usually multinodular solid, bilateral and smaller. The 
stage of the uterine tumour can also help distinguish primary from metastatic as the 
latter ones tend to have higher-grade tumours with deep myometrial invasion. Rarely 
this can also occur with a synchronous or metachronous endometriod tumour of the 
cervix, which is autochthonous. These tumours are usually cystic, 12-20cm in diameter 
and with multiple papillary projections and a smooth outer surface. The fluid may be 
blood stained. Alternatively it may be solid with haemorrhage and necrosis or a large 
solid papillary projection if within an endometrioma.  
 
Primary ovarian sarcomas are rare and are usually solid tumours with tongue like 
projections into adjacent tissue.  
 
Malignant clear cell tumours account for 5-10% primary ovarian malignancies and 
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occur predominantly in the 5th to 7th decades with 50-67% of the women being 
nulliparous. Paraneoplastic hypercalcaemia is a recognised association of these 
primarily unilateral tumours. Half are diagnosed at stage 1. Endometriosis is seen in 60-
65% of these women though synchronous endometrial tumours are not often seen. 
These 15-20 cm large tumours are thick-walled unilocular cysts with papillary 
projections and bloodstained fluid. 
 
Malignant Brenner tumours occur in the 6th decade and ranges from 10-30cm in 
diameter. These are usually unilateral cysts with soft multiple papillary projections.  
 
2.3.7.2. Germ cell tumours 
 
Dysgerminomas are fast growing tumours, but they metastases late. Two thirds of cases 
are FIGO Stage I at the time of diagnosis.  
 
Choriocarcinomas are characterised by presence of trophoblastic malignant cells and 
they can be gestational or non-gestational. Gestational choriocarcinomas include 
ovarian metastasis from primary uterine choriocarcinoma tumours, which can be 
associated with or occur after a normal pregnancy, spontaneous miscarriage, complete 
hydatidiform mole, or partial mole, and primary gestational ovarian choriocarcinoma 
tumours (1 in 369 million pregnancies) that arise from an ovarian ectopic pregnancy. 
(Axe, 1985) The nongestational type which accounts for ≤0.6% of all ovarian tumours, 
is as a component of a mixed germ cell tumour and a pure ovarian choriocarcinoma is a 
very rare aggressively malignant tumour. (Lv, 2011) These tumours are associated with 
high serum β-hCG levels and immunohistochemical staining with β-
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hCG, and placental lactogen are diagnostic. While they typically metastasize early via 
venous, lymphatic and transcoelomic routes, these tumours are highly chemosensitive. 
 
Embryonal Carcinoma are the least differentiated of the germ cell tumours with 
pluripotent potential and are homologous to their counterparts in the testes. Pure 
tumours are rare with peak presentation in the 2nd and 3rd decade of life with a mass or 
hormonal expressions in 67% (precocious puberty or abnormal vaginal bleeding). 
Tumours are usually large, soft solid and unilateral but they are highly malignant 
invading locally as well as spreading intra-peritoneally and distantly. Tumour cells 
express β-hCG and α-FP. Treatment is surgical followed by chemotherapy in all 
patients even though 60% present at stage 1A. Surveillance is with serum α-FP and β-
hCG alongside imaging. 
 
2.3.7.3. Sex cord-Stromal Tumours 
 
Thecomas, which are malignant, are rare and only a few examples are documented. 
 
2.2.8 Primary Peritoneal Cancer (PPC) 
 
PPC is a serous carcinoma of the peritoneal lining of the abdomen. Staging is the same 
for ovarian cancer but there only exists stages III and IV. Up to 15% patients diagnosed 
with advanced serous carcinomas are thought to have PPC instead. After a prophylactic 
BSO, women with BRA1/2 still carry a 1-5% risk of developing PPC after 7-27 years 
and low risk women have a 0.02% after up to 18 years. (Piver, 1993; Casey, 2005; 
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Gotlieb, 2006) 
 
Ultrasonographically the peritoneum appears globally thickened and ascites almost 
always present. Tumour grade was the main reported significant prognostic factor and 
treatment is as for ovarian cancer. (Lee, 2013) 
 
2.2.9 Pseudomyxoma peritonei (PMP) 
 
This is a condition where there is the presence of free gelatinous mucin in the peritoneal 
cavity and this may or may not have a cellular component. This gelatinous ascites is 
thought to be due to spread from a mucinous ovarian or gastrointestinal tumour and 
rarely of a tubal or an extraabdominal tumour. The ovarian tumour tends to be bilateral 
(66%) and shows penetration of the stroma with tracks of mucin (pseudomyxoma 
ovarii) while pseudomyxoma ovarii can occur without pseudomyxoma peritonei. 
Appendiceal mucoceles have a similar process causing the leakage of the mucin. 
Prognosis is dependant on the primary tumour and amenability of the tumour to 
clearance or cytoreduction and is therefore excellent for stage 1 tumours despite the 
presence of this condition. This suggests that PMP is not malignant spread. Recurrence 
of PMP is common. 
 
2.2.10 Metastatic Ovarian Tumours 
 
The ovary is commonly a site of metastases from malignant tumours, most often seen 
from the gastrointestinal tract (39-42%), the breast (28-29%) and the endometrium 
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(20%). (Young, 1991; Antila, 2006; de Waal, 2009).  Metastases account for 5-15% of 
all ovarian tumours. (Antila, 2006; de Waal, 2009) Ovarian metastatic tumours are 
bilateral in up to 69% cases. (de Waal, 2009) Tumours are often smaller, solid, well 
circumscribed tumours of high vascularity (stomach, breast, lymphoma and uterine) but 
they may also be larger, multilocular-solid or multilocular with irregular borders and 
less vascularity (colon, appendix, rectum and biliary tree). (Testa, 2007) The second 
group were often larger than the first (12cm versus 7cm) while the metastatic tumours 
as a group are often smaller than their primary counterparts (<10cm versus >15cm). 
(Young, 2006; Testa, 2007; Guerriero, 2012)  
Krukenberg tumours are the most well known of the metastatic tumours though not the 
most common. (Young, 2006) This name is assigned to metastatic tumours with a >10% 
component of the tumour made up of mucin secreting signet-ring cells and where the 
stroma often demonstrates a sarcomatoid reaction. They primarily metastasize from 
gastric tumours and can be seen in up to 55% patients with a gastric tumour. (Young, 
2006) These are typically bilateral bosselated surface solid tumours without necrosis 
unlike gastrointestinal type non-Krukenberg metastases, which tend to be unilateral, 
solid and cystic with necrosis. (Young, 2007) 
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2.3 Other Adnexal Tumours: Ultrasound Scan Appearance, Histology, 
Demographics and Treatment 
 
2.3.1 Non-ovarian Adnexal Masses 
 
2.4.1.1. Hydrosalpinx 
 
A dilated fallopian tube has a characteristic appearance of a sausage-shaped cystic 
structure with anechoic or low level fluid and ‘incomplete septa’ (septa that do not 
reach the opposite wall of the cystic structure in all planes), which are due to protruding 
mucosal folds. The pathognomonic feature is described as a ‘cog-wheel’ appearance or 
as a ‘beads-on-a-string’ appearance for more longstanding cases. (Timor-Tritsch, 1998). 
Treatment is conservative unless a woman is to have in vitro fertilisation (IVF) 
treatment, as success rates are higher after removal. 
 
2.4.1.2. Pyosalpinx / Hematosalpinx / Tubo-Ovarian abscess 
 
When the above described structure contained echogenic fluid this is often a sign of a 
pyosalpinx (pus containing) or a hematosalpinx (blood containing). When there is a 
tubo-ovarian abscess present, the structure involves the ovary and is often multilocular-
solid with thick septae and ground glass contents or it may be predominantly solid in 
appearance. (Valentin, 2004) It may demonstrate increased vascularity and is tender on 
palpation. Treatment of a pyosapinx or abscess is initially antibiotics with analgesia but 
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ultrasound guided transvaginal drainage or surgical drainage may be required if the 
patient does not respond to this. (Aboulghar, 1995) This may be misdiagnosed as a 
malignancy if important factors such as age, history, examination and inflammatory 
markers are not considered. (Hata, 1989; Varras, 2003) 
 
2.4.1.3. Fimbrial, Para-tubal, Paraovarian and Broad Ligament cysts 
 
These cysts are remnants from embryonic ducts of which most are paramesonephric 
(Müllerian) in origin and occurs anywhere between the ovary and the tube as well as 
lateral to the uterus within the broad ligament. (Genadry, 1977; Samaha, 1985; Grant, 
1992) These cysts are lined with epithelium and usually contain anechoic fluid. Most 
cysts are unilocular but they may have a range of appearances up to multi-locular solid 
with papillary projections in cystadenomas and cystadenofibromas. (Athey, 1985; 
Korbin, 1998; Savelli, 2006) They are separate from the ovary but this may occasionally 
be difficult to demonstrate. (Kim, 1995)  
 
Hydatid cysts of Morgagni are typically referred to as fimbrial cysts and are usually 
small, multiple, avascular, pedunculated cysts with anechoic fluid and which are 
attached to the fimbria.  These are more commonly seen in women with unexplained 
infertility; 52% versus 26% of those with explained fertility. (Rasheed, 2011) 
 
Management is usually conservative unless the cyst changes in appearance or becomes 
symptomatic which may occur if torsion occurs. (Said, 2008) 
Broad ligament leiomyoms (fibroids) may also occur and are often softer that their 
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intrauterine counterparts. (Chmaj-Wierzchowska, 2012) 
 
2.4.1.4. Peritoneal Pseudocysts 
 
When fluid is entrapped between peritoneal adhesions and pelvic organs, peritoneal 
pseudocysts are formed. Adhesions are fibrous bands of tissue between the abdominal 
organs and abdominal walls that are usually formed in response to peritoneal injury 
such as after infections commonly pelvic inflammatory disease and appendicitis, as seen 
in endometriosis or after a surgical procedure. On ultrasound these cysts are rarely 
rounded but instead are commonly irregular superiorly and follow the contours of the 
pelvic sidewalls laterally. Up to 81% of peritoneal pseudocysts are describes as having 
blurred, undefined margins and bizarre morphological features. The fluid is usually 
anechoic and septae may be seen within. The septae may be incomplete and the septae 
may be mobile on palpation with the endovaginal ultrasound scan probe, which is 
known as the “flapping sail sign”. (Savelli, 2004) The ipsilateral ovary is seen in up to 
84% of cases and may be seen adjacent or within the pseudocyst like a 'spider in a web'.  
 
Treatment is often conservative as surgical treatment has a moderately high risk of 
complications such as visceral injury or infection and a high risk of recurrence. 
 
2.4.1.5. Borderline and Malignant Non-Ovarian Adnexal Tumours 
 
Tubal malignancies are uncommon but are being detected more often during 
prophylactic risk-reducing bilateral salpingo-oopherectomies done for BRCA1/BRCA2 
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carriers or those with a strong family history. (Manchanda, 2011) In this series of 308 
high-risk women, 10 occult tubal cancers while only 4 occult ovarian cancers were 
detected. There are theories and some evidence that some primary ovarian epithelial 
adenocarcinomas specifically high-grade serous carcinomas and primary peritoneal 
cancers have a tubal origin. (Kurman, 2013; Nasser, 2014) 
 
Most paraovarian tumours are benign but borderline tumours have been reported. 
(Savelli, 2006; Suzuki, 2013) The literature describes a 2% malignancy rate. (Stein, 
1990) 
 
2.4 Epidemiology and Demographics of Ovarian cancer 
 
In the UK, ovarian cancer is the 5th most common cancer in women after breast, lung, 
bowel and uterus with 7,011 new diagnoses in 2010, 7,116 new diagnoses in 2011 and 
with 6,692 new diagnoses in 2012 (where it was the 6th most common after breast, lung, 
bowel, skin melanoma and uterine). (ISD Scotland online, 2013; Office for national 
statistics, 2012; Welsh cancer intelligence and surveillance unit, 2013; Northern Ireland 
cancer registry, 2013; IARC, 2012; Ferlay, 2010). The incidence rate is 17.1 new cases 
per 100,000 population and the mortality rate is 9.0 per 100,000 population. It was the 
4th most common cause of cancer deaths in 2011 after lung, breast and bowel and 
therefore the most common gynaecological malignancy causing death. (Cancer research 
UK, 2013; IARC, 2012) 
 
The lifetime risk of developing ovarian cancer is approximately 2% or 1 in 51 for 
women in England and Wales. This risk increases to 3% for women with one 
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affected first degree relative (up to 5% for when the affected relative was under the age 
of 50 years versus 2.5% when they were over 50 years). (Jervis, 2013) This risk 
increased even further to between 30 and 40% for women with two affected first-degree 
relatives. Ovarian cancer is predominantly a disease of post-menopausal women with 
almost 85% of cases being diagnosed in women over 50 years of age with the peak 
incidence rates seen in women aged 65. (Figure 2.4-1) Despite the fact that most cases 
of ovarian cancer occur in postmenopausal women, since the mid-1970s, the incidence 
in females aged 15-39 has increased by 56%. (Cancer research UK) 
 
Over the last 30 years the incidence of ovarian cancer has increased in England and 
Wales but it has decreased in Northern Ireland. The incidence went from 15 per 100,000 
women in 1975 to about 19 per 100,000 in the late 1990s and in 2011 it was 17 per 
100,000. (Figure 2.4-2)While the incidence has increased in England, the mortality rate 
has halved with a 43.5% 5-year survival. Stage I disease has a 92% 5-year survival 
while stage IV has a 5.6% 5-year survival. (Table 2.4-1)Survival rates at 1 year have 
significantly improved while longer-term survival has improved less. (Figure 2.4-
3)Survival has improved for women less than 65 years of age but it has worsened for 
those over the age of 70. (Figure 2.4-4)Worldwide the incidence of ovarian cancer was 
over 230,000 with a mortality of just over 150,000 in 2012. (IARC, 2012) It is the 7th 
most common cancer worldwide in women. 
 
The most important prognostic factor in ovarian cancer remains the stage of the disease 
at presentation. Unfortunately, around 75% of affected women present with advanced 
stage disease, which is thought to be due to the vague or absent symptoms of early stage 
disease. 
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Lataifeh et al. performed a retrospective study of 100 women with early stage ovarian 
cancer (stage I) and 100 women with advanced stage ovarian cancer (stage III) looking 
at symptomatology at presentation. (Lataifeh, 2005) They found that 90% of women 
with early stage ovarian cancer and 100% of women with advanced ovarian cancer had 
at least one symptom. When comparing women with early stage disease versus those 
with late stage disease, 51% versus 44% reported abdominal pain and 32% versus 62% 
reported abdominal distension. Most women (70%) in both groups had symptoms of a 
short duration (less than 3 months). Smaller tumours (<5 cm diameter) were three times 
more likely to have advanced disease (p=0.02). The authors found that those with early 
disease were more likely to be younger and to have well-differentiated tumours and that 
advanced disease was not usually due to a delay in diagnosis. Women with a BOT had a 
significantly longer average symptom time interval than women with a Stage I or II 
invasive malignancy (8.0 +/- 7.7 versus 3.4 +/- 3.7 months, respectively (P = 0.03). 
(Eltabbakh, 1999) 
 
Early ovarian cancer causes minimal, nonspecific, or no symptoms at all. Symptoms 
that may be experienced include bloating, abdominal distension, abdominal discomfort, 
fatigue, vaginal bleeding, constipation or sensation of a mass with or without pressure 
effects on the bladder and rectum. Women with borderline or early stage cancer are 
more likely to report a sensation of an abdominal mass or of urinary pressure symptoms 
due to the presence of large low-grade tumours. They are less likely to report 
gastrointestinal problems or general malaise as compared to those with advanced stage 
cancer. General malaise and other non-specific symptoms are least common in 
borderline disease.  
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Hippisley-Cox and Coupland performed a cohort study over 10 years, 9 months at the 
general practice level to find the risk factors for ovarian cancer and develop an 
algorithm. They found the independent predictors of increasing age, abdominal 
distension (23-fold higher risk), family history of ovarian cancer (9.8-fold higher), 
abdominal pain (7-fold higher), postmenopausal bleeding (6.6-fold higher), loss of 
appetite (5.2-fold higher), anaemia (2.3-fold increased risk), bleeding per rectum (2-fold 
higher) and weight loss (2-fold higher). (Hippisley-Cox, 2011) Using their algorithm, 
the 10% of women predicted to have the highest risk had 63% of all the ovarian cancers 
diagnosed over the consecutive 2 years. Higher parity older women, and those with a 
family history of breast or ovarian cancer, are more likely to be diagnosed at an 
advanced stage of disease (Webb, 2004). 
 
Risk factors associated with ovarian cancer include exposure to an increased number of 
ovulatory cycles seen in women with an early menarche, late menopause, nulliparity, 
infertility (36-46% risk increase) and recurrent fertility treatment. (Edmondson, 2001) 
Multiparous women have a 50% decreased risk compared to their nulliparous 
counterparts and those with multiple pregnancies have greater protection than those 
with singletons. Breastfeeding is also associated with reduced risk (34%) as well as the 
use of the combined oral contraceptive pill. (Table 2.4-2) 
 
Carrier status of genetic predispositions like BRCA1 and BRCA2 gene mutations 
(Malander, 2004), and family history of ovarian, breast or colorectal cancer are also risk 
factors for ovarian cancer. The average cumulative risk of ovarian cancer by age 70 
years was 39% (18%-54%) for BRCA1-mutation carriers and 11% (2.4%-19%) for 
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BRCA-2 carriers and of breast cancer of 65% (95% confidence interval 44%-78%) for 
BRCA-1 and of 45% (31%-56%) for BRCA-2 carriers. (Antoniou, 2003) There are 
other genetic mutations which have a higher risk of developing ovarian cancer such as 
the autosomal dominant Lynch II syndrome or HNPCC (hereditary nonpolyposis 
colorectal cancer) which is associated with a high risk for developing colorectal, 
endometrial, stomach, small bowel, breast, pancreas as well as ovarian cancers. 
 
 
 
 
 
62 
Figure 2.4-1: Ovarian Cancer (C56-C57), Average Number of New Cases per Year 
and Age-Specific Incidence Rates per 100,000 Population, Females, UK, 2009-2011 
(Cancer Research UK) 
 
 
http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/ovarian-cancer 
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Figure 2.4-2: Ovarian Cancer (C56-C57), European Age-Standardised Incidence 
and Mortality Rates, Great Britain, 1975-2008 (Cancer Research UK, 2011) 
 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_OVARY.pdf 
March 2011. 
 
Table 2.4-1: Ovarian Cancer, Five-Year Stage-Specific Relative Survival Rates, 
Adults (Ages 15-99), Anglia Cancer Network, 2004-2008 (Cancer Research UK, 
2011) 
Stage at 
Diagnosis 
Number of 
cases 
% of all 
cases 
5-year relative 
survival (%) 
95% Confidence 
Interval 
Stage I  424  29 92.0 (86.5-97.6) 
Stage II  62 4 55.1 (36.8-73.5) 
Stage III  652  45  21.9  (17.3-26.4) 
Stage IV  216 15 5.6 (1.9-9.4) 
Unstaged  89  6  27.6  (16.0-39.3) 
All stages  1443  100  43.5  (39.9-47.0) 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_OVARY.pdf 
March 2011. 
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Figure 2.4-3: Ovarian Cancer, One-, Five- and Ten-Year Age-Standardised 
Relative Survival Rates, Adults (Ages 15-99), England and Wales, 1971-1995, and 
England, 1996-2007 (Cancer Research UK, 2011) 
 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_OVARY.pdf 
March 2011. 
Figure 2.4-4: Ovarian Cancer (C56-C57), Age-Specific Mortality Rates, UK, 1971-
2008 (Cancer Research UK, 2011) 
 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_OVARY.pdf 
March 2011. 
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Table 2.4-2: Ovarian Cancer, Relative Risk by Parity and Duration of Oral 
Contraceptive (OC) Use (Cancer Research UK, 2011) 
Relative risk for 
ovarian cancer by 
parity 
Number of children Relative risk (95% CI) 
3+  
2  
1  
0 
1 
1.21 (1.10-1.32) 
1.60 (1.43-1.79) 
2.12 (1.81-2.48) 
Relative risk for 
ovarian cancer by 
duration of oral 
contraceptive (OC) use 
(mean) 
OC use  Relative risk (99% CI)* 
Never  
Less than 1 year (0.4 years) 
1-4 years (2.4 years)  
5-9 years (6.8 years)  
10-14 years (11.6 years)  
15 years or more (18.3 years)  
1.00 (0.96-1.04)  
1.00 (0.91-1.10) 
0.78 (0.73-0.83) 
0.64 (0.59-0.69) 
0.56 (0.50-0.62) 
0.42 (0.36-0.49) 
Risk reduction for 
ovarian cancer by time 
elapsed since cease of 
OC use (per five years 
of OC use)  
Time elapsed since cease  
 
Proportional risk 
reduction 
Less than 10 years  
10-19 years  
20-29 years  
29% 
19% 
15% 
* Relative risk stratified by study, age, parity and hysterectomy. 
Data sources: Beral et al. Lancet 2008; 371, 303-14; Granstrom C et al. BJC 2008; 98 
(1), 199-205 
http://publications.cancerresearchuk.org/downloads/product/CS_CS_OVARY.pdf 
March 2011. 
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2.5 Importance and Clinical Significance and Natural History of 
Ovarian Cancer 
 
2.5.1 Clinical Significance 
 
Ovarian cancer is the most common gynaecological malignancy causing death in the 
UK despite being only the second most commonly occurring malignancy after uterine. 
(Cancer research UK, 2011) Symptoms are vague and non-specific which contribute to 
diagnoses occurring at a late stage and therefore the reduced survival. Various models 
of tumourigenesis (as below) may also explain the reason for diagnoses occurring in the 
latter stages. No precursor markers on scan or in serum tests have been identified which 
thwarts plans to develop screening protocols. For these reasons, correct diagnosis and 
management of ovarian tumours is of paramount importance. 
 
2.5.2 Natural History 
 
A small study has suggested that approximately half of ovarian carcinomas develop 
from pre-existing, benign appearing cysts.  This pathway is called adenoma-carcinoma 
sequence. The remaining half seem to develop from normal appearing ovaries and this 
pathway is called de novo carcinogenesis. (Horiuchi, 2003) 
 
Shih and Kurman have suggested a different theoretical model of two main pathways of 
tumourigenesis. It suggests that surface epithelial tumours are divided into two broad 
categories designated type I and type II tumours. (Shih, 2004; Kurman, 2010) 
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Type I malignant ovarian tumours are comprised of low-grade serous, low-grade 
endometrioid, clear cell and mucinous carcinomas and Brenner (transitional cell) 
tumours. They are generally indolent, thought to develop from borderline tumours and 
generally present early in stage I. Type II tumours though are comprised of high-grade 
serous, high-grade endometrioid, malignant mixed mesodermal tumours 
(carcinosarcomas), and undifferentiated carcinomas. They are aggressive, are theorised 
to arise in normal ovaries and present in an advanced stage (III/IV). (Kurman, 2011) 
 
Li et al suggested that ovarian serous cancers might actually have a tubal origin rather 
than originating from Müllerian metaplasia of ovarian surface epithelium. (Li, 2011) It 
has been proposed that these serous tumours arise from the implantation of tubal 
epithelium (benign or malignant). Manchanda et al found more occult invasive/in situ 
tubal cancers than ovarian ones (4 ovarian and 10 tubal) amongst 308 high-risk women 
(191 with unknown mutation status; 117 known BRCA1/BRCA2 carriers) who chose 
risk-reducing surgery. The overall occult invasive cancer rate was 5.1% (95% CI 1.9-
10.83) in BRCA1/BRCA2 carriers and 1.05% (95% CI 0.13-3.73) in untested women.  
 
Endometriosis, known to be associated with endometrioid and clear cell tumors is 
regarded as the precursor of these malignant tumors. It is presumed that endometrial 
tissue is implanted on the ovary via retrograde menstruation. New data now also 
suggests that mucinous and transitional (Brenner) tumors arise via metaplasia from 
transitional-type epithelial nests at the tubal-mesothelial junction. (Kurman, 2010) 
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2.6 Ultrasound Scan Modality for the Assessment of Ovarian and 
Adnexal Tumours 
2.6.1 Lesion 
 
A lesion is defined as an area of the ovary or of an adnexal mass, which is considered to 
be a non-physiological change. Assessing this requires knowledge of the physiology of 
the ovary and this is dependant on the age and menopausal status of the woman and the 
day of her menstrual cycle.  
2.6.2 Solid versus Cystic 
 
Solid tumours are typically hyperechoic but may be isoechoic. A solid tumour has been 
arbitrarily defined, as one in which greater than 80% of the tumour is solid. 
(Timmerman, 2000) There are few instances where confusion may arise as to whether a 
tumour is solid or not such as with cysts with thick fluid, blood clot within a cyst and fat 
within a dermoid which appears white. Checking for vascularity, movement on 
palpation or looking for acoustic streaming may help. If after employing those 
techniques it is still unclear, it is recommended that the tumour be assumed to be solid. 
Solid tumours are noted to have a higher risk of malignancy when compared to other 
types of cysts but in particular to unilocular cysts. (Granberg, 1989) 
 
2.6.3 Locularity 
 
A locule is a cyst wall cavity or compartment, which is separated by septae. A cyst may 
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be unilocular with a single cavity, bilocular with 2 cavities or multilocular with multiple 
cavities. Unilocular cysts can have incomplete septae within it. To be considered 
bilocular or multilocular there must be complete septae present. Tumours can be 
broadly classified as unilocular, unilocular-solid, multilocular, multilocular-solid or 
solid. Cysts judged to be unilocular on ultrasound scan have been demonstrated to have 
a very low risk of malignancy while multilocular cysts have a greater risk. (Meire, 
1979; Granberg, 1989; Valentin, 2013)  
 
2.6.4 Cyst Contents 
 
The fluid within a cyst can vary in appearance. Thin fluid tends to be anechoic so serous 
cysts can be anechoic or contain low levels. Low-level echogenic fluid is seen as 
predominantly anechoic but with some echogenic specks within it. Thicker fluid tends 
to be more echogenic. Some cysts have a pathognomonic appearance. Haemorrhagic 
cysts can be described as having “cobweb” or “star-shaped” contents which may appear 
solid but which are in fact only clot within the cyst. Endometriomas are cysts that 
contain thick old blood and the fluid within them is described as having a “ground 
glass” appearance on ultrasound scan. Fat within cysts appear white or echogenic and 
hair has a classic appearance of streaks of bright white. Both of these are typically seen 
in dermoid cysts. 
 
2.6.5 Cyst Wall 
 
As a cyst is a fluid filled structure, it has an inner and outer surface called the cyst wall. 
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The cyst wall surface can be smooth or it can be irregular. Irregular cyst walls have 
papillary projections. Thicker cysts walls are associated with malignancy. (Granberg, 
1989) 
 
2.6.6 Septum 
 
A septum is a thin solid structure that extends from one part of the internal cyst wall to 
another. If it extends to another aspect of the internal cyst wall in all scanning planes 
visualised, then it is a complete septum. If it extends into the cyst cavity without 
touching the cyst wall in all scanning planes then it is an incomplete septum. A septum 
may be vascular (demonstrating blood flow though it) or it may be avascular. Thick 
septae are defined as those greater than 3mm. 
 
2.6.7 Papillary projections 
 
Papillary projections are solid areas arising from the cyst wall and typically extend into 
the cyst cavity. Its perpendicular distance from the inner cyst wall must be ≥3mm. 
Papillary projections themselves can have a smooth or irregular surface and they may or 
may not demonstrate vascularity on Doppler examination. The risk of malignancy has 
been found to be higher the greater the number of papillary projections is present. 
(Granberg, 1990; Bailey, 1998) Hydrosalpinges have a classic “cogwheel sign” or 
“beads on a string” appearance and as such can often be identified easily but if 
describing the cyst and the inner surface has raised areas ≥3mm, these should be 
described as papillary projections. (Timor-Tritsch, 1998) While papillary projections 
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occur in benign cysts, they have been found to be characteristic of borderline ovarian 
tumours (BOT) and stage 1 primary invasive epithelial ovarian cancer. (Valentin, 
2006b)  
 
2.6.8 Acoustic Shadowing 
 
Acoustic shadowing is the ultrasound phenomenon where a structure being examined 
reflects almost all the sound waves causing loss of the acoustic echo behind the 
structure and an anechoic “shadow” behind the structure. This commonly occurs with 
calcified structures such as pedunculated calcified fibroids, fibromas or dermoid cysts. 
 
2.6.9 Ascites 
 
Ascites is defined as free fluid in the peritoneal cavity, which is sufficient to be seen 
outside of the pouch of Douglas or to be seen anterior to the uterus. Free fluid in the 
peritoneal cavity is predominantly found in the pouch of Douglas due to gravity. A 
small amount of fluid, which is anechoic, or of low echogenicity is normal in a 
premenopausal woman. Ascites is a characteristic of intra-abdominal malignancies and 
is typical of ovarian cancers. The clinical detection of ascites to predict the presence of 
an ovarian malignancy has a positive predictive value (PPV) of 95% and a negative 
predictive value (NPV) of 64%. (Shen-Gunther, 2002) Only 17% of stage I and II cases 
have been found to have ascites and this is of smaller volume (all with <500mls) as 
opposed to 89% in stage III and IV malignancies (66% with >500mls). Fifty-two 
percent of borderline tumours had no clinical evidence of ascites. (Shen-Gunther, 2002) 
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2.6.10 Colour Doppler 
 
Doppler is a mode of ultrasound scanning that allows you to detect movement of fluid 
such as blood. Use of Doppler allows you to detect the velocity and direction of the 
blood flow within a vessel or within a tumour. Calculations such as the resistance index 
or the pulsatility index can be calculated. More often a tumour is subjectively described 
as avascular, poorly vascular or highly vascular. Alternatively a subjective score is 
given from ‘1’ to ‘4’ where ‘1’ is avascular or no colour seen in the lesion and ‘4’ is 
highly vascular. Highly vascular tumours have a greater risk of malignancy. (Timor-
Tritsch et al., 1998) 
 
2.6.11 Acoustic Streaming 
 
Acoustic streaming is use of Doppler power within a cyst to produce a steady current 
within the fluid which is driven by the absorption of the high amplitude acoustic 
oscillations (sound waves) from the probe. The fluid within the cyst is then seen to flow 
away from the source of the sound waves. Endometriomas, which contain thick fluid, 
may not demonstrate acoustic streaming. 
 
2.6.12 Qualitative classification 
 
Cysts or tumours can be classified as within 1 of the following 5 tumour groups.  
 
1. Unilocular tumours have a single cyst cavity with no or incomplete septae 
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and no papillary projections. The risk of malignancy has been round to be 0.3-1% with a 
benign odds ratio of 12.6 (95% CI: 1.61-99.10), P < 0.001. (Valentin, 2013; Granberg, 
1989; Gramellini, 2008) 
2. Unilocular-solid tumours are cysts with a single cavity but also contain at least 1 
papillary projection or a solid component. The risk of malignancy was found to be 
marginally higher at 2% by Granberg. (Granberg, 1989; Gramellini, 2008) 
3. Multilocular tumours are cysts with more than a single cyst cavity but no 
papillary projections or solid components. The malignancy risk has been found to rise 
slightly to 8-12.6% for these tumours but the odds ratio of it being benign was still 7.9 
(95% CI: 1.00-62.38), P < 0.05. (Granberg, 1989; Saunders, 2010) 
4. Multilocular-solid tumours are those with multiple cyst compartments and also 
at least 1 papillary projection or a solid component. The risk of malignancy for these 
tumours has been found to be high at 36% with Gramellini quoting an odds ratio of 
malignancy 6.4 (95% CI: 1.81-22.70), P < 0.001. (Granberg, 1989; Gramellini, 2008) 
5. Solid tumours, as classified by Timmerman, are tumours with more than 80% 
solid components. (Timmerman, 2000) The risk of malignancy has been found to be the 
highest (39%) when compared to the other tumour groups with Gramellini recording an 
odds ratio of 5.5 (95% CI: 1.48-20.92), P < 0.05.  (Granberg, 1989; Gramellini, 2008) 
 
2.6.13 Palpation and mobility 
 
Assessing mobility of the pelvic organs is often the part forgotten during an ultrasound 
scan assessment of the pelvis. Important information can be garnered from the location 
of pelvic organs in relation to other organs and to the pelvic sidewall but also their 
mobility in relation to the adjacent organs. 
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In a normal pelvis the organs slide over each other due to their visceral and parietal 
peritoneal coverings. Loss of this demonstrable mobility is usually due to adhesions and 
occasionally it may be due to the weight of the tumour preventing easy movement 
without causing discomfort to the patient. (Yazbek, 2007b; Guerriero, 2009) These 
adhesions may be due to previous pelvic infection such as pelvic inflammatory disease 
(PID) or appendicitis, endometriosis, previous operations, inflammatory conditions such 
as Crohn’s disease or due to a malignancy invading adjacent tissues. Knowledge of a 
patient’s medical history can give help determine which of the above conditions may 
have caused adhesions in a particular case. The type of adhesions and the location of the 
ovaries can give further information. Previous PID tends to cause filmy thin mobile 
adhesions while chronic inflammatory conditions or previous surgery tend to cause 
dense firm adhesions. Endometriosis adhesions tend to cause obliteration of the pouch 
of Douglas and tend to cause pathognomonic “kissing ovaries” which are ovaries 
adherent to the postero-lateral aspect of the uterus and that touch in the midline. 
(Ghezzi, 2005) Malignancies that invade surround tissues are often primary epithelial 
adenocarcinomas as opposed to non-epithelial or metastatic tumours. 
 
2.7 Current Modalities for Assessing Ovarian Cysts 
 
Many models have been developed to increase the accuracy of pre-operative diagnosis 
because non-invasive assessment of ovarian cysts is difficult.  
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2.7.1 Main Tumour Markers – CA125, HE4 
 
CA125 (cancer antigen 125, carcinoma antigen 125, or carbohydrate antigen 125) is a 
high molecular weight glycoprotein of the mucin family (also known as mucin 16), 
which is expressed on cell membrane surfaces and is also been found free in the serum.  
 
Serum measurements are used primarily for the diagnosis of ovarian cancers as well as 
monitoring of progression, response to treatment and recurrence. Increased tissue 
expression and raised serum levels have been found in epithelial ovarian cancers though 
this is often not the case in early stage and borderline tumours. 
 
Serum levels may also be raised in several benign conditions such as menstruation, 
endometriosis, recent ovulation, pelvic inflammatory disease, heart failure, liver 
cirrhosis, lung disease and recent surgery. (Miralles, 2003) It may also be raised in non-
ovarian malignancies, especially those with serosal involvement or spread. (Topalak, 
2002) 
 
An early study (1989) gave CA 125 a sensitivity of 86% and a specificity of 78% in the 
pre-operative identification of malignant ovarian tumours. (Mogensen, 1989) 
A systematic review of use of CA125 to diagnose ovarian malignancies including 17 
studies with 2374 women showed a pooled sensitivity of 80% (95% CI: 76%-82%) and 
the specificity was 75% (95% CI: 73%-77%). (Medeiros, 2009) 
 
Hirai et al looked at 146 women with stage IA ovarian cancers and found that women 
with normal CA125 levels (n=87, 60%) tended to have smaller tumours (<20 cm) with 
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less solid components (<50%) and had a slightly different histological type distribution 
when compared with those with elevated CA125 levels. (Hirai, 2011) Those with 
normal levels were more likely to have a clear cell adenocarcinoma with a unilocular 
cyst, which may have less than 50% solid components (n=12). Seventy percent of the 
clear cell tumours had normal CA 125 levels. Those with elevated CA125 levels tended 
to have unilocular cysts with 50% to 80% solid components (n=4, 100%) or an 
endometrioid adenocarcinoma in solid tumours (≥80% solid components). Mucinous 
adenocarcinoma tumours presenting as multilocular cysts with less than 50% solid 
components were found to have normal CA 125 levels (n=25) more often than elevated 
ones (n=19). Pattern recognition was found to be more accurate than CA 125 [93% 
(95% CI: 90.9% to 94.6%) versus 83% (95% CI = 80.3% to 85.6%)] (Van Calster, 
2007) 
 
Human epididymis protein 4 (HE4) is a four-disulfide core domain protein-2 
glycoprotein. The gene, found of chromosome 20 encodes a protein of the WFDC 
domain family and it may be involved in sperm maturation. 
 
The HE4 gene had highest expression in normal human trachea, salivary gland, lung, 
prostate, pituitary gland, thyroid, and kidney. (Galgano, 2006) It is also found in the 
glandular epithelium of the female genital tract though in low quantities and usually in 
tissue of Müllerian origin. (Hellström, 2002) Among tumours, gene expression was 
highest in ovarian serous and endometrioid carcinomas followed by lung 
adenocarcinomas, breast, renal, transitional cell, gastrointestinal, pancreatic carcinomas 
as well as mesotheliomas. (Galgano, 2006; Drapkin, 2005) 
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The median CA125 and HE4 serum concentrations were significantly higher in patients 
with epithelial ovarian cancers when compared with healthy females and those with 
benign tumours. (Montagnana, 2011; Sandri, 2013) 
 
Clinically HE4 can be used for diagnosis, response to treatment, progression and for 
surveillance for recurrence. A systematic review in 2013 with 13 studies found that HE4 
performed better when compared with CA125 for the diagnosis of ovarian cancer (ORs 
HE4 was 37.2 (95% CI: 19.0 to 72.7, adjusted for publication bias) versus CA 125 
which was 15.4 (95% CI: 10.4 to 22.8) ]. (Ferraro, 2013) A further systematic review of 
45 studies with 10,671 women and 3946 ovarian malignancies, the pooled sensitivity 
for the diagnosis of malignant tumours (borderline and invasive) was 78% (95% CI: 
77%-79%), and the specificity was 86% (95% CI: 85%-87%). (Macedo, 2014) 
 
2.7.2 Other Tumour Markers – LDH, α-FP, β-hCG, CEA, CA19-9 
 
Lactate dehydrogenase (LDH) is an enzyme involved in anaerobic glycolysis by 
converting pyruvate to lactate in low oxygen conditions. Serum levels are often raised 
in times of increased cell breakdown such as hemolysis but also in patients with a 
variety of cancer types. Very high levels are often found specifically in women with 
dysgerminomas. (Kawai, 1992; Konishi, 1986; Fujii, 1985) 
 
Human chorionic gonadotropin (hCG) is a glycoprotein produced by the embryonic 
syncytiotrophoblast or placenta. Apart from in normal or molar pregnancies, elevated 
levels of the β-chains (β-hCG) can be seen in women with choriocarcinomas, germ cell 
tumours, teratomas with elements of choriocarcinoma, and islet cell tumours.  
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Alpha-fetoprotein (α-FP) is the most abundant fetal plasma protein and is produced by 
the fetal yolk sac and liver. The levels of his glycoprotein fall dramatically after birth 
until it reaches adult levels by 1 year of life. Raised levels are found specifically in 
women with yolk sac tumours. (Kawai, 1992; Konishi, 1986) 
 
Kawai et al performed a study of 7 tumour markers (α-FP, CA125, CA19-9, tissue 
polypeptide antigen (TPA), carcinoembryonic antigen (CEA), human chorionic 
gonadotropin (hCG), and lactate dehydrogenase (LDH)) in 135 women with germ cell 
tumours. (Kawai, 1992) Dysgerminomas, particularly and yolk sac tumours, to a lesser 
extent had raised levels of LDH while hCG was raised in 11 of the 36 yolk sac tumours. 
The authors found raised α-FP in 100% of the yolk sac tumours (n=36), 61.9% of the 21 
immature teratomas and in 11.8% of the 17 dysgerminomas. The α-FP was normal in all 
the mature cystic teratomas with malignant transformation (n=7) and the mature cystic 
teratoma (n=31). (Kawai, 1992)  
 
Elevated serum levels of the antigens CA19-9 and CEA are predominantly found during 
the diagnosis of colon and biliopancreatic malignancies.  
 
Raised CA19-9 levels are also seen in teratomas. This includes benign mature cystic 
teratomas as well as malignant immature teratomas and mature cystic teratomas with 
malignant transformation. It therefore is unlikely to aid in the determination of whether 
the tumour is benign or malignant. TPA and CEA were not considered useful tumour 
markers for ovarian germ cell tumours. (Kawai, 1992; Dede, 2006)  
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Elevated CEA levels are found in 40.6% of epithelial adenocarcinomas and these are 
mostly in women with a mucinous adenocarcinoma. It is also found in women with 
pseudomyxoma peritonei, or a Krukenberg tumour (Konishi, 1986) 
 
2.7.3 Risk Malignancy Index (RMI) 
 
The most commonly used model for the diagnosis of ovarian cancer is the RMI (Jacobs, 
1990). This model calculates a score which is the product of the CA125 (U/ml) 
laboratory value, a score for menopausal status (1 if pre-menopausal and 3 if 
postmenopausal) and a greyscale ultrasound score of 0, 1 or 3 where 1 score is given 
each for bilaterality, ascites, multilocularity, solid areas and intra-abdominal metastases.  
 
Equation 2.7-1: RMI 
RMI = CA125 x M x U 
 
M = Menopausal status score 
U = Ultrasound score 
 
In the original study by Jacobs a score of >200 gave a sensitivity of 85% and a 
specificity of 97% for the diagnosis of ovarian cancer. A recent systematic review of 16 
studies assessing the diagnostic performance of RMI showed an overall sensitivity of 
78% (95% CI 71– 85%) and a specificity of 87% (95% CI 83–91%). (Geomini, 2009) 
 
The RMI is simple and widely used which is advantageous. The main disadvantage is 
that it includes a blood test for CA125, which adds to the cost, as well as to the 
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time taken to come to a conclusion. The other concern is that the diagnosis of an ovarian 
cancer may be delayed in up to 18-22% of cases due to normal CA125 values which 
occur particularly with early stage epithelial and as well as non-epithelial malignancies. 
(Bast, 1983; Rosen, 2005) 
 
The RCOG guidance uses the RMI for diagnostic evaluation of adnexal tumours.  The 
absolute value of the RMI and the serum level of CA125 are used to determine the 
management plan. For postmenopausal women with an RMI of < 25 are managed by a 
general gynaecologist. Those with a simple unilateral cyst of <5cm and who have a CA 
125 of < 30u/ml can be managed conservatively.  If the CA125 ≥ 30u/ml or the cyst is 
larger, has septations or solid areas then surgery is advised. For those with a RMI of 25 
– 250, management should be in a cancer unit. Those with a RMI >250 are offered 
management by gynaecological oncologists in a tertiary cancer centre. (RCOG, 2003)  
 
In premenopausal women, the RMI may still be used but its specificity falls 
significantly due to false positive results of the CA125 in this population. (Miralles, 
2003) 
 
2.7.4 The Risk of Malignancy Algorithm (ROMA) 
 
ROMA is the calculation using a patient’s menopausal status with the CA 125 (U/ml) 
and the HE4 laboratory values to estimate the risk of a patient having an ovarian 
malignancy. Ultrasound features do not influence this result, as it is purely laboratory 
based. 
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Moore et al found it to have a sensitivity of 94% and a specificity of 75% for the 
detection of epithelial ovarian malignancies. (Moore, 2011) The ROMA has shown 
better diagnostic performance in post-menopausal women (sensitivity of 82.5%) when 
compared to that in pre-menopausal women (sensitivity of 53.3%). (Sandri, 2013) 
 
The AUC for ROMA was significantly higher in comparison to CA125 alone (93.3% 
versus 90.3%, p=0.0018) in postmenopausal patients. Sub-analysis considering only 
patients with endometrioid disease showed the highest accuracy of HE4. (Sandri, 2013) 
 
The combination of HE4 and CA125 (ROMA) has not show better performance than 
HE4 alone. (Montagnana, 2011) 
 
2.7.5 Ultrasound scan Logistic Regression Models 
 
These are mathematical models using multivariate regression analyses of tumour 
characteristics, personal or family history or tumour markers to determine the risk of a 
tumour being malignant. 
 
In 1997 a model was created where 3 of the 10 recorded variables (age, papillary 
projection score [present=1, absent=0] and the time averaged maximum velocity 
[TAMXV]) were found to be useful.  (Tailor, 1997) The probability of malignancy was 
calculated using the following formula: 
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Equation 2.7-2: Tailor Logistic Regression Model 
 
1/(1 + e-z) 
 
Where z = 0.1273 x (Age) + 0.2794 x (TAMXV) + 4.4136 x (papillary projection score) 
– 14.2046. Using a cut-off value of 25%, they achieved the best sensitivity of 93.3% 
and sensitivity of 90.4%.  
 
The IOTA Group (International Ovarian Tumour Analysis) is a European multicentre 
group that started in 2000 and which devised a set of terms to define adnexal lesions. 
(Timmerman, 2000) There were almost 3000 patients assessed at 19 centres in 8 
countries.  
 
In 2005 the IOTA Group devised a logistic regression model based on those ultrasound 
factors and patient characteristics to determine the risk of a lesion being malignant. 
(Timmerman, 2005) The 12 factors are 1) personal history of ovarian cancer (yes=1, 
no=0), 2) current use of hormonal therapy (yes=1, no=0), 3) age of the patient (years), 
4) maximum diameter of lesion (mm), 5) presence of pain during the examination 
(yes=1, no=0), 6) presence of ascites (yes=1, no=0), 7) presence of blood flow within a 
solid papillary projection (yes=1, no=0), 8) purely solid tumour, 9) maximum diameter 
of the solid component (maximum of 50mm), 10) irregular internal cyst walls (yes=1, 
no=0), 11) presence of acoustic shadows (yes=1, no=0), 12) colour flow score (1-4 
where 1 is no flow and 4 is maximum flow). (Timmerman, 2005) 
 
LR1 used all 12 variables to determine the probability of malignancy. This was 
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calculated using the formula:   
 
Equation 2.7-3: IOTA Logistic Regression Model LR1 
 
y = 1/ (1 + exp[-z]) 
 
where z = – 6.7468 +1.5985 (1) – 0.9983 (2)+0.0326 (3) + 0.00841 (4) – 0.8577 (5) + 
1.5513 (6) + 1.1737 (7) + 0.9281 (8) + 0.0496 (9) + 1.1421 (10) – 2.3550 (11) + 0.4916 
(12) as described in the original IOTA study.The probability y is dichotomised at 0.1 to 
give a predictive diagnosis and this gave a sensitivity of 93% and a specificity of 76%. 
These tests were subsequently tested prospectively by the IOTA group. LR1 had a 
sensitivity of 92.2% and a specificity of 86.5% for external groups (997 women) and 
92.7% and 80.6% respectively for the internal groups (941 women). (Timmerman, 
2010a) 
 
Six variables were used for the calculation of LR2: 3) age of the patient (in years), 6) 
presence of ascites (yes=1, no=0), 7) presence of blood flow within a solid papillary 
projection (yes=1, no=0), 9) maximal diameter of the solid component (expressed in 
millimetres, but with no increase > 50 mm), 10) irregular internal cyst walls (yes=1, 
no=0), 11) presence of acoustic shadows (yes=1, no=0).  
 
The probability of malignancy was calculated using the formula: 
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Equation 2.7-4: IOTA Logistic Regression Model LR2 
 
y = 1/ (1 + exp[-z]) 
 
where z = - 5.3718 + 0.0354 (3) + 1.6159 (6) + 1.1768 (7) + 0.0697 (9) + 0.9586 (10) - 
2.9486 (11) as described in the original IOTA study.  
 
The probability y is dichotomised at 0.1 to give a predictive diagnosis, which had a 
sensitivity of 92% and a specificity of 75% for the diagnosis of ovarian cancer. When 
tested prospectively by the IOTA group LR2 had a sensitivity of 91.8% and a specificity 
of 85.6% for external groups (997 women) and 89.2% and 79.8% respectively for the 
internal groups (941 women). (Timmerman, 2010a) 
 
2.7.6 Other ultrasound scoring models 
 
In 2008 the IOTA collaboration proposed use of ‘Simple Rules’ to assess tumours. 
(Timmerman, 2008) The ‘Simple Rules’ are based on morphological features assessed 
on ultrasound scan. The ‘Simple Rules’ represent a simplified form of “pattern 
recognition” (see below) and allows systematic examination of tumour morphology to 
be performed in a structured way by less experienced operators.  
 
The ultrasound scan-based ‘Simple Rules’ use 10 rules to assess adnexal masses. There 
are five rules that predict malignancy (M-rules): (1) irregular solid tumour; (2) ascites; 
(3) at least four papillary structures; (4) irregular multilocular–solid tumour with a 
largest diameter of at least 100 mm; and (5) very high colour content on colour 
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Doppler examination (score 4). There are five rules to suggest that the tumour is benign 
(B-rules): (1) unilocular cyst; (2) presence of solid components where the largest solid 
component has a largest diameter of <7 mm; (3) acoustic shadows; (4) smooth 
multilocular tumour less than 100 mm in largest diameter; and (5) no detectable blood 
flow on Doppler examination (score 1). 
 
If one or more M-rules apply in the absence of a B-rule, the mass is classified as 
malignant. If one or more B-rules apply in the absence of an M-rule, the mass is 
classified as benign. If no rule applies or both M and B rules apply, the mass cannot be 
classified and an expert examiner is advised. (Table 2.7-1) 
 
These ten rules were applicable to 76% (937/1233) of all tumours in the study, where 
they resulted in a sensitivity of 93%, specificity of 90%, positive likelihood ratio (LR+) 
of 9.45 and negative likelihood ratio (LR−) of 0.08. Among those cysts that were not 
classifiable 82% were benign in the original study. When prospectively tested the rules 
were applicable in 76% (386/507) of the tumours, where they had a sensitivity of 95% 
(106/112), a specificity of 91% (249/274), LR+ of 10.37, and LR− of 0.06. The ‘Simple 
Rules’ were subsequently tested prospectively. (Timmerman, 2010b) The rules were 
applicable in 77% of the 1938 women with a sensitivity of 92% (95% confidence 
interval 89% to 94%) and specificity of 96% (94% to 97%). The ‘Simple Rules’ cannot 
be applied to all adnexal tumours, which makes this method less effective than pattern 
recognition. However, in cases where ‘Simple Rules’ are applicable, their diagnostic 
accuracy is very high. 
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Table 2.7-1: Simple Rules for the classification of benign and malignant tumours 
(Timmerman, 2008) 
 
Rules for predicting a malignant 
tumour (M-rules) 
Rules for predicting a benign tumour  
(B-rules) 
M1 Irregular solid tumour B1 Unilocular 
M2 Presence of ascites B2 
Presence of solid components: 
largest solid component < 7 mm 
M3 At least four papillary structures B3   Presence of acoustic shadows 
M4 
Irregular multilocular solid 
tumour with largest diameter ≥ 
100 mm 
B4 
Smooth multilocular tumour with 
largest diameter < 100 mm 
M5 
Very strong blood flow (colour 
score 4) 
B5 No blood flow (colour score 1) 
 
2.7.7 Artificial Neural Network Models 
 
Artificial neural networks (ANNs) are computer-based learning statistical algorithms 
which are modelled after the human central nervous system and which investigate non-
linear interactions between variables. ANNs consist of interconnected processing 
elements that respond simultaneously to various inputted data. (Shepherd, 1990; 
Haykin, 1994; Dayhoff, 2001) The ANN, through a learning process called training 
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acquires knowledge and interneuron connection strengths (known as synaptic weights) 
are used to store that knowledge. Information is exchanged between neurons in the form 
of numerical values via synaptic interconnections. ANNs have the ability to perform 
multifactorial analyses and to generalise. 
 
In a prospective study on 173 consecutive patients who were scheduled to undergo 
surgery for adnexal tumours, an ANN model using simple clinical and ultrasound-
derived criteria was tested to determine if the tumour was malignant. The prevalence of 
malignancy was 28.3% and the best ANN gave a sensitivity of 95.9%, specificity of 
93.5%, LR+ of 14.75 and LR- of 0.04. (Timmerman, 1999a) Another study tested ANN 
models on 67 women with adnexal masses, of which 22.4% were malignant. With an 
optimum cut-off value of 0.45, they reached a sensitivity of 100%, a specificity of 
98.1%, a LR+ of 52.6 and a LR- of 0. (Tailor, 1999) When prospectively tested, 
Tailor’s model did not perform similarly and only achieved a sensitivity of 43% (95% 
CI, 23 – 64), specificity of 92% (95% CI, 84 – 100), LR+ of 5.38 and LR- of 0.62. 
(Aslam, 2000b) 
 
2.7.8 Pattern Recognition 
 
While the differentiation between benign and malignant adnexal tumours is often 
difficult, he most accurate method thus far to assess the nature of an adnexal tumour is 
called ‘pattern recognition’. (Valentin, 1999a; Timmerman 1999b) This technique is 
based on systematic examination of the tumour’s morphological features on ultrasound 
scan. The ultrasound operator determines if the tumour is benign or malignant based on 
this examination finding and their experience.  
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Van Calster found pattern recognition to have an accuracy of [93% (95% CI: 90.9% to 
94.6%)]. (Van Calster, 2007) In a multicentre trial with 1066 women, pattern 
recognition was shown to predict malignancy in 97% (95% CI, 93–99%) (140/144) of 
the primary invasive malignant tumours. This included 93% of Stage 1 primary invasive 
tumours, 99% of Stage 2–4 primary invasive tumours, 93% (95% CI, 80–97%) (39/42) 
of the metastatic tumours and 60% (95% CI, 47–72%) (33/55) of the borderline 
tumours. (Sokalska, 2009) Yazbek et al found a similar accuracy with 68.6% (24/35) of 
the women with BOTs receiving the correct pre-operative diagnosis. (Yazbek, 2007a) 
 
The accuracy of pattern recognition has been shown to be affected by the degree of 
certainty or diagnostic confidence of the ultrasound operator with an accuracy varying 
between 75% and 98% for ‘certain’ or sure diagnoses. (Yazbek, 2010) Among 300 
patients with tumours, using the static ultrasound images, the greatest accuracy (91.7 %, 
95% CI 88 – 94.3) and the highest level of interobserver agreement was seen amongst 
the ultrasound operators with the greatest experience. (Timmerman 1999b) Its 
usefulness is therefore related to the experience and confidence of the operator. 
 
While this method is the most accurate, it can only be used by highly skilled and 
experienced ultrasound operators, which are not widely available. 
 
2.7.9 Magnetic Resonance Imaging (MRI) / Computed Tomography (CT) 
Scans 
 
When basic grey scale ultrasounds scans are unable to determine the risk of 
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malignancy of a tumour, second line imaging tests are utilised. A meta-analysis of 9 
studies evaluated the value of a second radiological test for an indeterminate adnexal 
mass detected on basic gray-scale ultrasound. (Kinkel, 2005)  
 
The prevalence of ovarian cancer was 8.75% in the premenopausal population and 
32.40% the postmenopausal population with an ovarian mass. After the initial gray-
scale ultrasound scan assessment, the positive predictive value (PPV) in pre-menopausal 
women changed from 8.75% to 25% and in postmenopausal women from 32.4% to 
63% for indeterminate results. Alternatively it fell to 2% (premenopausal women) and 
7% (postmenopausal women) for benign results.  
 
After performing the second test for those indeterminate tumours, the PPV increased 
more after MRI with IV contrast administration (premenopausal women, 80%; 
postmenopausal women, 95%) or with non-enhanced MRI (premenopausal women, 
70%; postmenopausal women, 92%) than it did after combined gray-scale and Doppler 
US (premenopausal women, 30%; postmenopausal women, 69%) or after CT scan 
(premenopausal women, 38%; postmenopausal women, 76%) (P < 0.001). It therefore 
determined that contrast-enhanced MRI provided the highest positive predictive value 
for the diagnosis of ovarian cancer when compared with CT, ultrasound scan with 
Doppler, or MRI without contrast administration. 
 
Both Doppler ultrasound and MRI are highly sensitive for identifying malignant lesions 
(ultrasound 100%, MRI 96.6%), while the specificity of both tests vary (ultrasound 
39.5%, and MRI 83.7% in 1 prospective study). (Sohaib, 2005; Iyer, 2010) 
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MRI criteria for the diagnosis of malignancy are a large solid component, wall thickness 
greater than 3 mm, septums greater than 3 mm thick with or without nodularity 
(papillary projections), and necrosis. Additional features include evidence of invasion 
into other pelvic organs or the sidewalls, evidence of peritoneal or omental disease, 
presence of ascites and lymphadenopathy. Borderline tumours as with ultrasound are 
more difficult to recognise and have no specific criteria. 
 
Amongst the benign tumours, MRIs are quite good at recognising the old blood in 
endometriomas and the fat in dermoid cysts. MRI also has some advantages when 
ultrasound scans may reach their limits such as being able to examine all parts of a cyst 
even when very large and even when the patient’s habitus or pathology such as fibroids 
impedes the ultrasound waves. 
 
CT scans find similar features of ovarian cancers as MRIs do and the tumours often 
demonstrate contrast uptake. 
 
Despite its lesser performance in the diagnosis of ovarian cancer, CT scans are currently 
the preferred technique for the evaluation and staging of tumours pre-treatment. CT 
scans are also used to predict the likelihood of successful surgical clearance. 
Diaphragmatic and the large bowel involvement are noted to be the most predictable 
determinant of suboptimal cytoreduction. Other features are involvement of the sidewall 
with hydroureter / hydronephrosis, omental disease involving the spleen, stomach or 
lesser sac and suprarenal paraaortic lymphadenopathy. (Iyer, 2010) 
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2.8 Current Management Options for Ovarian Cysts 
 
2.8.1 Conservative management with or without ultrasound surveillance 
 
The likelihood of an asymptomatic benign cysts requiring surgical intervention is very 
low. In a study of 134 postmenopausal women with asymptomatic adnexal cysts judged 
to be benign on ultrasound scan, only 9% required surgery. (Valentin, 2002) 
Histological diagnosis confirmed benign tumours in all surgical cases. (Valentin, 2002) 
There was cyst regression in 54% of women and the remaining cysts were unchanged 
during follow up. In large cohort studies of 31,834 - 15,106 women in whom 2,763- 
6,807 had cysts, 63-69% of these had complete resolution of their cysts. (Modesitt, 
2003; Pavlik, 2013) Simple unilocular cysts had a larger resolution rate (69%) when 
compared with more ‘complex’ appearing cysts (55%). (Modesitt, 2003; Bailey, 1998) 
Ovarian cysts can therefore resolve spontaneously and not all women need surgical 
management. Overall this data suggests that expectant management of adnexal cysts, 
which appear benign on ultrasound scan, is safe and the risk of subsequent surgical 
intervention is low.  
 
Despite this information, the knowledge of the presence of a cyst still produces anxiety 
and prompts further investigations and blood tests and subsequent removal even when 
asymptomatic. 
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The RCOG recommends conservative management for all simple, anechoic, unilocular 
cysts, which are <50mm in diameter in postmenopausal women. Cysts that are less that 
20mm do not need follow up with ultrasound scan surveillance. (RCOG, 2003) In 
premenopausal women ‘simple’ cysts < 50mm do not require any follow up according 
to the RCOG, as these are usually physiological and resolve in the subsequent menstrual 
cycles. (RCOG, 2011)  
 
2.8.2 Laparoscopic surgery 
 
For women who do not meet the RCOG criteria for conservative management are 
offered surgical management. When women are offered surgical management, it is 
recommended that this should be via a laparoscopic route where possible due to shorter 
hospital stays, lower morbidity and faster recovery. (Hilger, 2006; Mais, 1995) This 
applies to premenopausal women with cysts between 50mm and 70mm and 
postmenopausal women with intermediate risk. These are women for whom the risk of 
malignancy is considered to be moderate, the disease is considered to be early stage or 
for whom fertility sparing surgery is being considered. 
 
2.8.3 Fertility sparing surgery 
 
Younger women who have not completed their families and particularly those with 
early stage (stage 1) or low-grade tumours may wish to have fertility sparing surgery. 
The rate of tumour recurrence following fertility sparing surgery and radical surgery in 
early-stage and low-grade tumours are 9% and 11.6%, respectively. (Ayhan, 2003) 
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Overall survival rates and disease-free intervals are not dissimilar.  
 
 
2.8.4 Staging Laparotomy 
 
The best survival rates for women with ovarian cancer are achieved when treatment is 
organised and carried out by gynaecological oncologists working in cancer centres 
because the prognosis is better when they have optimal debulking. (Im, 2005; Junor, 
1999; Curtin, 1997) 
 
Favourable independent prognostic factors for 5-year overall survival for ovarian cancer 
include younger age, good performance status, histological types other than mucinous 
or clear cell, well-differentiated histological tumor grade, early stage at diagnosis, 
smaller tumor volume before surgical debulking, no residual tumor after debulking, and 
absence of ascites. (Pomel, 2007; Pereira, 2016) 
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Table 2.8-1: International Federation of Gynecology and Obstetrics (FIGO) staging of 
primary ovarian carcinoma (Shepherd, 1989) 
Stage Tumour characteristics  
I Growth limited to the ovaries 
Ia Growth limited to one ovary, no ascites present containing malignant cells, no 
tumour on the external surface, capsule intact 
Ib Growth limited to both ovaries, no ascites present containing malignant cells, 
no tumour on the external surfaces, capsules intact 
Ic Tumour either stage Ia or Ib but tumour found on surface of one or both ovaries 
or capsule(s) ruptured or ascites present containing malignant cells or 
peritoneal washings positive 
II Growth involving one or both ovaries with pelvic extension 
IIa Extension or metastases to the uterus or fallopian tubes 
IIb Extension to other pelvic tissues 
IIc Tumour either stage IIa or IIb but tumour found on surface of one or both 
ovaries or capsule(s) ruptured or ascites present containing malignant cells or 
peritoneal washings positive 
III Tumour involving one or both ovaries with histologically confirmed 
peritoneal implants outside the pelvis and / or positive retroperitoneal or 
inguinal nodes; superficial liver metastases; tumour limited to the true 
pelvis but with histologically confirmed malignant extension to small bowel 
or omentum 
IIIa  Tumour grossly limited to the true pelvis with negative nodes but with 
histologically confirmed microscopic seeding of abdominal peritoneal surfaces 
or extension to small bowel or mesentery 
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IIIb Tumour involving one or both ovaries with histologically confirmed implants 
of metastasis to abdominal peritoneal surfaces (lesions ≤2 cm), negative nodes 
IIIc Tumour involving one or both ovaries with histologically confirmed 
extrapelvic peritoneal metastasis (lesions >2 cm) or positive retroperitoneal or 
inguinal nodes 
IV Growth involving one or both ovaries with distant metastases, positive 
cytologic findings if pleural effusion is present; parenchymal liver 
metastases 
Permission to reproduce this data has been granted by John Wiley and Sons.
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Part III – Performing a Meta-Analysis 
 
A meta-analysis is a systematic quantitative approach to identify, appraise, synthesize 
and if suitable to combine and summate results of previous research to make 
conclusions about the entire body of research on a particular topic or to answer a 
particular question. It is a statistical process bringing together individual sections of 
evidence, which is similar enough to be combined. There are a number of pitfalls to be 
avoided to prevent the results of the meta-analysis from being biased and causing 
publication of misinformation. There are a number of important steps to be followed, 
which will be detailed below.  
 
The first step is to define the research question to be answered. A protocol should be 
written with objectives, patient characteristics, interventions, outcomes, index test 
investigated, reference test used, inclusion and exclusion criteria, study types, time flow 
and length of follow up. (Egger, 1997) 
 
The next step is to identify potential studies. Useful online databases are MEDLINE, 
which has published articles, EMBASE, which also includes conference abstracts and 
Cochrane. Cochrane includes the Cochrane Database of Systematic Reviews (CDSR), 
the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane 
Methodology register (CMR) and the Database of Abstracts of Effects (DARE). Other 
strategies for finding useful studies include searching through bibliographies of articles 
and especially of review articles as well as using online databases such as Cancer 
Research UK or trial registration websites to find studies with an International Standard 
Randomised Controlled Trial Number (ISRCTN). Including unpublished studies helps 
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reduce publication bias. Publication bias is the effect caused by the tendency for 
researchers to publish only positive results. This causes the overall effect to appear 
positive.  
 
Once the potential studies have been identified, those of most use must be chosen. 
These are usually those of highest quality and those that actually answer the question. 
Well-conducted double-blinded randomized controlled trials are often those of highest 
quality but these may not be available depending on the research question. Depending 
on the type of studies to be included, there are several tools to aid in the process and to 
specifically assess the quality of the studies.  
 
The Quality of Reporting of Meta-analyses (QUOROM) guidelines gives guidance on 
standards to improve the quality of reporting of meta-analyses of clinical randomized 
controlled trials (RCTs). (Moher, 1999) This includes 21 headings and subheadings for 
the abstract, introduction, methods, results and discussion on what should be reported 
on objectives, data searches, study selection criteria and characteristics, assessment of 
validity, data extraction, and quantitative data synthesis. 
 
CONSORT statement includes a 25-item checklist and a flow diagram and it provides 
instructions for reporting all randomized controlled trials. It is mainly for individually 
randomized, two group and parallel trials whereas other types require further 
information.  (Shultz, 2010) 
 
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
is a 27-point checklist for conducting and reporting a systematic review or a meta-
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analysis with a 4-step flow diagram for the selection of studies (identification, 
screening, eligibility and included). (Moher, 2009; Liberati, 2009) It is used to maintain 
the standards for reporting of RCTs and other types of studies such as intervention 
evaluation and has mostly superseded the QUOROM statement.  
 
The Institute of Medicine (IOM) has also issued guidance on recommended standards 
for systematic reviews of the comparative effectiveness of medical or surgical 
interventions. (Eden, 2011) They aim to ensure the systematic reviews are objective, 
transparent and produce high quality, scientifically valid results which can be used. 
 
Newcastle-Ottawa Scale is reported to be an easy, convenient tool for quality 
assessment of non-randomized studies such as case-controlled and cohort studies. 
(Wells, 2000; Wells, 2003; Wells, 2013; Hartling, 2012)  
 
Meta-analysis of Observational Studies in Epidemiology (MOOSE) describes 
recommendations for the conduct and reporting of meta-analyses in observational 
studies. (Stroup, 2000) A checklist has been created to aid with every step of the meta-
analysis process. This is the checklist that was used for our meta-analysis, as it was the 
checklist most appropriate for the type of studies done on our research question. 
 
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) 
statement are a list of recommendations developed on what should be included in an 
accurate and complete report of an observational study including cohort, case-control, 
and cross-sectional studies. (von Elm, 2007; V, 2007) The aim is for clarity, 
completeness, and transparency of the reporting, which will allow readers to appreciate 
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the true value and applicability of the results.  
 
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) is a modified 
assessment tool to individually assess each potential study for a meta-analysis of 
diagnostic accuracy. (Schueler, 2012; Whiting, 2011) This tool has 4 main domains on 
patient selection, the index test, the reference standard and flow of patients through the 
study alongside timing of the index test and reference standard.  
 
Diagnostic studies should have Standards for the Reporting of Diagnostic accuracy 
studies statement (STARD). (Bossuyt, 2003) Included studies should ideally have many 
if not all the standards and descriptions within the publication. 
 
When choosing the studies to include, those with high risk of bias should be noted as 
they can affect the final result. Some more common types of biases to scrutinise studies 
for are selection, exclusion, publication and verification bias. Selection bias occurs 
statistically when there is an error in choosing participants for the study. Sample 
selection bias is due to non-random or non-consecutive sampling of the population. This 
may be due to volunteering or self-selection when patients choose to be in the study or 
choose which group they wish to be in. (Hernán, 2004) Informative censoring occurs 
when there is a differential loss to follow up. This must be noted and accounted for 
when doing the statistical tests. Exclusion bias occurs when different criteria are used to 
select cases and controls.  
 
Publication bias is seen when studies are evaluating a medical or surgical treatment, as 
negative results are less likely to be published and would then affect the final meta-
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analysis. Funnel plots of reported sensitivities and specificities against study size can be 
used to evaluate this is such cases. It is dependant on the assumption that the large 
studies will be near the average and the small studies will be fairly equally dispersed 
around the larger studies. Therefore a symmetrical plot would be reassuring, whereas an 
asymmetric plot would suggest the presence of publication bias. (Sterne, 2011) 
Sourcing unpublished studies would help in reducing this type of bias. Verification bias 
is seen in a study when a new test is being investigated and the result of this new test 
determines if the reference test is performed (the gold standard test). Such verification 
bias can be adjusted for by using an alternative second reference test though it is likely 
to be of inferior quality and it may define the outcome differently to the original 
reference test. (de Groot, 2011) These 2 tests must not be considered equivalent though 
and this must also be adjusted for to avoid differential-verification bias. 
 
It is best if 2 independent authors do data extraction, as this helps to avoid errors. A 
standardised proforma is useful to ensure the correct standards are checked and that the 
all the necessary information is documented. Usual data extracted include sensitivity, 
specificity, prevalence of the disease in the study population, patient characteristics, 
confidence intervals, odds ratios, relative risks, standard errors and data for creation of 
the 2 x 2 contingency tables. 
Study methods must be scrutinised to ensure the study was carried out in a way that is 
suitable to allow it to be included in the meta-analysis and appropriate attempts were 
made to reduce bias. Outcome measures must be standardised if not already consistent 
between studies.  
 
A forest plot is a graphical display of all the studies included in a meta-analysis or 
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systematic review. It demonstrates the relative strength of each study, the range of its 
confidence intervals and its relation to the average or the line of no effect. For accuracy 
studies, the line would represent the pooled average sensitivity or specificity and each 
study will lie on either side or on the line itself. This range of difference can be 
calculated and this value indicates statistically how heterogeneous the studies’ results 
are. For studies assessing a treatment the vertical is called the line of no effect and any 
study whose line crosses this line of no effect suggests that at that confidence interval, 
the effect is no different from no effect. If the pooled data lies on the line then there is 
no evidence of effect but if it lies completely to one side or the other, it would 
demonstrate either a positive or a negative effect. (Sedgwick, 2012b)  
 
Statistical homogeneity exists when the relative risks of the studies are similar in size 
and when the variation between them is no more than expected when taking samples 
from the same population—that is, there was minimal variation between them. If this is 
not the case then there is statistical heterogeneity present. (Sedgwick, 2012a) Cochran’s 
Q Test is a statistical test of heterogeneity and any variation is assumed to be due to 
differences between studies when sampling from the same population, or alternatively 
minor differences in the study methodologies. Higgins I2 statistic is an alternative test 
and the lower the I2 test result, the greater the homogeneity of the study results. If 
>50%, significant heterogeneity is considered to be present. (Sedgwick, 2012a) If the 
studies are heterogeneous then efforts must be made to examine and assess why that is 
the case. 
 
Overall, when a meta-analysis is conducted well with use of the appropriate checklist 
and the included studies are of equally high quality the resulting data should be 
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usefulness to authors, reviewers, editors, readers, clinicians and decision- and policy-
makers. 
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Part IV – Performing a Randomized Controlled Trial 
 
A randomized controlled trial (RCT) is a type of clinical trial, which is considered the 
way to find the best evidence for relationship between cause and effect and to determine 
the cost effectiveness of the treatment. 
 
There are many important features of an RCT that improve its validity compared to 
other types of trials. Randomization of trial participants aims to ensure that there are no 
systematic differences whether known or unknown, between the intervention group and 
the control group (or the group with an alternative intervention) that can affect the 
outcome. When participants are randomized between 2 groups, it is assumed that the 2 
groups are similar and therefore any difference in outcome is due to the intervention. 
Randomization also avoids selection bias, which may be due to self-selection of 
selection based on symptoms as this can affect outcomes in the groups. 
 
Blinding is a trial method when either the participants or the trial operator is unaware of 
which group the participant is in. It is called single blinding when only the participant is 
unaware and double blinding when both participant and the trial operator is unaware. 
The benefit of blinding the participant is the avoidance of any impact on reporting of 
beneficial or side effects because of the knowledge of group allocation and pre-
determined perceived views of the groups. Meanwhile the benefit of blinding the trial 
operator is avoiding the affect that knowledge of the participant’s allocation can have on 
reporting of complications and outcomes. Blinding avoids bias but it is not always 
feasible or appropriate. 
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During the conduct of the trial, all intervention groups should be treated identically 
except for the experimental treatment, as this will ensure that any differences in 
outcome are due to the experimental treatment and not due to any other differences. 
 
Patients are normally analysed on an intention to treat basis. This is analysis based on 
allocation and not based on final intervention received, irrespective of whether they 
experienced the intended or the alternative intervention. 
 
The analysis is focused on estimating the size of the difference in predefined outcomes 
between the intervention groups. 
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Part V – Principles of Ethical Assessment and Approval 
 
The main purpose of an ethical committee’s review and approval is to safeguard 
researchers, participants and future research. Ethical committees base their assessment 
and decisions on the World Medical Association's Declaration of Helsinki. (World 
Medical Association, 2013) This declaration discusses the duties of a doctor to their 
patients and that the clinician’s actions should always be in the best interest of the 
patients as stated in the World Medical Association's Declaration of Geneva and 
International code of medical ethics. (World Medical Association, 1948; World Medical 
Association, 1949) The declaration also states that medical progress needs research, 
which must include patients but that the pursuit of this knowledge and progress must 
never override the rights of the patients and the conduct of the study must always be 
morally justifiable. 
 
A favourable ethical opinion allows researchers to conduct their study and publish the 
results without repeatedly having to defend the ethics of the study. During the ethical 
review process, questions may be raised that the researchers may not have considered 
and this can therefore facilitate, promote and champion ethical research. By obtaining 
ethical approval from an impartial committee that has robust systems in place, all ensure 
that any research conducted maintains a high ethical standard, is of sound integrity and 
is in accordance with good research governance and legal requirements. 
 
Clinicians have a duty to consider the ethical aspects of their study design and to ensure 
the health, dignity, safety, rights and wellbeing of all participants are maintained. There 
are many aspects to this, which will be detailed below. 
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The public must also be reassured that their interests are being guarded as this will help 
avoid potential participants declining to take part in future studies due to fear of being 
exploited. This therefore protects future research.  
 
Factors considered in an application for ethical approval are many.  
 
How much any new treatment or test deviate from the current, normal, accepted, local 
or national guidance or clinical practice will be noted. RCTs have raised ethical issues 
about patients sacrificing themselves for the good of future patients and future society. 
The concern about this is reduced if the trial employs the principle of clinical equipoise, 
which is the belief that there must be no decisive evidence that either arm of the trial is 
superior to the next. This allows the trial to begin with a null hypothesis. (Edwards, 
1998) This suggests that placebo-controlled trials are ethically wrong unless doing 
nothing is an equitable safe option. 
 
The evidence behind the research question must be presented to ensure that such a study 
is needed and that the question has not already been adequately answered by previous 
research. The scientific merit or value of the study will be assessed. The study should be 
designed so that it can answer the research question and address the study aim. 
 
The method of recruitment is examined to ensure there is no evidence of planned 
coercing. It must be clear how potential participants will be identified, approached and 
recruited and who are the persons performing this role. Any advertising or use of 
posters must be factually correct, restrained in tone and must not overemphasize any 
 
107 
inducements or payments for participating. Suitability of recruitment of vulnerable 
persons will be investigated to decide if they should be excluded. Non-English speakers 
should be offered professional translation services to aid communication rather than 
excluding them or using a relative. 
 
The potential risks (likelihood of occurrence and severity) and the burden (for example 
blood tests, number of hospital visits) will be weighed against the potential benefits to 
the participant (new treatment or increased surveillance). The importance of the 
objective outweighs the potential risks and burden to the participant. Potential benefits 
to society, healthcare and future patients will be noted. 
 
The planned procedure for gaining informed consent will be considered. This will 
scrutinise use of an information leaflet and the consent form itself. Information must be 
given using lay terms and making sure potential participants are aware that it is 
completely voluntary, does not affect their future medical care and that they can opt out 
at any time without jeopardising their treatment. Potential participants should be made 
aware of the name and contact details of the point person, the possible risks and the 
complaint procedure. 
 
Patients must be assured of confidentiality in care of their data. Persons with access to 
participants’ data should be kept to a minimum and their details should be anonymized 
and kept in a safe place such as a locked drawer or on password protected electronic 
storage. Participants’ general practitioners must be informed of the patient’s 
participation in a study, as they are often a patient’s first port of call for ailments. This 
information would therefore better be able to help the GP treat or give guidance to their 
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patient.  
 
All potential conflicts of interest should be declared as if a researcher stands to gain 
financially or otherwise, it could bias their conduct of the study. Source of funding 
should also be declared as if the funding source should also be unbiased. 
 
Peer review of the study protocol outside of the research group is encouraged including 
laypersons or patients who could be potential participants as they can provide insight to 
enhance and improve the protocol. Insurance/indemnity arrangements must be made 
clear so that should any participant be harmed, it is clear what arrangements are in place 
for them. Authors must ensure honest reporting of results. 
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Part VI – Aim 
 
Aims of this thesis and the studies are: 
 
• To evaluate current ultrasound tools used in the screening or the diagnosis of ovarian 
tumours. 
• To assess the accuracy of the IOTA (International Ovarian Tumour Analysis) Logistic 
Regression models LR1 and LR2 at diagnosing ovarian cancer in the hands of a level II 
ultrasound operator. 
• To evaluate the use of the IOTA (International Ovarian Tumour Analysis) Logistic 
Regression models LR1 and LR2 in an outpatient clinical setting including those with 
expectant management. 
• To assess the accuracy of the IOTA (International Ovarian Tumour Analysis) Simple 
Rules in the hands of a level II ultrasound operator to diagnose ovarian cancer. 
• To perform a meta-analysis to evaluate the overall accuracy of the IOTA 
(International Ovarian Tumour Analysis) Simple Rules in the diagnosis of ovarian 
cancer from published studies and available data. 
• To evaluate the use of the IOTA (International Ovarian Tumour Analysis) Simple 
Rules in an outpatient clinical setting including those with expectant management. 
• To test the hypothesis that use of the simple rules can reduce operative rates for 
women with benign disease when compared with the current Royal College of 
Obstetricians and Gynaecologists (RCOG) guidance with the use of RMI with a 
randomized controlled trial. 
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Part VII – Studies – Materials and Methods 
 
7.1 Setting and Timing 
 
All studies were conducted in the Gynaecological Diagnostic Outpatient Treatment Unit 
(GDOTU), which is the general gynaecology clinic at University College Hospital in 
London. Studies were conducted between May 2009 and May 2014. 
 
7.2 Patient population 
 
The University College Hospital, which is situated in the north of central London, is a 
teaching hospital and tertiary referral centre which primarily provides care for the 
people of Camden and Islington. It forms part of the University College London 
Hospitals NHS Foundation Trust (UCLH). The hospital was founded as the 'North 
London Hospital' in 1834. The name changed to UCH in 1837 and after further 
collaborations and incorporations of other hospitals, the trust gained foundation status in 
2004.  
 
In 2012/13 the trust had an annual turnover of £840 million with contracts with over 70 
clinical commissioning bodies. There were 870,000 outpatients, 120,000 A&E 
admissions and 150,000 inpatients that year. There are 665 in-patient beds and 12 
operating theatres. 
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The department of Women’s Health offers a range of specialist clinics including the 
GDOTU a gynaecological scanning clinic, a walk-in early pregnancy clinic, ambulatory 
gynaecology, urogynaecology, colposcopy, menopause, psychosexual health, 
gynaecological oncology, paediatric gynaecology, a specialist endometriosis centre, an 
assisted conception unit and a specialist clinic for African women.  
 
Patients recruited to the studies in this thesis were all seen in the gynaecological 
scanning clinic and were referred by their general practitioner (GP) or came via A&E, 
other hospital clinics or they were tertiary referrals from other hospitals requesting a 
second opinion. 
 
7.3 Ultrasound scans 
 
Ultrasound scans were performed on a General Electric Healthcare Voluson E8 
ultrasound scan machine. (© 2012 General Electric Company, Milwaukee, WI, USA) 
Transvaginal scans were done using a 4 – 9 MHz Wide Band Endocavity Volume 
Transducer with three dimensional capability while the transabdominal scans were done 
with the Wide Band Convex Transducer of 2 – 8 MHz. Transvaginal scans were 
performed in lithotomy using a standardised protocol and transabdominal scans were 
performed with the patient supine. Transabdominal scans were performed when the 
mass in question could not be seen in its entirety using the transvaginal probe. The 
adnexae were always examined after the uterus (if present) and in both the longitudinal 
and transverse planes.  
 
During ultrasound of the adnexa, detailed systematic examination and 
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documentation of its morphological features was conducted including details relevant to 
the RMI, the IOTA LR1/LR2 and the simple rules. Examination by an expert level III 
ultrasound operator performing pattern recognition was executed subsequently.  
 
7.4 Ultrasound Operators 
 
Gynaecologists who had a special interest in gynaecological ultrasonography, who had 
more than 10 years’ experience in gynaecological ultrasonography, who accepted 
tertiary referrals, who participated in multidisciplinary meeting, who audited their 
practice, who were recognised by the RCOG for teaching and training in gynaecological 
ultrasonography and who had been involved in research in this field, did level III 
ultrasonography in keeping with the guidelines of the European Federation of Societies 
for Ultrasonography in Medicine and Biology. (EFSUMB, 2006) 
 
Ultrasound operators with at least one year of experience, who were trained in 
gynaecological ultrasonography and who routinely assessed patients with adnexal 
tumours, did level II ultrasonography. I did all primary ultrasound scans except for the 
2nd half of the RCT. 
 
7.5 Serum CA 125 measurements 
 
Women who had a RMI assessment in any of the studies had a blood sample drawn for 
a CA 125 serum measurement. 
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The laboratory used the Roche Cobas Analyser Generation II (Cobas® CA 125 II, 
Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim) with a 
measuring range of 0.600-5000 kU/L (defined by the lower detection limit and the 
maximum of the master curve) with a further capability to dilute 5 x to measure up to a 
level of 25,000 kU/L. 
 
7.6 Randomization 
 
In the randomized controlled study, randomization took place in the GDOTU. 
Consecutively numbered, opaque, sealed envelopes were prepared at UCH by a nurse 
not involved in recruitment and the blocked randomization list was created using a 
computer-generated randomization sequence in Stata 12.1 (Stata Corp., College Station, 
Texas, USA) conducted by a hospital statistician and using varying block sizes. The 
envelopes were then kept securely in a box in a locked cabinet in a key-coded 
consultants' office. The nursing staff distributed the envelopes to the clinicians who 
were responsible for randomization and recruitment. 
 
All eligible patients were given an information leaflet, in addition to, as much time they 
needed to make a decision. After questions were answered, those who wished to 
participate gave written informed consent. Once this was done, the next envelope was 
withdrawn and given to the researcher. Once opened, the patient was assessed according 
to the ultrasound assessment protocol within the envelope. 
 
7.7 Histopathology and Staging 
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A trust histopathologist examined all tissue and fluid samples retrieved at surgery. 
Tumours were classified according to the World Health Organisation (WHO) guidelines 
and ovarian malignancies were staged according to the classification of the International 
Federation of Gynaecology and Obstetrics (FIGO). (Serov, 1973; Shepherd, 1989) 
 
7.8 Statistical Analysis 
 
Microsoft Excel (Redmond, Washington, USA) was used to establish the databases and 
for data entry. Statistical analyses were carried out using the software package Stata 
11.1 ® to 14.0 ® (Stata Corp., College Station, TX, USA). 
 
The required sample size was calculated before each study. A validation dataset should 
contain at least 100 events (borderline / malignant tumours) according to Harrell (2001) 
or it should satisfy the “rule of 10” according to Machin and Campbell (2005). These 
criteria were met for the validation studies. For the diagnostic accuracy studies, 
sensitivity, specificity, positive predictive value, negative predictive value, positive 
likelihood ratio (LR +ve), negative likelihood ratio (LR –ve) and the area under the 
receiver operating characteristic (ROC) curve (AUC) were calculated. The Chi-squared 
(c2) method was used to compare difference in proportions between original data and 
current studies. A p value < 0.05 was considered statistically significant and exact 95% 
confidence intervals were calculated.  
 
For the meta-analysis the sensitivity, specificity and accuracy of simple rules and 
pattern recognition were compared separately using McNemar’s test for 
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paired binary outcomes. Random effects meta-analysis was used to calculate univariate 
pooled estimates of sensitivity and specificity for the IOTA simple rules tool. 
(DerSimonian, 1986)A bivariate approach was also investigated to calculate these 
values. (Harbord, 2007) Forest plots were constructed to summarise the results, and 
heterogeneity was quantified using the I2 statistic. (Thompson, 2002a) Meta-regression 
was used to investigate any heterogeneity present in the results. (Thompson, 2002b) 
 
For the randomized controlled trial the data was collected on a predesigned proforma, 
which is then filed. This is transferred to a Microsoft Excel database in preparation for 
analysis. A Chi-squared test (χ²) test or Fisher’s exact test was used to assess significant 
differences in the intervention rates between the two management protocols. Analysis 
was on an intention-to-treat basis of all patients who fit the inclusion criteria.  
 
7.9 Ethical Committee Approval 
 
As morphological analysis of the tumours using IOTA characteristics is performed 
routinely in the Department and no therapeutic decisions were based on the results of 
the IOTA and simple rules models, the UCH local Research and Development 
Department advised that the validation studies did not require formal ethical assessment 
and approval.  
 
The North London Research Ethical Committee 2 ethics committee approved the 
randomized controlled trial (10/H0724/48) as well as the research and development 
committee at UCH and it was entered in the registry of randomized trials 
(ISRCTN89034131). 
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Part VIII – Studies – Introduction, Methods and Results 
8.1 Study 1 - A prospective validation of the IOTA Logistic Regression 
Models (LR1 and LR2) in comparison to Subjective Pattern 
Recognition for the diagnosis of ovarian cancer when utilised by 
an average ultrasound operator assessing adnexal lesions 
 
8.1.1 Introduction 
 
Preoperative differentiation between benign and malignant ovarian tumours is difficult. 
A large number of scoring systems and diagnostic models have been developed in 
recent years in order to facilitate the detection of ovarian cancer on ultrasound. (Jacobs, 
1990; Tailor, 1997; Alcazar, 1998) The majority of these tests have been developed 
based on retrospective analysis of small datasets and their accuracy tends to be poor 
when evaluated prospectively. (Aslam, 2000; Valentin, 2001) These findings indicate 
further work is required to improve pre-operative diagnosis of ovarian cancer by 
ultrasound. 
 
The main strengths of the IOTA collaboration are a uniform approach to ultrasound 
assessment of adnexal lesions, a large dataset and the use of robust statistical methods. 
The main aim of the collaboration was to design models for the diagnosis of ovarian 
cancer, which could be used in routine clinical practice by non-expert operators of 
average skill and experience. Sonographers who are usually classified as Level II 
ultrasound operators carry out the majority of routine gynaecological ultrasound 
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examinations worldwide. (EFSUMB, 2006; EFSUMB, 2010; Salvesen, 2011) Level II 
examiners tend to describe morphological appearances of adenxal tumours in detail, but 
unlike the experts (Level III operators), they are not trained to differentiate subjectively 
between benign and malignant tumours on ultrasound. (Salvesen, 2011)  
 
At present the subjective assessment of adnexal tumour morphology or “pattern 
recognition” method is the most accurate way to diagnose ovarian cancer on ultrasound 
scan. (Valentin, 2004) It has been hypothesised that a well-designed and accurate 
diagnostic model would help Level II sonographers and other examiners without 
particular expertise in gynaecological ultrasound to differentiate between benign and 
malignant adnexal tumours on ultrasound scan.  Although, the initial published results 
with the IOTA models were promising, the models have been developed and 
subsequently tested by expert ultrasound operators (Level III), who were also able to 
use the “pattern recognition” method to determine the nature of adnexal lesions. 
(Timmerman, 2005; Yazbek, 2008; Van Holsbeke, 2010c)  This could have positively 
contributed to the accuracy of the IOTA diagnostic models. It is therefore unknown 
whether the IOTA models would perform equally well if used by operators with less 
expertise in gynaecological ultrasound.  
 
The aim of this study was to prospectively evaluate the diagnostic accuracy of the IOTA 
Logistic Regression Models (LR1 and LR2) on a representative sample of adnexal 
lesions when a non-expert ultrasound operator performed all ultrasound examinations. 
 
8.1.2 Methods 
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This was a prospective single centre study, which was conducted initially over a 17-
month period from May 2009 to September 2010 and then extended to January 2012 for 
a total of 33 months. All women attending the UCH Gynaecological Diagnostic Unit 
routinely undergo a detailed transvaginal and transabdominal scan, which included a 
systematic examination of the uterus, ovaries, adnexa and pouch of Douglas.  
 
Women with ultrasound evidence of an adnexal tumour were assessed according to the 
IOTA protocol. The ultrasound examinations were all performed by myself, a single 
level II ultrasound operator (EFSUMB, 2006; EFSUMB, 2010; Salvesen, 2011), who 
received training in the systematic examination of ovarian tumours in accordance with 
the IOTA guidelines. (Timmerman, 2000) I did not receive training in tumour pattern 
recognition and I was discouraged from attempting to differentiate subjectively between 
benign and malignant tumours on ultrasound scan.  
 
Demographic data including the patient’s age, menopausal status as well as personal, 
medical and family history were all recorded as a part of routine assessment. Women ≥ 
50 years of age who previously had a hysterectomy were defined as postmenopausal as 
is the standard in literature. In addition, morphological and Doppler characteristics of 
adnexal tumours according to the IOTA protocol were also recorded. (Timmerman, 
2005) A family history that included the number of first-degree relatives with ovarian or 
breast cancer was taken from each patient routinely.  
 
As with the original IOTA study (Timmerman, 2005), pregnant women, those unable to 
undergo a transvaginal scan and those who had surgery in excess of 120 days after the 
ultrasound scan, were excluded from the final data analysis. In women with bilateral 
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lesions, the lesion, which was more likely to be malignant according to the IOTA 
model, was included in the analysis.  
 
The probability of an adnexal mass being malignant was estimated by using both the 
IOTA Logistic Regression Model (LR1 and LR2). Twelve variables were used for the 
LR1 calculation (1) personal history of ovarian cancer (yes=1, no=0): (2) current use of 
hormonal therapy (yes=1, no=0): (3) age of the patient (years): (4) maximum diameter 
of lesion (mm): (5) presence of pain during the examination (yes=1, no=0): (6) presence 
of ascites (yes=1, no=0): (7) presence of blood flow within a solid papillary projection 
(yes=1, no=0): (8) purely solid tumour: (9) maximum diameter of the solid component 
(expressed in millimetres, but with no increase > 50 mm): (10) irregular internal cyst 
walls (yes=1, no=0): (11) presence of acoustic shadows (yes=1, no=0): (12) colour flow 
score (1-4 where 1 is no flow and 4 is maximum flow). Six variables were used for LR2 
[variable (3), (6), (7), (9), (10) and (11)]. The probability of malignancy was calculated 
using the formula described above in the section on logistic regressions models. The 
results of the calculations were stored in the research file and it was not made available 
to clinicians who were making decisions about the management.  
 
A consultant expert operator then managed all the patients expectantly or surgically 
using the unit’s standard clinical protocols and based on their assessment of the patient. 
The expert operator was blinded to the IOTA assessments and scores. Only women who 
underwent surgery were included in data analysis. Surgical options varied from 
laparoscopic ovarian cystectomy to primary ovarian debulking surgery. The accuracy of 
the IOTA models were assessed using histology as the gold standard. A histopathologist 
examined all specimens and was blinded to the IOTA scores. Tumours were classified 
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according to the World Health Organisation (WHO) guidelines and ovarian 
malignancies according to the criteria recommended by the International Federation of 
Gynecology and Obstetrics. (Serov, 1973; Benedet, 2000) 
 
As morphological analysis of the tumours using IOTA protocol is performed routinely 
in the Department and no therapeutic decisions were based on the results of the IOTA 
models, the UCH local Research and Development Department advised that the study 
did not require formal ethical assessment and approval.  
 
8.1.3 Statistical Analysis and Results 
 
8.1.3.1. Statistical Techniques 
 
The 17 month LR2 statistical analysis was performed using the software package Stata 
11.1 ® (Stata Corp., College Station, TX, USA) while Stata 12.1 ® was used for the 33 
month analysis. The diagnostic accuracy of the IOTA Logistic Regression Model (LR2) 
was assessed by calculating its sensitivity, specificity, positive predictive value, 
negative predictive value, positive likelihood ratio (LR +ve), negative likelihood ratio 
(LR –ve) and the area under the receiver operating characteristic (ROC) curve (AUC). 
The Chi-squared (c2) method was used to compare difference in proportions between 
the results of original IOTA and current study. 
 
The sample size was calculated prior to commencement. Harrell (2001) suggests that 
the validation dataset should contain at least 100 events (borderline / malignant 
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tumours), whereas Machin and Campbell (2005) suggest that the validation dataset 
should satisfy the “rule of 10” guideline, which means that in this study, the dataset 
should have at least 120 events as the LR1 model contains 12 predictors and at least 60 
events for LR2.  This validation dataset had 132 events, therefore satisfying both 
requirements. 
 
 
8.1.3.2. Results  
8.1.3.2.1. Results	at	17	months	
 
A total of 332 women were diagnosed with adnexal tumours during the initial 17-month 
study period. Of these, 141/332 (42.5%) women had surgery or a biopsy; whilst the 
remaining 191 of 332 (57.5%) were managed conservatively. 17/141 (12.1%) women 
were excluded. Three were pregnant and 14 did not have surgery within 120 days of 
ultrasound examination. A total of 124 women were included in the final analysis. 
(Figure 8.1-1) The mean age of the study population was 53.2 years (range 20 – 91 
years). There were 63 (50.8%) premenopausal and 61 (49.2%) postmenopausal women. 
There were a range of referral sources; 46 (37.1%) were referred by their general 
practitioner, 68 (54.8%) were tertiary referrals from another unit, 8 (6.5%) attended as 
an emergency and 2 (1.6%) were referred via other routes. There were 58 (46.8%, 95% 
CI 38.2-55.5) benign, 9 (7.3%, 95% CI 3.9-13.2) borderline, 42 (33.9%, 95% CI 26.1-
42.6) primary invasive malignant adnexal tumours and 15 (12.0%, 95% CI 7.5-19) 
metastatic tumours to the ovary. Of the 42 primary invasive malignant lesions there 
were 14 (33.3 %) Stage I, 3 (7.1%) Stage II, 13 (31%) Stage III and 12 (28.6%) Stage 
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IV tumours. Primary invasive epithelial, borderline and metastatic tumours were 
grouped together for the purpose of data analysis as in the original study so there were 
66 (53.2%) malignant lesions in total.  
 
The LR2 IOTA model had a sensitivity of 97.0% (95% CI, 89.5 to 99.6) and a 
specificity of 69.0% (95% CI, 55.5 to 80.5). The positive predictive value was 78.0% 
(95% CI 67.5 to 86.4) and the negative predictive value was 95.2% (95% CI 83.8 to 
99.4). The positive likelihood ratio was 3.125 (95% CI, 2.124 – 4.597) and the negative 
likelihood ratio was 0.044 (95% CI, 0.011 - 0.174). The area under the ROC curve 
(AUC) was 0.93, standard error 0.022 (95% CI, 0.89 – 0.97).  
 
There were 18 false positive and 2 false negative cases (Table 8.1-1). Benign ovarian 
cystadenomas and mature cystic teratomas were responsible for 55.6% (10/18) of all 
false positive diagnoses of ovarian cancer.  The first false negative case was a 
premenopausal woman with large bilateral ovarian tumours whose histology showed a 
borderline mucinous tumour and an incidental finding of an appendix Goblet cell 
carcinoid tumour. The second patient was a postmenopausal woman, also with bilateral 
ovarian tumours, which were metastatic from a gastrointestinal primary. The tumours 
were smooth and multilocular with no solid areas and no ascites. There were tumour 
deposits seen though in the Pouch of Douglas but that factor is not tested in the IOTA 
models.  
 
In order to test for the possibility of bias due to increased operator experience during the 
study period, the dataset was divided in two halves. The performance of the IOTA 
Logistic Regression Model (LR2) in the first 62 consecutive patients was not 
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significantly different form the results in the 62 subsequently recruited women 
[sensitivity 94% versus 100% (p=0.152); specificity 61% versus 78% (p=0.063)].  
 
The AUC were not significantly different between this current study, the original IOTA 
report and the prospective IOTA validation study. (Table 8.1-2) (Timmerman, 2005; 
Timmerman, 2010)  Sensitivity in this study was significantly better in comparison to 
the original study (χ2=6.162, p=0.013), but it was not statistically different to the 
sensitivities in the validation study. Specificities in the IOTA validation study were 
significantly higher compared to this study (external χ2=21.1, p=0.001; temporal 
χ2=6.96,p=0.008). The specificities in this and the original study, however, were not 
significantly different. Alternative cut-off points were investigated for this study’s data. 
A cut-off of 6.4% instead of 10% would give us 100% sensitivity but the specificity 
would fall to 56.9%. (Figure 8.1-2) 
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Figure 8.1-1: Flow Diagram of eligibility for LR2. N = 124. (Nunes, 2012a) 
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Table 8.1-1: Histological findings in women with false positive diagnoses of ovarian 
cancer using the IOTA logistic regression model LR2. (N = 18 of total 124) (Nunes, 
2012a) 
 
Histological diagnosis N (%) 
 
Cystadenoma/cystadenofibroma 5 (27.8) 
Mature cystic teratoma 4 (22.2) 
Dermoid with cystadenoma 1 (5.6) 
Pedunculated leiomyoma 1 (5.6) 
Benign aspirate/Pseudocyst 2 (11.1) 
Torsion of benign cyst 2 (11.1) 
Brenner tumour 1 (5.6) 
Endometriosis 1 (5.6) 
Fat necrosis and inflammation - suspected actinomycosis 1 (5.6) 
Total 18 (100) 
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Table 8.1-2: Accuracy of the IOTA Logistic Regression Model (LR2): comparison of findings in the original (Timmerman, 2005) and 
prospective validation (Timmerman, 2010) IOTA studies with the current study. N = 124. (Nunes, 2012a) 
 
 AUC 
(95% CI) 
SE Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
LR+ve 
(95% CI) 
LR-ve 
(95% CI) 
 
Original IOTA study 
(Timmerman, 2005)   
(test set)             N=312 
 
0.92 
- 
 
 
0.018 
 
89 
- 
 
73 
- 
 
3.3 
- 
 
0.15 
- 
Prospective validation IOTA 
study (Timmerman, 2010) 
External N=997 
 
Temporal N=941 
 
0.95 
(0.93 – 0.96) 
 
0.92 
(0.90 – 0.94) 
 
- 
 
 
- 
 
91.8 
- 
 
89.2 
- 
 
85.6 
- 
 
79.8 
- 
 
6.36 
(5.33 – 7.63) 
 
4.42 
(3.78 – 5.19) 
 
0.10 
(0.06 – 0.14) 
 
0.14 
(0.1 – 0.19) 
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Current study  
 
N=124 
 
0.93 
(0.89 – 0.97) 
 
 
0.022 
 
97 
(92.3 – 98.9) 
 
69 
(60.4 – 76.5) 
 
3.12 
(2.12 – 4.6) 
 
0.044 
(0.01 – 0.17) 
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Figure 8.1-2: The receiver operating characteristic curves of the IOTA Logistic 
Regression Model (LR2). N = 124. (Nunes, 2012a) 
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8.1.3.2.2. Results	at	33	months	
 
There were 555 women with adnexal tumours who underwent pelvic ultrasound 
examination during the 33-month study period. Of those 555, 317 (57.1%) women had 
surgical intervention and the remaining 238 (42.9%) were managed conservatively.  
There were 25 women who were excluded from the study: 21 women had surgery >120 
days after ultrasound assessment and four women were pregnant.  
 
There were therefore 292 women included in the final analysis. (Figure 8.1-3) The mean 
age of the 292 women included in the study was 51 years (range of 16 to 91). Of those 
292 women, 155 (53.1%) were premenopausal and 137 (46.9%) were 
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postmenopausal. One hundred and sixty (54.8%) of the tumours were benign, 17 (5.8%) 
were borderline and 115 (39.4%) were invasive malignant tumours. The mean age of 
those with benign tumours was 43 years, which was significantly less than the mean age 
of 59 in those with malignant tumours (P < 0.0001).  Of the 115 invasive malignant 
tumours, there were 25 (21.7%) Stage I, 5 (4.3%) Stage II, 34 (29.6%) Stage III, 22 
(19.1%) Stage IV, 25 (21.7%) metastatic and 4 (3.5%) recurrent ovarian tumours. 
Borderline, primary invasive and metastatic tumours were analysed together in keeping 
with the original article and they accounted for a total of 132/292 (45.2%) of all 
tumours.  
 
Table 8.1-3 shows the diagnostic performances of LR1, LR2 and PR in this and 
previously published studies. There were no significant differences in AUC between the 
previous studies and this study. Despite this, the sensitivity of LR1 was significantly 
higher and the specificity was significantly lower in our hands compared to the external 
and temporal validation studies carried out by the IOTA group. (Table 8.1-4) There 
were also significant differences in the sensitivity and specificity of LR2 between this 
and previous validation studies. (Table 8.1-5)  We compared the performance of the 
models and the pattern recognition in the first half of the study with that in the second 
and we found no significant differences in the AUC. (Table 8.1-6) 
 
There were 47 false positives and 3 false negatives with the LR1 model and 43 false 
positives and 5 false negatives with the LR2 model. (Table 8.1-7) Pattern recognition 
had only 11 false positives and 6 false negatives giving it the highest diagnostic 
accuracy of the three tests. The accuracy of PR was 0.942 (95%CI, 0.908 to 0.966) 
compared to that of LR1, which was 0.829 (95%CI, 0.781 to 0.870) and to that of LR2, 
which was 0.836 (95%CI, 0.788 to 0.872). This was statistically significant (LR1 versus 
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PR: P < 0.001 and LR2 versus PR: P < 0.001).  
 
Cystadenomas and cystadenofibromas were the most commonly found tumours which 
were false positives in this study (15/47 (32%) LR1, 14/47 (30%) LR2, 6/47 (13%) PR). 
Mature cystic teratomas (Dermoid cysts) were the next single most common cause of 
false positives [5 of 24 (LR1), 6 of 24 (LR2), 1 of 24 (PR)]. These were though also the 
most common benign tumours found. The rare benign tumours, such as actinomycosis, 
myolipoma, Brenner tumour and struma ovarii were all misdiagnosed as cancers by 
both LR1 and LR2. Pedunculated leiomyomas (3 cases) were all wrongly diagnosed as 
cancers using LR1 and two out of three were also misdiagnosed by LR2.  Four out of 
five cases of torsion of benign cysts were diagnosed as cancers by both models although 
the diagnosis was correct in all cases when pattern recognition was used.  
 
The false negative results most commonly occurred in cases of borderline ovarian 
tumours. Two borderline tumours, which were both misclassified by LR2 and PR 
presented with large unilocular cyst, one of which contained a 13mm solitary papillary 
projection. All three diagnostic tests gave false negative results in a case of mucinous 
adenocarcinoma and a dermoid, which contained a 1.5mm focus of immature tissue. 
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Figure 8.1-3: Flow Diagram of eligibility LR1 and LR2. N = 292. (Nunes, 2013) 
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Table 8.1-3: Accuracy of the IOTA logistic regression models (LR1 and LR2): comparison of findings in the original and prospective 
validation IOTA studies with the current dataset Part A. N = 292. (Nunes, 2013) 
 
LR1 
  
AUC 
 
(95% CI) 
 
SE 
 
Sensitivity 
(%)  
(95% CI) 
 
Specificity 
(%) 
(95% CI) 
 
LR+ve 
 
(95%CI) 
 
LR-ve 
 
(95%CI) 
 
Accuracy 
 
(95%CI) 
Original IOTA study  
(test set) 
N=312 
 
0.94 
 
0.017 
 
93 
 
76 
 
 
3.81 
 
0.09 
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Prospective validation 
IOTA study  
External n=997 
 
Temporal n=941 
 
0.96 
(0.94 – 0.97) 
 
0.95 
(0.93 – 0.96) 
 
- 
 
 
- 
 
92.2 
- 
 
92.7 
 
 
86.5 
- 
 
80.6 
 
6.84 
(5.69 – 8.25) 
 
4.77 
(4.04 – 5.61) 
 
0.09 
(0.06 – 0.14) 
 
0.09 
(0.06 – 0.14) 
 
 
Current Study  
N=292 
 
0.94 
(0.92 – 0.97) 
 
0.013 
 
97.7 
(93.6 – 99.4) 
 
70.6 
(67.2 – 72.0) 
 
3.33 
(2.85 – 3.55) 
 
0.03 
(0.01 – 0.10) 
 
0.829 
(0.781 – 0.870) 
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Accuracy of the IOTA logistic regression models (LR1 and LR2): comparison of findings in the original and prospective validation IOTA 
studies with the current dataset Part B. N = 292. (Nunes, 2013) 
 
LR2 
  
AUC 
 
(95% CI) 
 
SE 
 
Sensitivity 
(%) 
(95% CI) 
 
Specificity 
(%) 
(95% CI) 
 
LR+ve 
 
(95%CI) 
 
LR-ve 
 
(95%CI) 
 
Accuracy 
 
(95%CI) 
Original IOTA study  
(test set) 
N=312 
 
0.92 
- 
 
0.018 
 
89 
- 
 
73 
- 
 
3.3 
- 
 
0.15 
- 
 
- 
- 
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Prospective validation 
IOTA study  
External n=997 
 
Temporal n=941 
 
0.95 
(0.93 – 0.96) 
 
0.92 
(0.90 – 0.94) 
 
- 
 
 
- 
 
91.8 
- 
 
89.2 
- 
 
85.6 
- 
 
79.8 
- 
 
6.36 
(5.33 – 7.63) 
 
4.42 
(3.78 – 5.19) 
 
0.10 
(0.06 – 0.14) 
 
0.14 
(0.1 – 0.19) 
 
- 
 
 
- 
 
Current Study  
N=292 
 
0.93 
(0.90 – 0.96) 
 
0.015 
 
96.2 
(91.4 – 98.8) 
 
73.1 
(65.6 – 79.8) 
 
3.58 
(2.77 – 4.63) 
 
0.052 
(0.022 – 0.123) 
 
0.836 
(0.788 – 0.872) 
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Accuracy of the IOTA logistic regression models (LR1 and LR2): comparison of findings in the original and prospective validation IOTA 
studies with the current dataset Part C. N = 292. (Nunes, 2013) 
 
Pattern Recognition 
  
AUC 
 
(95% CI) 
 
SE 
 
Sensitivity 
(%) 
(95% CI) 
 
Specificity 
(%) 
(95% CI) 
 
LR+ve 
 
(95%CI) 
 
LR-ve 
 
(95%CI) 
 
Accuracy 
 
(95%CI) 
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Prospective 
validation 
IOTA study  
External n=997 
 
Temporal n=941 
 
0.949 
(0.930 – 0.964) 
 
0.959 
(0.944 – 0.973) 
 
 
- 
 
 
- 
 
87.5 
 
 
93.0 
 
92.1 
 
 
93.4 
 
11.0 
(8.6 – 14.1) 
 
14.1 
(10.6 – 19.0) 
 
0.14 
(0.10 – 0.19) 
 
0.07 
(0.05 – 0.11) 
 
- 
 
 
- 
 
Current Study  
N=292 
 
- 
 
- 
 
95.5 
(90.4 – 98.3) 
 
93.1 
(88.0 – 96.5) 
 
13.9 
(7.84 – 24.6) 
 
0.049 
(0.022 – 0.107) 
 
0.942 
(0.908 – 0.966) 
AUC – Area under the Curve; SE – Standard Error; LR+ve – Positive Likelihood Ratio; LR-ve – Negative Likelihood Ratio; CI – Confidence interval 
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Table 8.1-4: Comparison of sensitivity and specificity between the current dataset 
and previous datasets for LR1. N = 292. (Nunes, 2013) 
 
Dataset Sensitivity Test** Specificity Test** 
Original (n=312) 70/75 0.14* 179/237 0.28 
External (n=997) 235/255 0.028 642/742 < 0.001 
Temporal 
(n=941) 
266/287 0.039 527/654 0.006 
Current Study 
(n=292) 
129/132 - 113/160 - 
 
* Fisher’s exact test (otherwise Chi-squared (c2) test) 
** With Current Study 
 
Table 8.1-5: Comparison of sensitivity and specificity between the current dataset 
and previous datasets for LR2. N = 292. (Nunes, 2013) 
 
Dataset Sensitivity Test**  Specificity Test** 
Original (n=312) 67/75 0.05 173/237 * 0.98 
External (n=997) 234/255 0.098 635/742 < 0.001 
Temporal (n=941) 256/287 0.017 522/654 0.065 
Current Study  
(n=292) 
127/132 - 117/160  
 
* Estimate (numerator between 172 – 174) 
** With Current Study 
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Table 8.1-6: Comparison of the two halves of this study (LR1 and LR2). N = 292. 
(Nunes, 2013) 
 
LR1 Model First half n=146 Second half n=146 P value 
LR1 
Sensitivity 98.6% 96.7%  
Specificity 62.7% 77.6% 0.038 
AUC 0.93 0.96 0.34 
LR2 
Sensitivity 95.8% 96.7%  
Specificity 68% 77.6% 0.17 
AUC 0.91 0.95 0.28 
PR 
Sensitivity 94.4% 96.7%  
Specificity 92% 94.1% 0.6 
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Table 8.1-7: Histological findings in women with false positive diagnoses of ovarian 
cancer using the IOTA logistic regression models (LR1 and LR2) and Pattern 
Recognition. N = 292. (Nunes, 2013) 
 
Histological diagnosis LR1 (N) LR2 (N) Pattern Recognition (N) 
Cystadenoma 13 11 6 
Cystadenofibroma 2 3  
Mature cystic teratoma 5 6 1 
Benign simple cyst/Pseudocyst 7 5 1 
Pedunculated leiomyoma 3 2  
Torsion of benign cyst 4 4 1 
Endometriosis 3 3 1 
Fat necrosis and inflammation - 
suspected actinomycosis 
1 1 1 
Fibroma 4 3  
Brenner tumor 1 1  
Myolipoma 1 1  
Struma ovarii 1 1  
Fibrothecoma 2 2  
Total 47 43 11 
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8.2 Study 2 – A prospective validation of the IOTA Simple Rules for 
the diagnosis of ovarian cancer 
 
8.2.1 Introduction 
 
Non-invasive pre-operative diagnosis of an adnexal tumour is the main goal of 
ultrasound assessments. Determination of the nature of the tumour is of paramount 
importance to guide management options. The “Simple Rules” were designed by the 
International Ovarian Tumour Analysis (IOTA) group collaboration using only 
ultrasound scan features to determine whether a tumour is benign or malignant.  
 
There are 5 benign features and 5 malignant features, which are used to determine the 
nature of the tumour. Benign features were B1) Unilocular, B2) Presence of solid 
components where the largest solid component has a largest diameter < 7 mm, B3) 
Presence of acoustic shadows, B4) Smooth multilocular tumour with largest diameter < 
100 mm and B5) No blood flow (colour score 1). Malignant features were M1) Irregular 
solid tumour, M2) Presence of ascites, M3) At least four papillary structures, M4) 
Irregular, multilocular solid tumour with largest diameter ≥ 100 mm and M5) Very 
strong blood flow (colour score 4).  If one or more benign features exist in the absence 
of any malignant features being present then the tumour is defined as benign. If one or 
more malignant features exist in the absence of any benign features being present, then 
the tumour is defined as malignant. If no features exist or if both types of features are 
present then the tumour is unclassified.  
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The aim of this study is to assess the diagnostic accuracy of the simple rules protocol 
when performed by a level II operator to diagnose ovarian cancer. This is an external 
validation study.  
 
8.2.2 Methods 
 
This prospective single centre study was performed over a 33-month period from May 
2009 to January 2012.  This is the same population of women as in study 2 and the 
conduct of the study and the exclusion criteria are as described above for studies 1 and 
2. In this case though, all consecutive patients diagnosed with an adnexal tumour were 
assessed according to the simple rules protocol. Once again the expert was blinded to 
the simple rules category to which the patient was assigned. This was of particular 
importance for the patients in whom the rules were not applicable. The level II 
ultrasound operator was instructed only to describe the various features of the tumour 
and assign it M or B features according to the simple rules criteria and not to assign a 
particular diagnosis.  
 
In women with bilateral tumours, both tumours were assessed and categorised. If one 
was assessed as benign or indeterminate while the other assessed as malignant, then the 
malignant tumour was used in the final analysis. If one tumour was assessed as benign 
but the other as indeterminate, then her tumours were categorised as indeterminate and 
if both tumours fell into the same category then the larger was used.  
 
Surgical intervention options and histological assessment and analysis were as 
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previously described. The histopathologist was blinded to the result of the simple rules 
assessment and was only aware of the surgical opinion of the surgeon. 
 
The UCH local Research and Development Department determined that formal ethical 
assessment and approval was not required as ultrasound scan examination of all adnexal 
masses was routine practice including morphological analysis of the tumours using the 
IOTA terms (Timmerman, 2000) and also because therapeutic decisions were not based 
on the simple rules results. 
 
Guidance on the STARD initiative was followed in the conduct, analysis and reporting 
of this study. (Bossuyt, 2003) 
 
8.2.3 Statistical Analysis and Results 
 
8.2.3.1. Statistical Techniques 
 
Analysis was performed using software package Stata 11.1 ® (Stata Corp., College 
Station, TX, USA). A p value < 0.05 was considered statistically significant and exact 
95% confidence intervals were calculated. The required sample size was calculated 
prior to commencement of the study. A validation dataset should contain at least 100 
events (borderline / malignant tumours) according to Harrell (2001) or it should satisfy 
the “rule of 10” according to Machin and Campbell (2005) requiring the same 100 
events in this study. These criteria were met. The sensitivity, specificity and accuracy of 
simple rules, pattern recognition, and simple rules followed by pattern recognition were 
squared (c2) test for independent binary compared separately using the Chi-
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outcomes. The sensitivity, specificity and accuracy of simple rules and pattern 
recognition were compared separately using McNemar’s test for paired binary 
outcomes. 
 
8.2.3.2. Results 
 
There were 555 women who were initially assessed and diagnosed with adnexal 
tumours. Of those 335 (60.4%) went on to have surgery. There were 4 pregnant women 
in the surgical group who were excluded as per the original study as well as a further 28 
who were excluded because of not having had surgery within the stipulated 120 days 
from last ultrasound scan. (Figure 8.2-1) 141 (46.5%) of the women were 
postmenopausal and the average age was 50 (range 16-91). Most of the referral routes 
(53.1%) were via the general practitioner, accident and emergency or an internal 
referral. The remainder were referred from other hospitals. There were 11 women with 
bilateral tumours and one of them had one of her tumours classified as malignant and 
the other as indeterminate. Her tumour that was classified as malignant was included in 
the final analysis. Of the histological confirmations, there were 168 (55.4%) benign 
tumours, 19 (6.3%) borderline tumours, 86 (28.4%) primary invasive ovarian cancers, 1 
(0.3%) primary tubal cancer, 22 (7.3%) metastatic tumours, 4 (1.3%) primary non-
gynaecological tumours and 3 (1%) recurrent ovarian cancers. Among 86 women with 
primary invasive ovarian cancers, 27 (31.4%) had stage I disease, 5 (5.8%) stage II, 34 
(39.5%) stage III and 20 (23.3%) stage IV.   
 
The rules were applicable in 237 (78.2%) of the 303 tumours. This proportion is in 
keeping with the original and validation studies. For these women in whom the rules 
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were applicable, the simple rules had a sensitivity of 96.2% (95%CI: 90.5-99.0) and a 
specificity of 88.6% (95%CI:82.0-93.5). The accuracy was 92.0% (95%CI:87.8-95.1) 
(Table 8.2-1) For the same population of women the sensitivity of pattern recognition 
was 97.1% (95%CI: 91.9-99.4) and the specificity was 93.2% (95%CI:87.5-96.8). The 
accuracy of pattern recognition was 94.9% (95%CI:91.3-97.4). For those 66 tumours for 
which the rules were not applicable 36 (55%) were benign. (Figure 8.2-2) For these 
patients there was a fairly equal distribution of those for who neither M nor B rules 
applied (34 / 52%) or whether both types of rules applied (32 / 48%). Whether both 
types of rules or neither types of rules applied, gave no strong indication to whether the 
tumour was benign or malignant as 56% of the benign tumours and 47% of the 
malignant tumours classified as indeterminate had no rules applicable. While the 
prevalence of malignant lesions was similar in women in whom neither or both rules 
applied [41.2 % versus 50% (P>0.05)], these malignancies were more likely to be 
borderline when both rules applied as opposed to when neither type applied [43.8% 
versus 7.1% (p<0.05)]. 
 
The prevalence, as expected was much higher for post-menopausal patients [67.4% 
(95/141)] than pre-menopausal patients [24.7% (40/162). This discordance was greater 
in the populations of women in whom the rules were applicable [postmenopausal 71.0% 
(76/107); premenopausal 22.3% (29/130).  Among the 162 premenopausal women the 
rules were applicable in 80.2% (130/162) with a sensitivity of 89.7% (95%CI:72.6-
97.8), a specificity of 89.1% (95%CI:81.3-94.4)  and an accuracy of 89.2% (95% 
CI:82.6-94.0). There were 141 postmenopausal women in our population and the rules 
were applicable for 75.9% (107/141). For these women, when compared to the 
premenopausal women, there was an increased sensitivity of 87.1% (95%CI:70.2-96.4), 
similar specificity of 98.7% (95%CI:92.9-100) and increased accuracy of 95.3% 
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(95%CI:89.4-98.5). (Table 8.2-1) 
 
When pattern recognition was used on the 66 tumours which could not be classified by 
the simple rules, the sensitivity was lower though the specificity was much higher 
(86.7%(95%CI:69.3-96.2) and 94.4% (95%CI:81.3-99.3) respectively, when compared 
to the performance of the simple rules. Further analysis was done using pattern 
recognition as the second line test when the rules were not applicable. The final analysis 
of the entire 303 population had a sensitivity of 94.1% (95%CI:88.7-97.4), a specificity 
of 89.9% (95%CI:84.3-94), and an accuracy of 91.7% (95%CI:88.1-94.6). When pattern 
recognition alone was used for all 303 tumours, there was a sensitivity of 94.8% 
(95%CI:89.6-97.9), a specificity of 93.5% (95%CI:88.6-96.7) and an accuracy of 94.1% 
(95%CI:90.8-96.4).  
 
If all tumours which were not classifiable by the simple rules were assumed to be 
malignant the sensitivity increased but the specificity and accuracy decreased: 97% 
(95%CI:92.6-99.2), 69.6% 95%CI:62.1-76.5), and 81.8% (95%CI:77.0–86.0) 
respectively. 
 
There were 4 false negative diagnoses and these included a borderline tumour, a 
dermoid cyst with a 1-2mm area of immature cells, an invasive stage III 
adenocarcinoma and a primary peritoneal cancer. (Table 8.2-2) There were 15 false 
positive diagnoses amongst which were found a range of histological diagnoses, as 
shown in table form. (Table 8.2-3) 
 
The sensitivity, specificity and accuracy of simple rules, pattern recognition, and simple 
rules followed by pattern recognition were compared separately using the Chi-squared 
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(c2) test for independent binary outcomes. (Table 8.2-4) The sensitivity, specificity and 
accuracy of simple rules and pattern recognition were compared separately using 
McNemar’s test for paired binary outcomes.  These analyses are based on the 237 
patients for whom the simple rules were applicable.  Of these, only 11 patients had 
differing diagnoses under simple rules and pattern recognition.  The results suggest that 
the specificity of simple rules is inferior to that of pattern recognition. (p=0.03) (Table 
8.2-5) Comparative analyses between our results and the original and validation IOTA 
studies showed no significant difference for most of the tests apart from the specificity 
of simple rules in the validation study (p< 0.001). (Timmerman, 2010) (Table 8.2-6)  
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Figure 8.2-1: Flow Diagram of Study Eligibility for the Simple Rules. N = 303. 
(Nunes, 2014) 
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Figure 8.2-2: Flow Diagram of Results for the IOTA Simple Rules. (N = 237 of 
303). (Nunes, 2014) 
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Table 8.2-1: Accuracy of the IOTA Simple Rules: comparison of findings in the original and prospective IOTA validation studies with the 
current study - Part A. N = 237. (Nunes, 2014) 
 
Simple Rules 
  
Rules 
applicable 
 
Sensitivity 
(%) 
(95% CI) 
 
Specificity 
(%) 
(95% CI) 
 
LR+ve 
 
(95% CI) 
 
LR-ve 
 
(95% CI) 
 
PPV 
 
(95% CI) 
 
NPV 
 
(95% CI) 
 
Accuracy 
 
(95% CI) 
Original SR study 
(test set) N=386 
 
76% 
386/ 507 
 
94.6 
(88.7-98.0) 
 
90.9 
(86.8-94.0) 
 
10.4 
(7.1-15.1) 
 
0.059 
(0.027-0.129) 
 
80.9 
(73.1-87.3) 
 
97.6 
(94.9-99.1) 
 
92.0 
(88.8-94.5) 
Prospective 
validation SR study 
N=1501 
External and 
Temporal  
 
77% 
 
1501/ 1938 
 
92.1 
 
(88.9-94.7) 
 
95.7 
 
(94.3-96.8) 
 
21.3 
 
(16.2-28.0) 
 
0.082 
 
(0.058-0.117) 
 
87.4 
 
(83.7-90.5) 
 
97.4 
 
(96.3-98.2) 
 
94.8 
 
(93.6-95.9)  
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Accuracy of the IOTA Simple Rules: comparison of findings in the original and prospective IOTA validation studies with the current study - 
Part B. N = 237. (Nunes, 2014) 
 
Current Study 
 Rules 
applicable 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
LR+ve 
(95% CI) 
LR-ve 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Accuracy 
(95% CI) 
Rules applicable 
population 
N=237 
78% 
237/303 
96.2 
(90.5-99.0) 
88.6 
(82.0-93.5) 
8.46 
(5.3-13.7) 
0.043 
(0.016-0.113) 
 
87.1 
(79.6-92.6) 
96.7 
(91.8-99.1) 
92.0 
(87.8-95.1) 
Pre-menopausal 
N=130 
80%  
130/162 
89.7 
(72.6 - 97.8) 
89.1 
(81.3 - 94.4) 
8.23 
(4.7 - 14.6) 
0.116 
(0.040 - 0.340) 
70.3 
(53 - 84.1) 
96.8 
(90.9 - 99.3) 
89.2  
(82.6 - 94.0) 
Postmenopausal 
N=107 
76% 
107/141 
98.7 
(92.9 - 100) 
87.1 
(70.2 - 96.4) 
7.65 
(3.1 - 19.1) 
0.015 
(0.002 - 0.106) 
94.9 
(87.5 - 98.6) 
96.4 
(81.7 - 99.9) 
95.3 
(89.4 – 98.5) 
SR+PR † 
N=303 
 94.1 
(88.7 - 97.4) 
89.9 
(84.3 – 94) 
9.3 
(5.9 – 14.6) 
0.066 
(0.034 - 0.129) 
88.2 
(81.8 – 93) 
95 
(90.3 - 97.8) 
91.7 
(88.1 – 94.6) 
PR ‡ 
N = 66 
 86.7 
(69.3 - 96.2) 
94.4 
(81.3 - 99.3) 
15.6 
(4.0 - 60.4) 
0.141 
(0.057 - 0.353) 
92.9 
(76.5 - 99.1) 
89.5 
(75.2 - 97.1) 
90.9 
(81.3 – 96.6) 
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SR+MA § 
N=303 
 97 
(92.6 - 99.2) 
69.6 
(62.1 - 76.5) 
3.2 
(2.5 - 4.0) 
0.043 
(0.016 - 0.112) 
72 
(64.9 - 78.4) 
96.7 
(91.8 - 99.1) 
81.8 
(77.0 – 86.0) 
 
† SR+PR – Simple rules and use of pattern recognition for all those in whom the rules were not applicable (indeterminate tumours). 
‡ PR – Pattern recognition used for those patients in whom the rules were not applicable (indeterminate tumours). 
§ SR+MA – Simple rules and malignancy assumed for all those in whom the rules were not applicable. 
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Accuracy of the IOTA Simple Rules: comparison of findings in the original and prospective IOTA validation studies with the current study - 
Part C. N = 237. (Nunes, 2014) 
Pattern Recognition 
Same population where rules 
applicable 
 
 
Sensitivity (%) 
(95% CI) 
 
Specificity (%) 
(95% CI) 
 
LR+ve 
(95% CI) 
 
LR-ve 
(95% CI) 
 
PPV 
(95% CI) 
 
NPV 
(95% CI) 
 
Accuracy 
(95% CI) 
Prospective validation 
SR study 
External and Temporal 
N=1501 
 
91.1 
 
(87.7-93.8) 
 
95.7 
 
(94.3-96.8) 
 
21 
 
(16.0-27.7) 
 
0.094 
 
(0.068-0.129) 
 
87.3 
 
(83.5-90.4) 
 
97.0 
 
(95.9-98.0) 
 
94.5 
 
(93.3-95.6)  
 
Current Study  
N=237 
 
 
 
97.1 
 
(91.9-99.4) 
 
93.2 
 
(87.5-96.8) 
 
14.2 
 
(7.6-26.8) 
 
0.031 
 
(0.010-0.094) 
 
91.9 
 
(85.2-96.2) 
 
97.6 
 
(93.2-99.5) 
 
94.9 
 
91.3-97.4 
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Table 8.2-2: Histology Results for False Negative Simple Rules Analyses. (N = 4 of 
237). (Nunes, 2014) 
 
Histology Number 
Borderline 1 
Dermoid cyst with 1-2mm foci of immature cells 1 
Stage III Adenocarcinoma 1 
Primary peritoneal cancer 1 
Total 4 
 
Table 8.2-3: Histology Results for False Positive Simple Rules Analyses. (N = 15 of 
237). (Nunes, 2014) 
 
Histology Number (%) 
Cystadenoma / Cystadenofibroma 6 (40) 
Dermoid 2 
Endometriosis 2 
Leiomyoma 1 
Actinomycosis 1 
Torsion 1 
Benign 1 
Fibrothecoma 1 
Total 15 
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Table 8.2-4: Accuracy of the IOTA Simple Rules: comparison of findings in the original and prospective validation studies with the current 
study for all patients. N = 303. (Nunes, 2014) 
All Patients Simple Rules followed by pattern recognition 
 Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
LR+ve 
(95% CI) 
LR-ve 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Accuracy 
(95% CI) 
Prospective 
validation IOTA 
SR study 
External and 
Temporal N=1938 
 
91.1 
 
(88.4– 93.4) 
 
 
 
92.7 
 
(91.2– 94.0) 
 
12.5 
 
(10.3 – 15.1) 
 
0.0955 
 
(0.0729 – 0.125) 
 
82.9  
 
(79.6 – 85.8) 
 
96.4 
 
(95.3 – 97.4) 
 
92.3 
 
(91.0 – 93.4) 
 
Current Study  
N=303 
 
 
 
94.1 
 
(88.7 – 97.4) 
 
89.9 
 
(84.3 – 94.0) 
 
9.3 
 
(5.91 – 14.6) 
 
 
0.0659 
 
(0.0336 – 0.129) 
 
88.2 
 
(81.8 – 93.0) 
 
95.0 
 
(90.3 – 97.8) 
 
91.7 
 
(88.1 – 94.6) 
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Pattern Recognition alone 
 Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
LR+ve 
(95% CI) 
LR-ve 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
Accuracy 
(95% CI) 
Prospective 
validation IOTA 
SR study 
External and 
Temporal N=1938 
 
90.4 
 
(87.6 – 92.8) 
 
92.7 
 
(91.2 – 94.0) 
 
12.4 
 
(10.2 – 14.9) 
 
0.104 
 
(0.0799 – 0.134) 
 
82.8 
 
(79.6 – 85.7) 
 
96.1 
 
(95.0 – 97.1) 
 
92.1 
 
(90.8 – 93.2) 
 
Current Study  
N=303 
 
 
 
94.8 
(89.6 – 97.9) 
 
93.5 
(88.6 – 96.7) 
 
14.5 
(8.17 – 25.7) 
 
0.0555 
(0.0269 – 0.114) 
 
92.1 
(86.3 – 96.0) 
 
95.7 
(91.4 – 98.3) 
 
94.1 
(90.8 - 96.4) 
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Table 8.2-5: P-values from comparisons of sensitivity, specificity and accuracy of 
simple rules and pattern recognition using Nunes (2014). N = 303. (Nunes, 2014) 
 
Current Study Sensitivity Specificity Accuracy 
Simple vs. Pattern  0.56 0.03 0.13 
 
Table 8.2-6: P-values from comparisons of sensitivity, specificity and accuracy of 
simple rules, pattern recognition and simple rules + pattern recognition (Nunes, 
2014) 
 
Current Study  Sensitivity Specificity Accuracy 
SR vs. Original (2008) 0.59 0.48 1.00 
SR vs. Validation (2010) 0.15 < 0.001 0.08 
    
PR vs Validation. (2010) 
(SR patients only) (N=237) 
0.04 0.20 0.80 
    
SR+PR vs. Validation (2010) 0.27 0.19 0.76 
    
PR vs. Validation (2010) 
(All patients) (N=303) 
0.10 0.72 0.22 
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8.3 Study 3 – A prospective evaluation of the IOTA Logistic Regression 
Models (LR1 and LR2) in comparison to Subjective Pattern 
Recognition for the diagnosis of ovarian cancer in the outpatient 
setting using two reference standards 
 
8.3.1 Introduction 
 
The International Ovarian Tumour Analysis (IOTA) group developed two logistic 
regression models (LR1&LR2), aiming to improve the accuracy of pre-operative 
ultrasound diagnosis of ovarian cancer diagnosis by non-expert operators of average 
ability and experience.   
 
Non-expert or Level II ultrasound operators tend to describe the morphology of adnexal 
tumours without attempting to state their nature, while expert operators (Level III) often 
use subjective pattern recognition to differentiate between benign and malignant lesions 
and to determine their likely histological type. (EFSUMB, 2006; EFSUMB, 2010) 
A number of previous original and validation studies showed that LR1 and LR2 perform 
well in the hands of expert operators and can facilitate differentiation between benign 
and malignant tumours in women scheduled for surgical treatment of adnexal tumours. 
(Timmerman, 2005; Timmerman, 2010; Nunes, 2012; Nunes, 2013; Kaijser, 2014) Only 
a minority of women with an ultrasound diagnosis of an adnexal tumour however, 
require surgery and in the routine clinical practice the critical issue is not who will 
perform surgery but whether an intervention is required at all. There have been no 
studies so far, which assessed the suitability of IOTA models for the diagnosis of 
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ovarian cancer in outpatient setting and for triaging women with adnexal tumours for 
surgical interventions. The prevalence of malignancy in women attending outpatient 
clinics in likely to be lower, which could result in a larger number of interventions in 
women with benign disease even if the good diagnostic accuracy of IOTA models is 
maintained. 
 
Another difficulty with using a test in outpatient setting is only a proportion of women 
would be selected for surgical treatment. Histological findings, which are traditionally 
used to assess as the reference standard for assessing the accuracy of models for the 
diagnosis of ovarian cancer are not applicable to population of women managed 
conservatively. In such circumstances delayed type cross sectional studies may provide 
best evidence that harvest the reference standard information from a prospectively 
planned and prolonged clinical follow up. (Knottnerus, 1997) It is unknown; however, 
what is the required length of follow up and appropriate frequency of visits to determine 
the nature of an adnexal tumour. 
 
In this prospective study we assessed the accuracy of IOTA models for the diagnosis of 
ovarian cancer in outpatient settings using histology as the first reference standard and 
the tumour change at follow up ultrasound scans as a second reference test.  We also 
assessed the potential impact on the intervention rates of a policy, which would replace 
pattern recognition with the IOTA models for triaging women with adnexal tumours for 
surgery 
 
 
8.3.2 Methods 
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This was a single centre prospective observational study of consecutive women 
attending our gynaecological diagnostic unit for a variety of gynaecological complaints.   
The first phase of the study lasted for 33-months from May 2009 to January 2012. 
During that time women attended for their initial visits which included history taking, 
clinical examination and ultrasound scans. A woman’s menopause is defined as her last 
menstrual period preceding 12 consecutive months of amenorrhoea with no 
physiological, pathological or medical cause other than the age-related loss of ovarian 
follicular activity. Women who were over the age of 50 years and had had a 
hysterectomy were also classified as being postmenopausal. All those with evidence of 
adnexal tumours were examined by a Level II operator (myself), who was trained in use 
of the IOTA protocol (Timmerman et al 2000), but not in tumour “pattern recognition”. 
(Valentin, 1999b; Yazbek, 2007a) Attempting to designate a histological diagnosis or 
attempting to differentiate subjectively between benign and malignant tumours on 
ultrasound scan was discouraged. The probability of malignancy within an adnexal 
mass was estimated by using the IOTA Logistic Regression Model (LR1 and LR2) as 
per section 2.7.5. 
 
All women had a detailed assessment including history as well as clinical and 
ultrasound examination.  
 
The level II operator recorded the IOTA assessments in the research file and these 
assessments were not available to the clinicians who made the clinical decisions about 
the patients’ plan of care. Pregnant women and those unable to undergo a transvaginal 
scan were excluded from the final data analysis. In cases of multiple lesions, the lesion, 
more likely to be malignant according to the IOTA model score, was included into the 
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analysis, as the diagnosis of malignancy in one lesion supersedes the diagnosis of any 
coexisting benign lesions. Following the examination by the level II operation, the 
women with adnexal tumours were re-examined independently by an expert ultrasound 
operator who used subjective pattern recognition to determine the nature of the adnexal 
tumour. Women with suspected ovarian cancer following the expert exam were referred 
to our gynaecological oncology team for further management.  Women with presumed 
benign lesions were offered choice between conservative management and surgery 
taking into account their clinical symptoms and personal preferences. 
 
Women who opted for conservative management were offered regular follow up 
ultrasound scans starting with 4 monthly intervals for a minimum of 12 months. Women 
who become symptomatic during follow up, those who requested intervention and those 
in whom ultrasound findings became suspicious of cancer were offered surgery.  Only 
when the data collection was completed at the end of the study, were the IOTA LR1 and 
LR2 calculations of the risk of malignancy performed and included in the data 
collection sheets. Histopathology was the primary reference standard used. Tumours 
were classified according to the World Health Organisation (WHO) guidelines and 
malignancies were staged according to the International Federation of Gynecology and 
Obstetrics criteria. (Serov, 1973; Benedet, 2000) For the women in whom surgery was 
not required, an ultrasound scan at 12 months or more after the primary scan confirming 
the initial diagnosis of benign lesion was used as the second reference standard.  
 
It was determined by the local Research and Development Department that formal 
ethical assessment and approval was not required as the steps in the conduct of the study 
were routine practice in the unit. This refers to ultrasound scan analysis including 
morphological analysis of the tumours using the IOTA protocol for the assessment of 
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adnexal masses. In addition to this, therapeutic decisions were not based on the IOTA 
model scores.  
 
8.3.3 Statistical Analysis and Results 
 
8.3.3.1. Statistical Techniques  
 
The sample size for this study was determined using Harrell’s recommendation that a 
validation dataset should contain at least 100 “events”, that is borderline or malignant 
tumours (Harrell, 2001).  Our validation dataset has 137 events, therefore satisfying this 
requirement. 
 
Initially, the data was analysed after assuming that both reference tests had perfect 
(100%) sensitivity and specificity.  The sensitivity, specificity and overall accuracy of 
the three diagnostic tests (LR1, LR2 and pattern recognition) were calculated under this 
assumption and presented with exact 95% confidence intervals.  Formal comparisons 
across different index tests were made using McNemar’s test; the exact version of this 
test was used when necessary.  These analyses were performed in the software package 
Stata 14.0 © (Stata Corp., College Station, TX, USA). 
 
A secondary analysis was performed using a Bayesian approach similar to that of de 
Groot (de Groot, 2011).  In detail, we assumed that the choice of reference test 
(histology or ultrasound) was related to the underlying status of the patient (that is, 
patients with cancer were more likely to be assessed using histology).  In addition, we 
assumed that the histology results were always correct whereas the ultrasound results 
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were imperfect.  The prior distributions for ultrasound sensitivity and specificity were 
chosen to reflect our belief that both values were probably close to 90% and almost 
certainly within the range 80-100%.  Low information priors were used for all other 
parameters.  Two MCMC chains of 3000 samples were run in OpenBUGS (Lunn, 2012) 
with the first 1000 of each discarded as the burn-in period.  All results are presented as 
medians with 95% credible intervals.  To check the robustness of our results, additional 
analyses were run where the priors for ultrasound performance were changed to reflect 
worse performance. 
 
8.3.3.2. Results 
 
A total of 555 consecutive women attended for ultrasound assessment during the study 
period.  11 women were pregnant and they were excluded from the data analysis. A 
flow chart showing the management of 544 women included in the trial is shown in Fig. 
1. (Figure. 8.3-1.)  A total of 342/544 (62.9%) women had surgery while 147/544 
(27.0%) were managed conservatively. (Table 8.3-1) 41/544 (7.5%) were lost to follow 
up, 13 women died soon after the diagnosis of adnexal tumour was made and one 
woman received chemotherapy as the primary treatment for presumed metastatic bowel 
cancer. Among the 13 women who died, 5 had a non-ovarian malignancy (oesophageal 
(2), pancreatic, cervical and endometrial), 4 had non-malignant medical conditions 
(amyloidosis, chronic renal failure and bronchiectasis, dementia with urinary sepsis and 
alcoholic induced liver failure) and 4 had suspected ovarian malignancies. The patients 
ranged from 16 to 91 years of age with an average age of 50 years.  237/544 (43.6%) of 
women were post-menopausal.  
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After excluding the 55/544 (10.1%) women who had neither reference test, the final 
diagnosis of a malignant tumour was made in 137/489 (28.0%) women and benign 
tumours were diagnosed in the remaining 352 (72.0%) women. Histological diagnosis 
was available in 342 women and they are shown in Tables 8.3-2, 8.3-3 and 8.3-4. The 
most common indications for surgery were suspected ovarian cancer and pelvic pain. 
(Table 8.3-5) Only 8 tumours increased in size during follow up whilst the remaining 
139 (94.6%) were the same size, smaller or completely resolved. (Table 8.3-6) In these 
8 women the cyst increased in size between 21% and 94% but none of the women had 
surgery for that reason as many of the cysts were still less than 5cm in diameter and the 
tumours were morphologically unchanged. In women managed expectantly the average 
follow-up was 27 months for all who had an ultrasound scan with a range from 12 to 68 
months.  
 
Using pattern recognition as the primary diagnostic test, 147 women were diagnosed 
with cancer. The management of women in respect of the predicted nature of pelvic 
tumour is shown in Fig 2. (Figure 8.3-2) Over 95% of women diagnosed with a 
malignant lesion had surgery compared to 50% of women with benign lesions. The 
predicted diagnoses of the nature of adnexal tumour at the initial visit using PR, LR1 
and LR2 are shown in Table 8.8-7. There were significant difference in the proportion 
of women diagnosed with malignancy between PR and LR1/LR2. (P < 0.0001) (Table 
8.8-8) Assuming that the rate of intervention would be identical in women diagnosed 
with cancer and benign disease regardless of the diagnostic method used, there would 
also be a significant difference in the number of women having surgery for presumed 
malignancy. This is because the false positive rate for LR1/LR2 was significantly higher 
that of pattern recognition. The overall intervention rates including both benign and 
malignant lesions for PR, LR 1 and LR2, however would not be significantly different. 
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(Table 8.3-7) 
 
 
There were 10 patients who had surgery after completing 12 months follow up which 
enabled a comparison of the two tests performed. In one of them there were discordant 
results for histology and the follow-up ultrasound scan. These results suggest a good 
level of agreement between histology and the follow up visit strategy. The woman with 
the discordant results had surgery because her tumour had changed morphologically. 
Histology result however was benign polypoid endometriosis. 
 
The primary analysis was performed assuming that both reference tests (histology and 
follow up ultrasound scans) had the same perfect accuracy.  (Table 8.3-9) This showed 
LR1, LR2 and pattern recognition all demonstrated high sensitivities, but there were 
significant differences in the specificities for the diagnosis of ovarian cancer between 
PR and the IOTA models when tests were used at the initial visit. When assuming 
differing accuracy for histology (100%) and follow up ultrasound scans (90%), the 
results were similar to when both reference tests were assumed to be 100% accurate. 
(Table 8.3-10) 
 
There were eight women with cancer (borderline [5] and invasive [3]) who were 
misdiagnosed as benign disease using pattern recognition (8/132; 6.1% [95% CI: 2.0% 
to 10.1%]). This caused delayed interventions in one woman who was eventually 
diagnosed with a borderline tumour. Among the invasive malignancies, all were stage 1 
with two dermoid tumours with early malignant transformation within and the one 
seromucinous adenocarcinoma. Using LR1 there would have been four false negative 
cancer diagnoses (borderline [2] and invasive [2]) (3.0% [95%CI: 0.1% to 6.0%]) (P = 
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0.238 when compared to PR) compared to seven (borderline [3] and invasive [4])  
(5.3% [95%CI: 1.5% to 9.1%]) using LR2 (P=0.787 when compared to PR) neither of 
which was statistically significant. The tumours missed by LR1/LR2 were those missed 
by PR except for 1 metastatic tumour detected by PR and missed by LR1. 
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Figure 8.3-1: Flowchart of Study Eligibility IOTA Logistic Regression Models LR1 
and LR2  - IOTA LR1 and LR2 Follow-Up Study. N = 544 
 
Yes	
Surgical	Management	n	=	343	 Expectant	Management		n	=	187	Excluded:	Lost	to	follow-up		n	=	41		
Total	Surgical	Management		 n	=	342/544	(62.9%)	 Total	Expectant	Management			n	=	147/544	(27.0%)	
Changed	to	Expectant	Management	n	=	17		Choice	(15)	Pregnancy	(2)		
No	
*	Deceased	n	=	13:	Presumptive	diagnoses:		Ovarian	malignancy	(4),	Non-ovarian	malignancy	(5),	Medical	conditions	(4)	
Non-pregnant	women	with	ultrasound	diagnosis	of	an	adnexal	tumour	(n=544)			
Deceased	*	n	=	13	Chemotherapy	n	=	1		
Surgery	planned	
Changed	to	Surgical	Management	n	=	16		Request	(7)	Infertility	(4)	Other	operation	(3)	Morphology	change	(1)	Risk	reduction	(1)		
Legend	
	 Excluded	patients																									 											Patient	flow		
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Table 8.3-1: Final Patient Reference Standard Allocation - IOTA LR1 and LR2 
Follow-Up Study. N = 544. 
 
 Minimum 12 month Follow up 
Number of Patients (%) 
Histology Only 332 (61.0) 
Follow-up USS Only 147 (27.0) 
Both 10 (1.8) 
Neither 55 (10.1) 
Total 544 (100) 
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Table 8.3-2: Benign Histology - IOTA LR1 and LR2 Follow-Up Study. Histology 
N=342 Benign Tumours N=205.  
 
Histology Number (%) 
Cystadenoma (n=43) /Cystadenofibroma (n=14) 57 (27.8) 
Endometrioma 47 (22.9) 
Mature cystic teratoma (Dermoid) 31 (15.1) 
Benign functional (haemorrhagic cyst, follicular cyst) 29 (14.1) 
Fibroma 10 (4.9) 
Normal adnexae at surgery 5 (2.4) 
Torsion (3 x Benign, 1x Cystadenofibroma, 1 x Fibroma) 5 (2.4) 
Pedunculated Leiomyoma 4 (2.0) 
Pelvic Inflammatory Disease 4 (2.0) 
Fibrothecoma 3 (1.5) 
Hydrosalpinx 3 (1.5) 
Pseudocyst 2 (1.0) 
Brenner 2 (1.0) 
Actinomycosis 1 (0.5) 
Struma Ovarii 1 (0.5) 
Myolipoma 1 (0.5) 
Total 205 
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Table 8.3-3: Malignant Histology - IOTA LR1 and LR2 Follow-Up Study. 
Histology N = 342. Malignancies N = 137.      Outcome of Follow-up Ultrasound 
Scans - IOTA LR1 and LR2 Follow-Up Study. N = 171. N = 189. 
 
Malignant Tumours Number (%) 
Borderline 21 (15.3% all Malignancies)  (6.1% of all Histology) 
Invasive: 116 (84.7% all Malignancies) (33.9% of all Histology) 
Total 137 
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Table 8.3-4: Malignant Histology Tumour Type and Stage - IOTA LR1 and LR2 
Follow-Up Study. Histology N = 342. Malignancies N = 137. 
Tumour Type and Stage N (%) 
Borderline 21 (15.3% all Malignancies)  
(6.1% of all Histology) 
Borderline 
n=21 
Serous 7 
Mucinous 6 
Serous papillary 4 
Endometrioid 1 
GCT 1 
Undefined 2 
Stage 1 21 
Invasive: 116 (84.7% all Malignancies)  
(33.9% of all Histology) 
Invasive 
Malignancies 
n=116 
Epithelial 84 
Germ cell 3 
Sex chord Stromal 1 
Metastases, Recurrence, 
unknown 
28 
Invasive 
Malignancies 
n=116 
Stage I 26/116 (22.4% of invasive malignancies) 
Stage II 5/116 (4.3% of invasive malignancies) 
Stage III 37/116 (31.9% of invasive malignancies) 
Stage IV 22/116 (10.0% of invasive malignancies) 
Metastases / Recurrence 26/116 (22.4% of invasive malignancies) 
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Table 8.3-5: Indication for Surgery - IOTA LR1 and LR2 Follow-Up Study. N = 
342.  
 
Suspected cancer 152 
Pain 75 
Women’s Choice 62 
Sub-fertility 30 
Pressure symptoms 13 
Other operation needed 5 
UKCTOCS / Prophylactic 4 
Abnormal Follow-up USS 1 
TOTAL 342 
 
Table 8.3-6: Morphological changes of expectantly managed adnexal tumours on 
follow up scans- IOTA LR1 and LR2 Follow-Up Study. N = 147. 
 
 Follow-up USS 
Only (%) 
Resolved 34 (23.1) 
Smaller*  21 (14.3) 
Unchanged 84 (57.1) 
Larger* 8 (5.4) 
Total 147 
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Figure 8.3-2: Flowchart Showing Management of Women with Adnexal Tumours 
with regard to ultrasound diagnosis of malignancy based on Pattern Recognition 
(n=544) 
Non-Pregnant Women with ultrasound diagnosis of an adnexal tumour n=544 
 
Malignant  
n = 147 
Benign   
n = 397 
RIP 
n = 4 
(2.72%) 
Expectant 
Management 
n = 147 
(37.0%) 
Lost to  
follow-up 
n = 40 
(10.1%) 
Surgery 
n = 141  
(95.9%) 
Surgery 
n = 201 
(50.6%) 
Chemotherapy 
n = 1 
(0.68%) 
Refused surgery 
n = 1 
(0.68%) 
RIP 
n = 9 
(2.3%) 
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Table 8.3-7: Intervention based on initial ultrasound scan diagnosis by LR1, R2 
and PR - IOTA LR1 and LR2 Follow-Up Study. N = 544. 
 
 Malignant 
Diagnosis 
n 
Intervention rates for 
Malignant Diagnoses  
n (%) 
Intervention rates 
for All Diagnoses 
n (%) 
Pattern Recognition 142 142/489 (29.0%) 342/489 (69.9%) 
LR1 213 213/489  (43.6%)* (76.1%)# 
LR2 212 212/489  (43.4%)*  (76.0%)# 
*Malignant diagnosis: Assumption that in keeping with PR (n=142), all women with a malignant 
diagnosis with LR1/2 would have had surgery. 
#Benign Diagnosis: Assumption that in keeping with PR where 200/347 (57.6%) with benign 
diagnoses had surgery, 57.6% of women with benign diagnoses by LR1/2 would also have had 
surgery.  
#LR1 rate = (213 + 57.6% of 276)/489 = 76.1% 
#LR2 rate = (212 + 57.6% of 277)/489 = 76.0% 
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Table 8.3-8: LR1 versus Pattern Recognition - IOTA LR1 and LR2 Follow-Up 
Study. N = 489. 
 
REF = Benign  PR 
  Benign Malign 
LR1 Benign 271 1 
Malign 68 12 
P < 0.0001 
 
REF = Malignant  PR 
  Benign Malign 
LR1 Benign 4 0 
Malign 4 129 
P = 0.13 (Exact) 
 
 
Table 8.3-9: Primary Analysis Both Reference Standards - Sensitivity, Specificity 
and Accuracy - IOTA LR1 and LR2 Follow-Up Study. All patients N = 480, 27.7% 
malignancy 
 
Test Number Sensitivity Specificity Accuracy 
PR 489 94.2 (88.8 to 97.4) 96.3 (93.8 to 98.0) 95.7 (93.5 to 97.3) 
LR1 489 97.1 (92.7 to 99.2) 77.3 (72.5 to 81.5) 82.8 (79.2 to 86.1) 
LR2 489 94.9 (89.8 to 97.9) 76.7 (71.9 to 81.0) 81.8 (78.1 to 85.1) 
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Table 8.3-10: Secondary Bayesian Analysis Assuming ‘High’ performance Follow 
up USS (90% accuracy) – Sensitivity and Specificity - IOTA LR1 and LR2 Follow-
Up Study. All patients N = 489, 28.0% malignancy. 
 
Test Number Sensitivity Specificity 
PR 489 93.8 (88.9 to 97.0) 96.4 (94.1 to 98.0) 
LR1 489 96.7 (92.8 to 98.8) 77.5 (73.0 to 81.5) 
LR2 489 94.5 (89.8 to 97.6) 76.8 (72.3 to 81.0) 
Presented as medians and 95% credible intervals.  
 
 
178 
8.4 Study 4 - A prospective evaluation of the IOTA “Simple Rules” as 
a triage tool for the diagnosis of ovarian cancer in the outpatient 
setting using two reference standards 
 
8.4.1 Introduction 
 
Study 4 looked at the simple rules protocol and its accuracy for the diagnosis of ovarian 
cancer. In this study, the reference standard was histology in keeping with the literature. 
There were though, patients who were excluded because they did not have the preferred 
reference test (histology). These patients had an alternative reference test (follow up 
USS over at least 12 months) and the exclusion of these patients leads to some partial or 
incomplete verification bias. It should not be assumed that the alternative reference test 
has 100% accuracy and the difference in the accuracies of the 2 reference tests should 
ideally be considered during the analysis.  
 
8.4.2 Methods 
 
This was an extension of the prospective study (Study 2). Initial assessments were 
conducted over a 33-month period from May 2009 to January 2012 and follow up 
ultrasound scans were conducted until January 2014 as was done in Study 3. Patient 
assessment was as per the methods of study 2 but the analyses did not only include the 
women who had a histological diagnosis but also those who had expectant management 
and a follow up ultrasound scan of a minimum of 12 months, that showed complete 
resolution or which exceeded 6 months as per Study 3. 
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8.4.3 Statistical Analysis and Results 
 
8.4.3.1. Statistical Techniques 
As was the case in Study 3, the 2 reference standards were histology and follow-up 
ultrasound scans and both primary and secondary analyses were done. (See section 8.3.3 
Statistical Analysis and Results of Study 3 – Subsection 8.3.3.1 Statistical 
Techniques).  
 
8.4.3.2. Results 
After excluding the 11 pregnant patients from the initial 555 consecutive women, there 
were 544 women included in the analysis. There were 342/544 (62.9%) women who 
had surgery while 147/544 (27.0%) women had expectant management with follow up 
ultrasound scans. (Figure 8.4-1) This is the same patient population with the same 
demographics as in Study 3. (See section 8.3.3 Statistical Analysis and Results of 
Study 3 – Subsection 8.3.3.2 Results). (Table 8.3-1, Table 8.3-2, Table 8.3-3, Table 
8.3-4, Table 8.3-5, Table 8.3-6) 
 
The simple rules were applicable in 80.3% (437/544) (95% CI: 76.7% to 83.6%) of the 
entire population while the rules were applicable in 77.2% (264/342) (95% CI: 72.8% to 
81.7%) of women who had surgery and in 87.8% (129/147) (82.5% to 93.1%) of those 
who had expectant management only. (P = 0.0067) 
 
When those who had surgery was analysed, the rules were applicable in 264/342 
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(77.2%) women with 146/342 (42.7%) classified as benign and 118/342 (34.5%) 
classified as malignant. Of those classified as benign, 142/146 (97%) were confirmed as 
benign and of those classified as malignant, 101/118 (85.6%) were confirmed as 
malignant.  (Figure 8.4-2) 
 
When the expectant group was analysed, the rules were applicable in 129/147 (87.8%) 
women. There were 128/147 (87.1%) assessed as benign and 1/147 (0.7%) as malignant 
and on follow up ultrasound scan, none of these showed any morphological changes to 
raise the suspicion of malignancy and the one assessed as malignant completely 
resolved on follow up ultrasound scan. 
 
For the entire population who had either of the reference tests performed, the simple 
rules were applicable in 393/489 (80.4%) with 274/489 (56.0%) assessed as benign and 
119/489 (24.4%) assessed as malignant. (Table 8.4-1) 270/274 (98.5%) of those 
assessed as benign were confirmed as benign and 101/119 (84.9%) of those assessed as 
malignant were confirmed as malignant.  
 
Primary analysis assuming the same 100% accuracy for both reference tests showed a 
similar sensitivity and specificity for SR as for PR and for SR+PR. (P>0.05).  As 
expected, SR+MA had a trend towards the highest sensitivity (P>0.05) and the lowest 
specificity (P < 0.0001) of all the tests. (Table 8.4-2)  
 
Inclusion of the women who did not have surgery improved the specificity of all 
models, as the specificity of the models for those who did not have surgery was 
significantly greater than for those who did have surgery because of the greater 
likelihood that the women who had expectant management only, had benign disease. 
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(Tables 8.4-3 and 8.4-4) 
 
There were eight women with cancer who were misdiagnosed as benign disease using 
pattern recognition (8/132; 6.1% [95% CI: 2.0% to 10.1%]). This caused a delay in 
surgery for one woman, who was eventually diagnosed with a borderline tumour. Using 
SR there would have been four false negative cancer diagnoses (3.0% [95%CI: 0.1% to 
6.0%]), which was not statistically significant. (P = 0.238) When assuming differing 
accuracy for histology (100%) and a follow up ultrasound scan (90%) the median 
sensitivity and specificity with the 95% credible intervals for SR+PR, SR+MA and 
pattern recognition were similar to when both reference tests were assumed to be 100% 
accurate. (Table 8.4-5) 
 
On comparing the results of PR, LR1, LR2 and SR, SR was seen to match the 
performance of PR when the rules were applicable (Specificity P = 0.04 [exact], 
Sensitivity P = 1.00 [exact]). (Table 8.4-6) SR had a better specificity when compared 
with LR1/LR2 (P = 0.0001) though sensitivity was similar (P = 0.50 [LR1]). (Table 8.4-
7) 
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Figure 8.4-1: Flowchart of Study Eligibility Simple Rules - IOTA Simple Rules 
Follow-Up Study. N = 544.  
 
 
Yes	
Surgical	Management	n	=	343	 Expectant	Management		n	=	187	Excluded:	Lost	to	follow-up		n	=	41		
Total	Surgical	Management	n	=	342/544	(62.9%)	 Total	Expectant	Management		n	=	147/544	(27.0%)	
Changed	to	Expectant	Management	n	=	17		Choice	(15)	Pregnancy	(2)		
No	
*	Deceased	n	=	13:	Presumptive	diagnoses:		Ovarian	malignancy	(4),	Non-ovarian	malignancy	(5),	Medical	conditions	(4)	
Non-pregnant	women	with	ultrasound	diagnosis	of	an	adnexal	tumour	(n=544)			
Deceased	*	n	=	13	Chemotherapy	n	=	1		
Surgery	planned	
Changed	to	Surgical	Management	n	=	16		Request	(7)	Infertility	(4)	Other	operation	(3)	Morphology	change	(1)	Risk	reduction	(1)		
																			 Excluded	patients												 Patient	flow		
Rules Applicable  
 Included Patients:  
n=264 (77.2%) 
Benign =  146 
Malignant = 118 
 
Rules not 
Applicable 
n=78  
(22.8%) 
Rules Applicable 
Included Patients:  
n=129 (87.8%) 
Benign = 128 
Malignant = 1 
 
Rules not 
Applicable 
n=18  
(12.2%) 
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Figure 8.4-2: Flow Diagram of Study Results Stratified by Management Simple 
Rules - IOTA Simple Rules Follow-Up Study. N = 544.  
 
 
Expectant Management 
N = 147 (27.0%) 
 
Surgical Management  
N = 342 (62.9%) 
 
Yes Yes No No 
Rules Applicable 
Included Patients:  
n=264 (77.2%) 
Benign = 146 
Malignant = 118 
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n=129 (87.8%) 
Benign = 128 
Malignant = 1 
 
Rules not 
Applicable 
n=78  
(22.8%) 
Rules not 
Applicable 
n=18  
(12.2%) 
 
SR Benign 
n=146 
(42.7%) 
SR Malignant 
n=118  
(34.5%) 
SR Malignant 
n=1  
(0.7%) 
SR Benign 
n=128  
(87.1%) 
Benign 
n=142 
97.3% 
Benign 
n=17 
14.4% 
Benign 
n=128 
(100%) 
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n=1 
(100%) 
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n=46 
59.0% 
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n=18 
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*Mal 
n=4 
2.7% 
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n=101 
85.6% 
Mal 
n=32 
41.0% 
Mal 
n=0 
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n=0 
Mal 
n=0 
* Mal = Malignant 
 
Included (n=303) 
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Table 8.4-1: Patient Outcomes after use of either of the 2 Reference Standards Simple Rules - IOTA Simple Rules Follow-Up Study. N = 489. 
 Rules Applicable N = 393 (80.4%) Rules not Applicable N=96 (19.6%) 
 Simple Rules assessed as Benign  Simple Rules assessed as 
Malignant 
Simple Rules assessed as Indeterminate 
Simple Rules N = 274/489 (56.0%) N = 119/489 (24.4%) N = 96/489 (19.6%) 
Benign 
Outcome 
N = 270/274 (98.5%) N = 18/119 (15.1%) N = 64/96 (66.7%) 
Diagnosis from: 
Histology  
USS  
 
142 
128 
Diagnosis from: 
Histology  
USS (Resolved) 
 
17 
1 
Diagnosis from: 
Histology  
USS (Resolved x 5, Smaller x 3, Same x 10) 
 
46 
18 
Malignant 
Outcome 
N = 4/274 (1.5%) N = 101/119 (84.9%) N = 32/96 (33.3%) 
Diagnosis from: 
Histology: 
- Borderline  
- Invasive Malignant  
USS  
 
 
1 
3 
0 
Diagnosis from: 
Histology: 
- Borderline  
- Invasive Malignant  
USS  
 
 
10 
91 
0 
Diagnosis from: 
Histology: 
- Borderline  
- Invasive Malignant  
USS  
 
 
9 
23 
0 
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Table 8.4-2: Primary Analysis Both Reference Standards - Sensitivity, Specificity 
and Accuracy - IOTA Simple Rules Follow-Up Study. All patients N = 489, 28.0% 
malignancy. Simple Rules Applicable N = 393. 
 
Test Number Sensitivity Specificity Accuracy 
PR 489 94.2 (88.8 to 97.4) 96.3 (93.8 to 98.0) 95.7 (93.5 to 97.3) 
SR 393 96.2 (90.5 to 99.0) 93.8 (90.3 to 96.3) 94.4 (91.6 to 96.5) 
SR+PR † 489 93.4 (87.9 to 97.0) 94.3 (91.4 to 96.5) 94.1 (91.6 to 96.0) 
SR+Mal § 489 97.1 (92.7 to 99.2) 76.7 (71.9 to 81.0) 82.4 (78.7 to 85.7) 
† SR+PR – Simple rules and use of pattern recognition for all indeterminate tumours  
§ SR+MA – Simple rules and malignancy all indeterminate tumours 
 
Table 8.4-3: Primary Analysis Histology Only - Sensitivity, Specificity and 
Accuracy - IOTA Simple Rules Follow-Up Study. N = 342, 40.1% malignancy. 
Simple Rules Applicable N = 264. 
 
Test Number Sensitivity Specificity Accuracy 
PR 342 94.2 (88.8 to 97.4) 93.7 (89.4 to 96.6) 93.9 (90.8 to 96.2) 
SR 264 96.2 (90.5 to 99.0) 89.3 (83.4 to 93.6) 92.0 (88.1 to 95.0) 
SR+PR † 342 93.4 (87.9 to 97.0) 90.7 (85.9 to 94.3) 91.8 (88.4 to 94.5) 
SR+Mal 342 97.1 (92.7 to 99.2) 69.3 (62.5 to 75.5) 80.4 (75.8 to 84.5) 
† SR+PR – Simple rules and use of pattern recognition for all indeterminate tumours  
§ SR+MA – Simple rules and malignancy all indeterminate tumours 
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Table 8.4-4: Primary Analysis - Comparison of Specificity between Histology and 
Follow-Up Ultrasound Patients - IOTA Simple Rules Follow-Up Study.  
 
 Histology USS  
Test Number Specificity Number Specificity P-value 
PR 195 93.8 (89.5 to 
96.8) 
147 100.0 (97.5 to 
100.0) 
0.006 
SR 151 89.4 (83.4 to 
93.8) 
129 99.2 (95.8 to 
100.0) 
0.002 
SR+PR † 195 90.8 (85.8 to 
94.4) 
147 99.3 (96.3 to 
100.0) 
0.003 
SR+Mal § 195 69.2 (62.2 to 
75.6) 
147 87.1 (80.6 to 92.0) 0.001 
† SR+PR – Simple rules and use of pattern recognition for all indeterminate tumours  
§ SR+MA – Simple rules and malignancy all indeterminate tumours 
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Table 8.4-5: Secondary Bayesian Analysis Assuming ‘High’ performance Follow 
up USS (90% accuracy) – Sensitivity and Specificity - IOTA LR1 and LR2 Follow-
Up Study. All patients N = 489, 28.0% malignancy. 
Test Number Sensitivity Specificity 
PR 489 93.8 (88.9 to 97.0) 96.4 (94.1 to 98.0) 
SR+PR † 489 93.2 (88.0 to 96.5) 94.4 (91.9 to 96.6) 
SR+Mal § 489 96.7 (92.7 to 98.8) 76.8 (72.4 to 81.2) 
Presented as medians and 95% credible intervals.  
† SR+PR – Simple rules and use of pattern recognition for all indeterminate tumours  
§ SR+MA – Simple rules and malignancy all indeterminate tumours 
 
Table 8.4-6: Pattern Recognition versus Simple Rules - IOTA LR1 and LR2 
Follow-Up Study - Rules Applicable (n = 393). 
 
REF = Benign  SR 
  Benign Malign 
PR Benign 269 8 
Malignant 1 10 
P = 0.04 (Exact) 
REF = Malign  SR 
  Benign Malign 
PR Benign 2 1 
Malignant 2 100 
P = 1.00 (Exact) 
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Table 8.4-7: LR1 versus Simple Rules - IOTA LR1 and LR2 Follow-Up Study - 
Rules Applicable (n = 393). 
 
REF = Benign  SR 
  Benign Malignant 
LR1 Benign 251 1 
Malignant 19 17 
P = 0.0001 
REF = Malignant  SR 
  Benign Malignant 
LR1 Benign 2 0 
Malignant 2 101 
P = 0.50 (Exact) 
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8.5 Study 5 - Use of the IOTA Simple Rules for the diagnosis of 
ovarian cancer: a Meta-Analysis 
 
8.5.1 Introduction 
 
The aim of this study was to perform a meta-analysis of the results of studies using the 
International Ovarian Tumour Analysis (IOTA) simple rules tool for the diagnosis of 
ovarian cancer.  
 
8.5.2 Methods 
 
8.5.2.1. Data sources 
 
Articles were identified from a number of electronic databases. A search was performed 
on MEDLINE using the terms “simple rules and adnexal”, “simple rules and ovarian” 
and “simple rules and ultrasound”.  A search was also performed on EMBASE using the 
terms “Simple Rules” after using terms “ovar tumour” and “Ultrasound”.  A Cochrane 
search was also performed for “ovary” and “tumour”. Additionally, hand searches were 
performed on the bibliographies of included studies and any reviews found. Studies 
from 1st January 2008 until the 8th November 2013 were included for review. Our own 
data was included as one of the studies. 
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8.5.2.2. Study selection 
 
Along with another reviewer, I selected articles from the search results. I read all 
abstracts. To be included in this meta-analysis, the study had to include data on use of 
the Simple Rules protocol when applied to adnexal masses for the diagnosis of ovarian 
cancer. All women must also have had surgery and a histological diagnosis for 
comparison as the gold standard or reference test. (Figure 8.5-1) Only prospective 
studies and preferably those with a clear indication that the sample selection was 
random or consecutive were included. This was to avoid selection bias and improve the 
applicability and generalisability of the results.  
 
After choosing relevant articles, the full text articles were read and 2 by 2 contingency 
tables were created with the data extracted independently by myself and 1 other 
reviewer. QUADAS 2 assessments were performed on each included study by two 
independent reviewers (N.N. and X.F.) and discrepancies were resolved between them.  
 
Studies that combined simple rules with another format of assessment were excluded 
because it was not possible to extract data on the simple rules alone as was the case with 
Sayasneh et al. (Sayasneh, 2013b) A further exclusion was Di Legge et al and as it 
incorporated data from IOTA Phase 1b (n=507) and Phase 2 (n=1938) both of which are 
already included in the data from Timmerman 2008 and Timmerman 2010. (Di Legge, 
2012; Timmerman, 2008, Timmerman, 2010) Kaijser et al 10 was a summary article 
describing all the IOTA studies and giving a summary. (Kaijser, 2013) The authors 
included IOTA Phase 1, 1b and 2 (temporal and external validation studies) and this 
data is already included. Ameye et al included patients who were already included from 
other studies. (Ameye, 2012) These were IOTA Phase 1 data patients as well as Phase 2 
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data patients. The author also went on to exclude a significant proportion of the patients 
who could be classified according to simple descriptors.  This study was therefore 
excluded. 
 
Guerriero et al used five examiners to analyse stored data. This study was excluded as it 
was a retrospective study and as it had different results for each of the five examiners. 
(Guerriero, 2013)  Ruiz de Gauna et al performed a similar study with two ultrasound 
operators analysing the tumours in real time and four doing so retrospectively in order 
to assess the inter-observer agreement and was therefore excluded as no single result 
was available. (Ruiz de Gauna, 2013) Prompeler was a summary and did not include 
any original data but instead presented the data from Timmerman 2008. (Prömpeler, 
2011) Nunes et al is a published protocol for an ongoing study and has no data attached. 
(Nunes, 2012) 
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Figure 8.5-1: Flowchart of Study selection process for the Meta-analysis of use of 
Simple Rules for the identification of malignant adnexal tumours (Nunes, 2014) 
 
 
 
 
 
Total number of citations retrieved from electronic searches and manual 
searches of references: n = 88 
Full manuscripts retrieved for detailed evaluation: n = 14 
Duplicates excluded: n = 18 
 
Excluded (n=4) 
Citations excluded after screening year 
of publication, titles and/or abstracts:  
n = 56 
eeNo 
g year of publication, titles and/or 
abstracts:  
n = 56 
 
Articles excluded with reasons: n = 8 
 
• Retrospective and inter-observer 
agreement study:  
n = 1 (Guerriero, 2013) 
• Lack of original data (summary):  
n = 1 (Prömpeler, 2011) 
• A protocol: n = 1 (Nunes, 2012) 
• Data duplication: n = 3 (Di Legge, 
2012; Kaijser, 2013; Ameye, 2012) 
• Inter-observer agreement study and 
non-consecutive:  
n = 1 (Ruiz de Gauna, 2013) 
• Simple rules data combined with 
alternative scan protocol:  
n = 1 (Sayasneh, 2013b) 
Primary articles included in systematic review: n = 6  
Additional articles 
included: 
Current study n= 1 
Primary articles included in systematic review plus current study: n = 7 
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8.5.2.3. Quality assessment 
 
The quality of each study was assessed using the QUANDAS-2 tool looking at the 4 
domains of patient selection, the index test used, the reference standard or gold standard 
and the flow and timing of the study. (Whiting, 2011) Quality characteristics were 
documented for the selected publications according to QUADAS 2 criteria. (Figure 8.5-
2) (Table 8.5-1) Verification bias, which is also known as “workup” or “referral” bias, 
occurs if the decision to perform the reference test (surgery with resultant histology) is 
based on the result of the index test under assessment (simple rules). If the decision for 
surgery was based on the result of the simple rules model, verification bias was 
considered to have occurred. There are various types of verification bias. Partial 
verification bias occurs if only a selected subset of the population who underwent the 
index test undergo the reference test and the decision about which subset undergoes it, 
is dependent on the results of the test. Differential verification bias occurs when the 
index test result affects whether the participant receives the same reference standard 
test. Incorporation bias occurs if the index forms part of the reference standard. 
 
Only prospective studies with no significant evidence of the various types of 
verification, selection and incorporation bias were included. These patients must all 
have had transvaginal ultrasound scans and they should have had surgery within 120 
days of performing the ultrasound scan.  
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Table 8.5-1: Simple Rules Study Quality QUADAS 2 Criteria (Nunes, 2014) 
 Domain 1: Patient selection Domain 2: Index test Domain 3: Reference Standard Domain 4: Flow and Timing 
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Timmerman2008 Y Y Y Y Y L L L Y Y Y L L L Y Y U L L U Y Y Y Y Y Y L L 
Timmerman2010 Y Y Y Y Y L L L Y Y Y L L L Y Y L L L L Y Y Y Y Y Y L L 
Fathallah 2011 Y Y Y Y Y L L L Y Y Y L L L Y Y U L L U Y N U Y Y Y U H 
Hartman 2012 Y Y Y Y Y L L L Y Y Y L L L Y Y U L L U Y Y Y Y Y Y L L 
Sayasneh 2013 Y Y Y Y Y L L L Y Y Y L L L Y Y U L L U Y Y Y Y Y Y L L 
Alcazar 2013 Y Y Y Y Y L L L Y Y Y L L L Y Y U L L U Y Y Y Y Y Y L L 
Nunes 2014 Y Y Y Y Y L L L Y Y Y L L L Y Y L L L L Y Y Y Y Y Y L L 
Legend: Y=Yes; U=Unclear; N=No; H=High risk bias; L=Low risk of bias 
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Figure 8.5-2: Simple Rules Study Quality QUADAS 2 Criteria (Nunes, 2014) 
 
 
Low=low risk of bias; Unclear=risk of bias unclear; High=high risk of bias. 
 
8.5.3 Statistical Analysis and Results 
 
8.5.3.1. Statistical Techniques 
 
Analysis was performed using the packages metan (Harris, 2007; Harris, 2008), metareg 
(Harbord, 2005; Harbord, 2008a) and metandi (Harbord, 2008b; Harbord, 2009) in Stata 
13.1 ® (Stata Corp., College Station, TX, USA).  
 
The sensitivity, specificity and accuracy of simple rules and pattern recognition were 
compared separately using McNemar’s test for paired binary outcomes.  These analyses 
are based on the 237 patients for whom the simple rules were applicable as well as the 
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full 303 population separately.  The sensitivity, specificity and accuracy of simple rules 
were compared with the original and the validation IOTA studies separately using the 
Chi-squared (c2) test for independent binary outcomes. (Timmerman, 2008; 
Timmerman, 2010) 
 
Random effects meta-analysis was used to calculate univariate pooled estimates of 
sensitivity and specificity for the IOTA simple rules tool. (DerSimonian, 1986) A 
bivariate approach was also investigated to calculate these values (Harbord, 2007).  
Forest plots were constructed to summarise the results, and heterogeneity was 
quantified using the I2 statistic.  Meta-regression was used to investigate any 
heterogeneity present in the results and a funnel plot of the diagnostic odds ratio against 
study size was created to investigate the possibility of publication bias. (Thompson, 
2002) 
 
8.5.3.2. Results 
 
There were 88 studies identified with the initial search. (Figure 8.5-1) After excluding 
duplicates (18) and studies that did not include the simple rules protocol (56), there 
were 14 studies left for detailed reading. These full text articles were then read fully. A 
further 8 studies were excluded because they were using simple rules combined with 
another ultrasound tool [1] (Sayasneh, 2013b) , a reanalysis of previously published 
data included here from another study and therefore of already included patients [3],  
(Di Legge, 2012; Kaijser, 2013; Ameye, 2012), a retrospective study looking at inter-
observer variability [1] (Guerriero, 2013), a mixed prospective and retrospective 
assessment of inter observer variability 13 [1] (Ruiz de Gauna, 2013), a summary [1] 
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(Prömpeler, 2011) or a protocol [1] (Nunes, 2012). That left 6 studies added to our data. 
(Table 8.5-2) 
 
All women in each study had the same index test, which was a simple rules assessment 
via a transvaginal ultrasound scan, and all had histology as the reference standard. Two 
of the seven studies did not state whether all pregnant patients were excluded though in 
one of those studies, two patients were excluded, because for each of them, the adnexal 
mass was an ectopic pregnancy. (Fathallah, 2011; Hartman, 2012) Exclusion criteria 
varied in the studies. Alcázar et al and Hartman et al appeared to have a high exclusion 
rates but they included patients who would have been excluded at the start of other 
studies such as patients who never attended for the first scan, patients who had no mass 
or those who chose expectant management or had surgery at a different institution. 
(Alcázar, 2013; Hartman, 2012) The exclusions were therefore appropriate and the lost 
to follow up rates were low. All studies therefore had a low risk of bias in relation to 
domain 1, ”Patient Selection”.  In all studies, the index test was performed 
independently of the reference standard with a pre-determined threshold for diagnosis 
resulting in a low risk of bias in relation to domain 2 “Index Test”. One study had 5/282 
(1.8%) participants without a histological diagnosis (2 cases of ovarian torsion 
untwisted at surgery, 3 cases of abscesses confirmed on microscopy and culture). 
(Sayasneh, 2013b) Only one study other than the author’s study declared blinding of the 
pathologist who performed the reference standard. (Fathallah, 2011) This caused 
domain 3 “Reference Standard” to have a large segment where the risk of bias was 
unclear (70%). Timing of surgery was unknown for only 1 study (Fathallah, 2011) 
whereas in all others, surgery occurred within 21 days (Alcázar, 2013), 112 days 
(Hartman, 2012) or 120 days (Timmerman, 2008; Timmerman, 2010; Sayasneh, 
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2013b).  This therefore meant that domain 4 “Flow and Timing” had a low risk of bias 
in over 80% of the studies. (Figure 8.5-2) (Table 8.5-1) 
 
Details of the prevalence of malignancy and statistical results for each study are shown. 
(Table 8.5-2) The pooled sensitivity value for all 7 studies was 0.93 (95%CI:0.90-0.96). 
(Figure 8.5-3) The I2 value of 32% suggests moderate heterogeneity amongst the 
studies. The pooled specificity value was 0.95 (95%CI:0.93-0.97) and the I2 value of 
78% suggests considerable heterogeneity between the studies. (Figure 8.5-4) Very 
similar pooled values for sensitivity and specificity were obtained using the bivariate 
method (results not shown). A sub-analysis was done on only the externally validated 
studies and the pooled sensitivity decreased slightly to 0.92 (95%CI:0.88-0.96) whereas 
the pooled specificity increased slightly to 0.96 (95%CI:0.94-0.98). (Table 8.5-3) 
(Figure 8.5-5 and 8.5-6) Sub-analyses were done for pre and postmenopausal women. 
(Figures 8.5-7 to 8.5-10) Sensitivity was higher in postmenopausal women 
[0.94(95%CI:0.89-0.99)]when compared with premenopausal women 
[0.89(95%CI:0.82-0.95)] while specificity was similar but lower [0.94 (95%CI:0.88-
0.99) and 0.97 (95%CI:0.94-0.99) respectively]. 
 
When sensitivity is plotted against specificity, there appears to be a decreasing 
relationship between sensitivity and specificity. (Figure 8.5-11)  Meta-regression was 
subsequently performed for both sensitivity and specificity adjusting for prevalence.  
(Figures 8.5-12 & 8.5-13) The results suggest that the sensitivity and specificity values 
for the IOTA simple rules depend, at least in part, on the patient population to which it 
is being applied.  In particular, the meta-regression results suggest that all the 
heterogeneity in sensitivity, and over 50% of the heterogeneity in specificity, is due to 
differences in prevalence across the studies. 
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A further meta-regression of sensitivity and specificity was performed on operator level 
but not all studies made it clear the level of their operators and for those studies in 
which it was know, there was not enough information to assess whether operator level 
was the cause of heterogeneity. Meta-regression was also used to investigate whether 
differences in the percentage of the population for whom the rules were applicable was 
related to the observed heterogeneity. However, this percentage only explained a small 
amount of the heterogeneity in the sensitivity results and none of the heterogeneity in 
the specificity results (results not included). We plotted odds ratio against study size but 
there was no evidence of publication bias. This assessment was also done for the 
external validation studies alone and this confirmed no evidence of publication bias. 
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Table 8.5-2: All Studies included in the Simple Rules Meta-analysis (Nunes, 2014) 
 
 Study 
(First Author, 
Year of 
publication) 
Popula
-tion  
Number of 
Patients 
where Rules 
are 
Applicable 
(RA)  
(% of Total 
Population) 
Number of 
Malignant 
Tumours  
(% of Total 
Population) 
Number of 
Benign 
Tumours  
(% of Total 
Population) 
Prevalence 
of 
Malignancy 
in 
Population 
where Rules 
are 
Applicable 
(%) 
TP FP FN TN Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
1 Timmerman 
2008 
507 386 (76.1)   29.0 106 25 6 249 0.95  
(0.89 to 0.98)  
0.91  
(0.87 to 0.94) 
2 Timmerman 
2010 
1938 1501 (77.5) 542 (28.0) 1396 (72.0) 24.6 340 49 29 1083 0.92  
(0.89 to 0.95)  
0.96  
(0.94 to 0.97) 
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3 Fathallah 
2011 
122 109 (89.3) 14 (11.5) 108 (88.5) 10.1 8 3 3 95 0.73  
(0.39 to 0.94)  
0.97  
(0.91 to 0.99) 
4 Hartman 
2012 
103 91 (88.3) 30 (29.1) 73 (70.9) 24.2 20 9 2 60 0.91  
(0.71 to 0.99)  
0.87  
(0.77 to 0.94) 
5 Sayasneh 
2013 
255 214 (83.9) 74 (29.0) 181 (71.0) 24.8 46 3 7 158 0.87  
(0.75 to 0.95)  
0.98  
(0.95 to 1.00) 
6 Alcázar  
2013 
340 270 (79.4) 55 (16.2) 285 (83.8) 12.2 29 6 4 231 0.88  
(0.72 to 0.97)  
0.97  
(0.95 to 0.99) 
7 Nunes 
2014 
303 237 (78.2) 135 (44.6) 168 (55.4) 44.3 101 15 4 117 0.96 (0.91 to 
0.99)  
0.89 (0.82 to 
0.93) 
Sensitivity and specificity given with 95% Confidence Intervals (CI). FN, false negative; FP, false positive; TN, true negative; TP, true positive
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Figure 8.5-3: Forest Plot – Sensitivity (All Simple Rules Studies) (Nunes, 2014) 
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Figure 8.5-4: Forest Plot – Specificity (All Simple Rules Studies) (Nunes, 2014) 
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Table 8.5-3: External Validation Studies included in the Simple Rules Mata-
analysis (Nunes, 2014) 
All women 
Study Patient 
Number 
Malignancy 
Prevalence 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Timmerman 2010* 796 22.2% 0.91 (0.86 - 0.95) 0.96 (0.94 - 0.98) 
Fathallah 2011 ¶ 109 10.1% 0.73 (0.39 - 0.94) 0.97 (0.91 - 0.99) 
Hartman 2012 91 24.2% 0.91 (0.71 - 0.99) 0.87 (0.77 - 0.94) 
Sayasneh 2013 214 24.8% 0.87 (0.75 - 0.95) 0.98 (0.95 - 1.00) 
Alcazar 2013 270 12.2% 0.88 (0.72 - 0.97) 0.97 (0.95 - 0.99) 
Nunes 2014 237 44.3% 0.96 (0.91 - 0.99) 0.89 (0.82 - 0.93) 
Premenopausal Women 
Timmerman 2010*  526 9.5% 0.90 (0.78 - 0.97) 0.97 (0.95 - 0.98) 
Hartman 2012  39 23.1% 0.89 (0.52 - 1.00) 0.90 (0.73 - 0.98) 
Sayasneh 2013  143 15.4% 0.82 (0.60 - 0.95) 1.00 (0.97 - 1.00) 
Alcazar 2013  217 7.4% 0.88 (0.62 - 0.98) 0.97 (0.94 - 0.99) 
Nunes 2014  130 22.3% 0.90 (0.73 - 0.98) 0.89 (0.81 - 0.94) 
Postmenopausal Women 
Timmerman 2010*  270 47.0% 0.91 (0.85 - 0.96) 0.94 (0.88 - 0.97) 
Hartman 2012  36 30.6% 0.91 (0.59 - 1.00) 0.80 (0.59 - 0.93) 
Sayasneh 2013  71 43.7% 0.90 (0.74 - 0.98) 0.93 (0.80 - 0.98) 
Alcazar 2013  53 32.1% 0.88 (0.64 - 0.99) 1.00 (0.90 - 1.00) 
Nunes 2014  107 71.0% 0.99 (0.93 - 1.00) 0.87 (0.70 - 0.96) 
*  External centre only. ¶ No menopausal status data from Fathallah et al. 
 
204 
Figure 8.5-5: Forest Plot – Sensitivity (External Validation Simple Rules Studies) 
(Nunes, 2014) 
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Figure 8.5-6: Forest Plot – Specificity (External Validation Simple Rules Studies) 
(Nunes, 2014) 
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Figure 8.5-7: Forest Plot – Sensitivity (External Validation Simple Rules Studies 
Premenopausal Women) (Nunes, 2014) 
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Figure 8.5-8: Forest Plot – Specificity (External Validation Simple Rules Studies 
Premenopausal Women) (Nunes, 2014) 
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Figure 8.5-9: Forest Plot – Sensitivity (External Validation Simple Rules Studies 
Postmenopausal Women) (Nunes, 2014) 
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Figure 8.5-10: Forest Plot – Specificity (External Validation Simple Rules Studies 
Postmenopausal Women) (Nunes, 2014) 
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Figure 8.5-11: Sensitivity versus Specificity (All Simple Rules Studies) (Nunes, 
2014) 
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Figure 8.5-12: Meta-regression Sensitivity on Prevalence (All Simple Rules 
Studies) (Nunes, 2014) 
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Figure 8.5-13: Meta-regression Specificity on Prevalence (All Simple Rules 
Studies) (Nunes, 2014) 
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8.6 Study 6 – A pilot study of comparison of the potential intervention 
rates when asymptomatic postmenopausal women with an adnexal 
tumour were assessed by two management protocols 
 
8.6.1 Introduction 
 
The incidence of ovarian cancer is known to increase with age. The incidence was 
found to be 0.4 -13% in premenopausal women and 45% in postmenopausal women 
who had a laparotomy for an ovarian tumour in a 10-year retrospective review. 
(Koonings, 1989) The risk of malignancy increased 12 fold for women in their sixties 
versus those in their twenties. The population in this study are likely to have been 
symptomatic as they are described as being almost exclusively self-referring women 
who had exploratory laparotomies. 
 
Since 1989, there has been significant advancement of technology of imaging 
techniques. With the use of ultrasound and these various other imaging modalities such 
at CT and MRI to assess a variety of non-gynaecological conditions, there has been an 
increase in detection of adnexal cysts or tumours in asymptomatic postmenopausal 
women. These are cysts that would not have been detected 10 or 20 years ago. As 
postmenopausal women have a greater incidence of ovarian cancer as compared with 
premenopausal women, these discoveries have the potential to cause significant 
concern. Adnexal cysts have been found in up to 28% of asymptomatic women in 
previous studies. (Levine, 1992; Sladkevicius, 1995; Valentin, 2003)  
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A recent study has suggested that simple small unilocular cysts have a benign natural 
history. (Valentin, 2002) As cysts become larger or develop features of “complexity” 
such as septations, papillary projections, larger solid areas and increasing vascularity, it 
becomes more difficult to assess the risk of malignancy. Although the vast majority of 
incidentally detected cysts are benign, all women are routinely offered a blood test to 
measure serum CA 125 levels in order to facilitate the diagnosis of ovarian cancer. 
Women with raised CA 125 levels and those with a cyst of complex appearance are 
offered surgery for fear of missing an ovarian cancer. Many these interventions could be 
avoided if ultrasound assessment of an ovarian cyst could discriminate better between 
benign and malignant ovarian lesions. This would result in a significant decrease in 
morbidity and mortality associated with surgery, as postmenopausal women are more 
likely to suffer with co-morbidities that increase their operative and anaesthetic risks. 
This is also likely to result in substantial savings for the NHS due to fewer operations 
and fewer complications.  
 
In the United Kingdom, the diagnostic evaluation of adnexal tumours in the Royal 
College of Obstetricians and Gynaecologists (RCOG) green top guidance is based on 
the calculation of RMI. The absolute value of the RMI score, the laboratory level of 
serum CA125 and the appearance of the tumours are used to determine the management 
plan. Women with an RMI of < 25 are managed by a general gynaecologist in any unit. 
Those with a simple unilateral cyst of <5cm and who have a CA 125 of < 30u/ml can be 
managed conservatively with 4 monthly ultrasound scans for 1 years followed by yearly 
scans for a total of 5 years.  If the CA 125 ≥ 30u/ml or the cyst is larger (≥5cm) or has 
septations or solid areas then surgery is advised. For women who have a RMI of 25 – 
250, it is advised they be managed in a cancer unit. Management in a tertiary cancer 
centre is the recommendation for those with a RMI >250, whatever the appearance of 
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the tumour. (RCOG, 2003)  (Figure 8.6-1) 
 
The simple rules as described above have 5 benign features and 5 malignant features 
and are purely dependant on the ultrasound scan without the use of any blood tests. 
Both the RMI within the RCOG guideline and the simple rules have a good detection 
rate for malignant tumours. This study’s aim was to test the hypothesis that use of the 
simple rules can reduce operative rates for women with benign disease when compared 
with the current RCOG guidance without increasing the false negative rate.  
 
There are several issues with using the RMI. It includes a blood test in addition to a 
scan, which can elicit additional distress to patients as well as additions to the cost. 
There is the additional time to await the result of the test and there is the need to ensure 
a system is in place to check the result, do the calculation and inform the patient.  There 
is reduced tissue expression of CA 125 in 22% cases of ovarian cancers and normal 
serum CA 125 in 8-18% which is especially the case in borderline, Stage I and non-
epithelial tumours. CA 125 is non-specific and can be raised in non-ovarian tumours 
such as endometrial, tubal, breast, lung and gastrointestinal. Serum levels can also be 
raised in many normal physiological states and benign conditions such ovulation, 
menstruation, pelvic infection, diarrhoea, endometriosis and adenomyosis. (Bast, 1983; 
Rosen, 2005) The advantages of the RMI are that it has extensive and wide use and it is 
well known and fairly easy to address the features on ultrasound scan It also allows 
clinicians to dissolve themselves of responsibility of the decision when a blood test is 
involved. 
 
The aim of this study was to perform a pilot study to determine the potential 
intervention rates of the 2 management protocols when utilised to assess adnexal 
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tumours in asymptomatic post-menopausal women. 
 
8.6.2 Methods 
 
This prospective cross sectional observational study was conducted over a 1-year period 
between 1st December 2009 and 30th November 2010. Consecutive postmenopausal 
women who presented to the Gynaecology Diagnostic and Outpatient Treatment Unit at 
the University College Hospital, London, UK for assessment of an asymptomatic 
adnexal tumour or found to have an asymptomatic adnexal tumour, had their tumour 
assessed according to the ‘Simple Rules’ as well as according to the Royal College of 
Obstetricians and Gynaecologists (RCOG) Green top Guideline number 34 (October 
2003) which uses the Risk of Malignancy Index (RMI). These postmenopausal women 
were judged to be asymptomatic if they did not present with pain localised to the area of 
the cyst or the lower abdomen.   
 
The unit consultants then assessed the women fully and determined their plan of care. 
Therapeutic decisions were not based upon the results of either of the management 
protocols. Therefore, the study was not subject to institutional ethical review board 
approval. The potential intervention rates were then compared between the 2 
management protocols. 
 
8.6.3 Statistical Analysis and Results 
 
At a preliminary analysis done at the 8-month mark, there were 67 asymptomatic 
women who were seen with an adnexal mass. (Study 7a) At that point, 41/67 
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(61.2%) were in the group where surgery was indicated according to the RCOG 
guideline while only 5/67 (7.5%) would be offered surgery according to the simple rules 
protocol. This data was used for the power calculation for the randomized controlled 
trial. (Study 8) 
 
At the 1-year mark, there were 93 women analysed. (Study 7b) From the 153 women 
initially assessed, those who had simple unilateral cysts less than 2 cm were excluded 
(n=38), as according to the RCOG guideline these women do not need follow up. There 
were 8 women who never had their CA 125 blood tests, 1 who was a tertiary referral 
and 4 who died before surgery or before a follow up scan was performed. There were 
9(5.8%) who did not attend or declined a follow-up scan.  
 
Among the 93 women, the age range was 47 to 90 years with a mean age of 66 years. 
Parity ranged from 0 to 8 and time since the menopause ranged from 1 up to 40 years 
with the average being 14 years. Indications for the ultrasound scan were incidental 
detection of the adnexal mass during imaging done for a non-gynaecological cause 
(40/93 [43%]), post-menopausal bleeding (22/93 [24%]), “check-up” of a known cyst 
(10/93 [11%]), gastrointestinal complaints (6/93 [4%]), urogynaecological assessment 
(4/93 [3%]), or other causes (11/93 [12%]) such as vaginal discharge, cervical cysts 
seen at time of smear, experiencing a dragging sensation or having pain elsewhere in 
her abdomen. The RCOG guidance recommended surgery for 70/93 (75%), whereas 
simple rules recommended surgery for 11/93 (12%). (Table 8.6-1) There were 13/93 
(14%) women with a raised CA125 (≥30). When looking purely at the RMI result 48/93 
(52%) women had an RMI ≥ 25. (Table 8.6-2) 
 
There were 16 patients who had surgery and 59 who had follow up ultrasound scans. 
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Amongst those who had expectant management, follow-up occurred between 6 and 
21months with an average of 12 months and no missed malignancies were detected. 
Most tumours were unchanged (49/59 [83.1%]) and only 5/59 [8.5%] were larger 
(>20% increase in the largest diameter). (Table 8.6-3) 
 
The women determined to have tumour of low risk by either protocol, all had benign 
tumours as qualified by histology or an ultrasound scan which continued to have benign 
features. (Table 8.6-4) There were 2 malignancies in the entire group. The first was 
assessed as malignant or of high risk by both protocols and the second was assessed as 
being of indeterminate or intermediate risk by both protocols.  Appropriately, both 
women with a malignancy on histology were identified correctly for surgery by both 
protocols. The decision for surgery was made independently of either protocol. 
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Figure 8.6-1: Flow Diagram of Pilot Study. N = 93.  
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Table 8.6-1: Results of the Assessments for all Patients - RCOG/RMI and Simple 
Rules (Pilot Study). N = 93.  
 
 RCOG/RMI Simple Rules 
Benign / Low Risk – No surgery 23 (24.7%) 82 (88.2%) 
Indeterminate Risk - Surgery 64 (68.8%) 8 (8.6%) 
Malignant / High Risk - Surgery 6 (6.5%) 3 (3.2%) 
Surgery recommended 70 (75.3%) 11 (11.8%) 
 
Table 8.6-2: Results of RMI for all Patients (Pilot Study). N = 93. 
 
RMI Number of patients (%) 
<25 45 (48%) 
≥ 25 - <250 42 (45%) 
≥ 250 6 (7) 
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Table 8.6-3: Patient Outcomes (Pilot). N = 93. 
 
Surgical Management 
 Number of Patients (%) 
Benign 14 (87.5%) 
Borderline 0 
Malignant 2 (12.5%) 
  
Total N=16 
(17.2% of total 93) 
 
 
Expectant Management 
 Number of Patients (%) 
Resolved 3 (3.9%) 
Smaller 3 (3.9%) 
Same 65 (84.4%) 
Larger 6 (7.8%) 
Total N=77 
(82.8% of total 93) 
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Table 8.6-4: Breakdown of Risk Categories as assessed by both Protocols (Pilot 
Study). N = 93. 
 
 RCOG/RMI Simple rules 
Low Risk Total N = 18 Total N = 82 
Surgery 0  Surgery 10 
 
Benign (n=10) 
Malignant (n=0) 
Expectant 18 All Benign Expectant 72 All Benign 
Intermediate 
Risk 
Total N = 64 Total N = 8 
Surgery 13 Benign (n=12) 
Malignant (n=1) 
Surgery 4 Benign (n=3) 
Malignant (n=1) 
Expectant 51 All Benign Expectant 4 All Benign 
High Risk Total N = 6 Total N = 3 
Surgery 3 Benign (n=2) 
Malignant (n=1) 
Surgery 2 Benign (n=1) 
Malignant (n=1) 
Expectant 3 All Benign Expectant 1 Benign 
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8.7 Study 7 – Comparison of the use of two ultrasound-based protocols 
for the management of asymptomatic post-menopausal women 
with adnexal tumours – A randomized controlled trial 
 
8.7.1 Introduction 
 
In recent years, there has been an increase in the number of women diagnosed with 
asymptomatic adnexal tumours. This is mainly due to liberal use of modern high-
resolution abdominal and pelvic imaging such as ultrasound, MRI and CT. The 
diagnosis of an adnexal tumour often causes concerns to women and health 
professionals due to perceived difficulties in distinguishing between benign and 
malignant ovarian tumours.  
 
The best survival for patients with ovarian cancer is achieved when treatment is 
organised and carried out by gynaecological oncologists who work in cancer centres. 
(Vernooij, 2007) However, patients with asymptomatic benign tumours can be managed 
expectantly or by minimally invasive surgery if symptomatic. General gynaecologists in 
their local hospitals can safely undertake these procedures. Achieving the right balance 
between desire to treat all ovarian cancers effectively and without delay against the need 
to avoid unnecessary interventions in women with benign and clinically insignificant 
lesions is particularly important in postmenopausal women. They are more likely to 
have ageing-related, pre-existing co-morbid conditions such as cardiac or pulmonary 
disease or diabetes mellitus that increase their risk of surgical and anaesthetic 
complications.  They are also more likely to have had previous abdominal operations 
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increasing further their risk of surgical complications. (Ansaloni, 2010; Neufeld, 2013, 
Sztark, 2013; RCOG, 2003)  
 
In 2003, the RCOG published a guideline on the management ovarian cysts in 
postmenopausal women (RCOG 2003).  The guideline uses the RMI model-based 
management protocol to facilitate triaging of women with adnexal tumours for surgery 
and it provides advice whether the operation should be carried in a specialised cancer 
centre or by a general gynaecologist.  In our previous study, we found that there may be 
significant differences in the number of postmenopausal women with adnexal cysts who 
are selected for surgery when the RMI based protocol is compared to ‘Simple rules’, 
which is a more recent method to diagnose ovarian cancer on ultrasound. This 
difference occurred despite previous meta-analyses showing that both tests have similar 
accuracy for the diagnosis of ovaran cancer.  (Geomini – RMI, Nunes - Simple rules) 
(Geomini, 2009; Nunes, 2012)  
 
The aim of this prospective randomised trial was to determine whether there are 
significant differences between the two management protocols in the proportion of 
postmenopausal women with incidentally detected adnexal tumours, who are triaged for 
and who receive surgical treatment. 
 
8.7.2 Methods 
 
This was a prospective non-blinded single-centre randomised controlled trial conducted 
in a general gynaecology clinic at University College Hospital, London, UK. 
Asymptomatic postmenopausal women who were diagnosed with adnexal tumours on 
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ultrasound scan or other imaging modalities were invited to join the study. 
 
The North London Research Ethical Committee 2 ethics committee approved the 
randomised controlled trial (10/H0724/48) as well as the research and development 
committee at UCH. 
 
8.7.2.1. Participant Identification 
 
Eligible patients were identified when they attended the general gynaecology clinic and 
were found to have an adnexal tumour and no pain. An information leaflet about the 
study was given to all eligible women before assessment. A member of the research 
team, who took a detailed clinical history, did a physical examination and performed an 
ultrasound scan then reviewed them. If the diagnosis of an adnexal mass was confirmed 
women were invited to join the study. Written informed consent was obtained from all 
women who agreed to take part after which they would be randomized as described 
below and in section 7.6 and then proceed to have their assigned protocol assessment 
performed. 
 
8.7.2.2. Inclusion and exclusion criteria 
 
Women were eligible for inclusion if they were postmenopausal and found to have an 
adnexal tumour. They were considered asymptomatic if they did not present with pain 
localised to the area of the cyst or the lower pelvis. Postmenopausal women were 
defined as those who have had one year of spontaneous amenorrhoea at or above the 
age of 40 where no illness or medication may have caused the cessation of periods or 
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those at or above the age of 50 who have had a hysterectomy with ovarian conservation. 
Women aged 40 to 80 inclusive were eligible. We excluded all women who were unable 
or unwilling to give written consent and those with simple, unilateral, unilocular cysts 
of less than 2cm. (Table 8.7-1) Women referred from other hospitals as tertiary referrals 
to the Oncology clinic and those who were considered unfit for surgery were also 
excluded.  
 
8.7.2.3. Randomization and Blinding 
 
A blocked randomisation list with varying block sizes was generated by an independent 
statistician using a Stata 12.1 (Stata Corp., College Station, Texas, USA). The 
randomisation numbers were placed in consecutively numbered, sealed, opaque 
envelopes and kept in a box locked in a filing cabinet. This randomisation ensured 
allocation concealment. When a patient consented, a clinic nurse, who was not part of 
the research team, opened the next envelope and informed the recruiting doctor of 
woman’s trial allocation. 
 
Neither the patient nor the recruiting doctors were blinded to the protocol allocation but 
the operating surgeons and the pathologists were. The surgeons were informed whether 
the tumour was of high or intermediate risk of cancer, but not about the protocol which 
was used to determine that.  The pathologist was informed of the operating findings 
only and their report was used to determine the nature of adnexal tumours. 
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8.7.2.4. Procedures: Trial Arms and Interventions 
 
The women were randomised into either of two groups. The first group was assessed 
and managed in accordance with the current Royal College of Obstetricians and 
Gynaecologists (RMI/RCOG) protocol for the management of cysts in postmenopausal 
women. (RCOG, 2003) The second group of women were assessed using a structured 
approach to morphological analysis of ovarian tumours referred to as ‘simple rules’ 
(SR), which enables discrimination between benign and malignant lesions without the 
need to measure tumour markers. According to the literature both methods provide 
similar levels of accuracy for the diagnosis of ovarian cancer. (Jacobs, 1990; Geomini, 
2009; Timmerman, 2008; Nunes, 2014)  
 
In the RMI/RCOG arm all the women underwent an ultrasound examination and had a 
CA 125 blood test on the same day. The RMI was calculated as the product of the 
CA125 (U/ml) laboratory value, a score for menopausal status (1 if pre-menopausal and 
3 if postmenopausal) and a greyscale ultrasound score of 0, 1 or 3 where 1 score is 
given each for bilaterality, ascites, multilocularity, solid areas and intra-abdominal 
metastases. (RMI = CA125 x M x U)  
 
Women with simple unilateral unilocular cysts < 5cm, CA 125 <30 U/ml and RMI<25 
were classified as low risk of cancer and were offered conservative management. Those 
with a RMI of 25 – 250 were considered to be at indeterminate risk and were offered 
surgical removal by gynaecologists. Those with a RMI<25 but with a cyst which is not 
simple, unilateral, unilocular and <5cm were also considered of indeterminate risk. 
Women with an RMI >250 were referred for surgery to the tertiary cancer centre as they 
were considered high risk. (Figure 8.7-1) 
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The second trial arm used a management protocol based on ‘Simple Rules’ (SR) 
diagnostic model. Women in this arm had an ultrasound scan assessment according to 
the simple rules protocol. The SR model uses 10 rules to assess adnexal masses. There 
are five rules that predict malignancy (M-rules): (1) irregular solid tumour; (2) ascites; 
(3) at least four papillary structures; (4) irregular multilocular–solid tumour with a 
largest diameter of at least 100 mm; and (5) very high colour content on colour Doppler 
examination (score 4). There are five rules to predict benignity (B-rules): (1) unilocular 
cyst; (2) presence of solid components where the largest solid component has a largest 
diameter of <7 mm; (3) acoustic shadows; (4) smooth multilocular tumour less than 100 
mm in largest diameter; and (5) no detectable blood flow on Doppler examination 
(score 1). If one or more M-rules apply in the absence of a B-rule, the mass is classified 
as malignant. If one or more B-rules apply in the absence of an M-rule, the mass is 
classified as benign. If no rule applies or both M and B rules apply, the mass cannot be 
classified and is considered indeterminate. Ultrasound scans were performed in section 
7.3 and 7.4. 
 
Women with a cyst classified as benign using ‘simple rules’ were considered low risk 
and they were offered conservative management. Those classified as malignant were 
high risk and were managed in the tertiary oncology unit.  Women with tumours of 
indeterminate nature were considered intermediate risk and were offered surgery by 
general gynaecologists.  
 
Women selected for conservative management were offered 3-monthly ultrasound scans 
for 12 months. Those located to the RMI/RCOG arm had another CA125 test at their 
final follow up visit. At follow up visits women were asked about any change in their 
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symptoms. The tumours were assessed on ultrasound scan looking for any changes in 
their morphology and size.  
 
The decision about the surgical approach; i.e. open versus minimally invasive, was 
made by the operating surgeon.   
  
8.7.2.5. Outcome Measures 
 
Primary Outcome 
 
The primary outcome was the proportion of women who were selected for surgery using 
the two assessment protocols. We analysed both the assigned and the actual surgical 
intervention rates in both arms of the trial within 12 months from randomisation.  
 
Secondary Outcomes 
 
Secondary outcomes included the number of staging surgical procedures carried out by 
a gynaecological oncologist, number of women suffering surgical complications and the 
number of delayed diagnoses of ovarian cancer. 
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8.7.2.6. Statistical analysis 
 
Pilot Study 
 
A pilot study was conducted on a sample of 67 women. (Nunes, 2012) In this group of 
women 41/67 (61.2%; 95% CI: 48.5% to 72.9%) would be offered surgery according to 
the RCOG guideline while only 5/67 (7.5%: 95% CI: 2.5% to 16.6%) would be offered 
surgery according to the simple rules guidance.  
 
Sample Size 
 
We estimated that by using the ‘Simple Rules’ management protocol the intervention 
rate would be halved from 62% to 31%. To achieve a 5% significance level and 90% 
power, 59 patients were required in each group. Allowing for a 20% drop out rate, we 
planned to recruit 148 women. 
 
Statistical tests 
 
A Chi-square test was used to assess the significance of the difference between the two 
intervention rates. Fisher’s exact test was used to assess the significance of the 
difference between the complication rates and gynaecological oncology referrals. The 
relative risk (RR) ratio with 95% confidence intervals (CI) was used to compare the 
numbers of women triaged for surgery and per protocol intervention rates.  
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An intention to treat analysis was done of all patients who fit the inclusion criteria. The 
analysis of surgery offered included all randomized patients and the analysis of those 
who had surgery included those who had surgery within 1 year or completed 1 year of 
follow-up ultrasound scans.  
 
At the end of the study, an independent statistician (GA) analyzed the results. Statistical 
analysis was performed using Stata 14 software (Stata Corp, College Station, TX, 
USA). 
 
Any adverse events were assessed for severity according to the University College 
Hospital Trial Coordinating Centre’s criteria and recorded in the database. 
 
8.7.2.7. Ethical Committee Approval 
 
The North London Research Ethical Committee 2 ethics committee approved the 
randomized controlled trial (10/H0724/48) as well as the research and development 
committee at UCH and it was entered in the registry of randomized trials 
(ISRCTN89034131). http://www.controlled-trials.com/ISRCTN89034131/. 
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Figure 8.7-1: Flow Diagram of Patient selection and randomization for the RCT simple rules versus RCOG/RMI 
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Figure 8.7-2: CONSORT Flow Diagram of Results – RCT (N = 148) 
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8.7.3 Statistical Analysis and Results 
 
From April 2011 to June 2014, 951 postmenopausal women were diagnosed with 
adnexal tumours in our centre.  751 were excluded for various reasons. (Table 8.7-1) 
There were 200 women who fulfilled the inclusion criteria, 148 of whom agreed to take 
part in the study. 73 women were randomised to RMI/RCOG and 75 to SR. Their ages 
ranged from 49 to 80 with a mean age of 63. Both groups were similar in their 
demographic characteristics. (Table 8.7-2) Follow-up at 12 months was completed in 
June 2015. 
 
8.7.3.1. Data Analysis 
 
Primary Outcome 
 
8.7.3.2. Intention to Treat Analysis 
 
With an intention-to-treat analysis, a significantly higher proportion of women were 
assigned to surgical treatment using the RMI/RCOG protocol compared to SR [44/73 
(60.3%: 95% CI: 48.1% to 71.5%) versus 5/75 (6.7%: 95% CI: 2.2% to 14.9%). (P < 
0.001, χ2 test) (Table 8.7-3) The relative risk was 9.04 (95% CI: 3.80 to 21.5) so there 
was a 9 times higher chance of an assessment of Indeterminate or Malignant by 
RMI/RCOG compared to assessment via Simple Rules. The difference in these 
proportions is 53.6% (95% CI: 41.0% to 66.2%) so therefore, for every 100 patients we 
expect an additional 53 patients to be assessed as either Indeterminate or 
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Malignant by RMI/RCOG compared to assessment via SR. 
 
Initial Management 
Out of the 44 women triaged for surgery in the RMI/RCOG arm, 18 (40.9% 95% CI)) 
had surgery as planned, 7 (15.9% (95%) were not fit for surgery and 19 (43.2%95%) 
declined the operation for various reasons.   Those judged as benign (29/73 [39.7%: 
95% CI: 28.5 to 51.9]) all had conservative management. (Figure 8.7-2) 
 
All five women assigned to surgery in the SR arm had operations.  The remaining 70 
women (93.3%: 95% CI: 85.1% to 97.8%) had their tumours classified as benign. 68/70 
(97.1% 95%) of them were managed conservatively whilst the remaining 
2/70(2.9%95%) had surgery:  one woman had pelvic clearance for concomitant 
endometrial cancer and the other had a concurrent breast cancer and she was referred to 
the oncology unit by her breast physician for risk reducing surgery. In both of them the 
adnexal lesions were benign on histological examination. 
 
A total of 136 (91.9%) women had surgery or had completed 12 months follow-up, 
whilst 12 (8.1%) women were lost to follow up.  There were 18/68 (26.5%: 95% CI: 
16.5% to 38.6%) women in the RMI/RCOG arm who had surgery versus 7/68 (10.3%: 
95% CI: 4.2% to 20.1%) women in the SR arm. (P < 0.015, c2 test). The relative risk 
was 2.57 (95% CI: 1.15 to 5.76) so there is a 2.6 times higher chance of surgery 
following assessment by RMI/RCOG protocol compared to assessment by SR.  The 
difference in these proportions is 16.2% (95% CI: 3.4% to 28.9%) so therefore, for 
every 100 patients we expect an additional 16 patients to have surgery after assessment 
by RMI/RCOG compared to assessment via Simple Rules.   
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Secondary Outcomes 
 
Two women, one in each arm were identified as having high-risk tumours and they both 
had staging procedures (one laparoscopy and one laparotomy) by gynaecological 
oncologists. In both cases the histological diagnosis was a borderline tumour. 
Additional six women with low or intermediate risk tumours were referred to the 
oncology centre for the following indications: concomitant breast cancer (1), 
concomitant endometrial cancer (1), metastatic bowel cancer (1), technically difficult 
surgery (1) and women’s request (2). There were no significant differences between the 
proportions of women referred to the oncology units between the two groups of women 
(3/73 (4.1%) in RMI/RCOG and 5/75 (6.7%) in SR. The risk difference is 2.6% (-4.7% 
to 9.8%). The relative risk is 1.62 (0.40 to 6.54). (P=0.72) 
 
Surgical complications occurred in 4/73 (5.5% (%% CI) women in the RMI/RCOG arm 
and 2/75 (2.7% 95%CI) in the SR arm. (P = 0.44) Most complications were minor. 
(Table 8.7-4) There were no delayed diagnoses of ovarian cancer detected up to 12 
months of follow up. 
 
Histological diagnoses are listed in Table 8.7-5.  There were 25 women who had their 
surgery within the 1st year following the initial assessments. Six women with malignant 
tumours on histology (2 invasive tumours and 4 borderline tumours) were identified as 
high or intermediate risks by either diagnostic model. Five of them had surgery within 
two months of the initial visit whilst the remaining woman with a cardiac condition had 
her surgery delayed for eight months to optimise her general health. 
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23/26 women who were assessed as needing surgery but were either deemed surgically 
unfit (7) or declined operations (19) completed their 12 months’ follow-up. Two of 
them went on to have surgery after one year. They were found to have benign lesions on 
histological examination. Of the remaining three women who did not attend for follow 
up visits, one had her 12-month scan elsewhere. The examination did not reveal any 
significant changes in the appearance of her adnexal lesion. We had no information 
about the remaining two women who were lost to follow up.  
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Table 8.7-1: Patients excluded pre-randomisation in RCT. N = 803  
 
Reason for Exclusion Number 
Small - <2cm, unilocular, anechoic cyst 269 
Oncology tertiary referral 179 
Age <40 or >80 121 
Pelvic pain 87 
Declined  52 
Severe pelvic adhesions 30 
Surgery planned/ Urogynaecological management 24 
Familial Cancer Clinic/UKCTOCS 21 
Longstanding Patient – stable cyst 8 
Cognitive disability 3 
Transabdominal scan only 2 
Ongoing VTE on treatment 1 
Other 6 
Total excluded 803 
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Table 8.7-2: Baseline patient characteristics by trial arm in the RMI/RCOG and 
the ‘Simple Rules” arms of the RCT. N = 148. 
 
  RMI / RCOG 
(n = 73) 
Simple Rules 
(n = 75) 
Age (years) 62.7 (7.6) 
(range: 49 to 80) 
63.8 (8.1) 
(range: 50 to 80) 
Parity 0 22 (30%) 27 (36%) 
 1 11 (15%) 8 (11%) 
 2 20 (27%) 19 (25%) 
 ≥3 20 (27%) 21 (28%) 
Time since menopause (years) 12.5 (8.8) 
(range: 0 to 37) 
13.7 (9.3) 
(range: 1 to 33) 
UK* 2 3 
Current HRT use yes 10 (14%) 11 (15%) 
Past HRT use yes 12 (16%) 19 (25%) 
 no 49 (67%) 45 (60%) 
 n/a 10 (14%) 11 (15%) 
 UK* 2 (3%) 0 
*Unknown  
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Table 8.7-3: Results: Patient Outcomes in RCT. N = 148. 
 
Results / Outcome RMI/ RCOG Simple rules 
Completed 4 months 68 73 
Completed 6 months 64 65 
Completed 8 months 63 62 
Completed study 61 58 
Protocol = Benign 29 70 
Protocol = Indeterminate 43 4 
Protocol = Malignant 1 1 
Protocol = Surgery 44 5 
Surgery £ 1 year 18 7 
Declined surgery 26 0 
 
Table 8.7-4: Complications experienced in RCT N = 25 
 
Results / Outcome RMI/ RCOG Simple rules 
Unable to remove other ovary due to adhesions 2  
Left ear bleeding post-operatively- ENT review 1  
Malignant cyst rupture, Wound infection 1  
Small bowel injury  1 
Acute dyspnoea and fluid overload  1 
Total surgical complications 4 (5.5%) 2 (2.7%) 
Nil 13 5 
Total 18 7 
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Table 8.7-5: Histological Diagnoses at 1 year in RCT N = 25 
 
Histology RMI/ 
RCOG 
Simple 
rules 
Benign Cystadenoma/ Cystadenofibroma  
(2 with a Fibroma and 1 with a 
Brenner tumour) 8 3 
Endometriomas 3  
Fibroma 2  
Fibrothecoma 1  
Benign stromal tumour and simple 
cyst 1  
Inclusion cyst with hydrosalpinx 1  
Total Benign 16 3 
Borderline Borderline serous 1 2 
Borderline mucinous  
(with a contralateral benign serous 
cystadenoma)  1 
Total Borderline 1 3 
Invasive 
Malignancies 
Papillary thyroid type carcinoma 
within a dermoid  1 
Metastatic colorectal cancer 1  
Total Invasive Malignancies 1 1 
Total Histology 18 7 
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Part IX – Discussions 
 
9.1 Study 1 Discussion – A prospective validation of the IOTA Logistic 
Regression Models (LR1 and LR2) in comparison to Subjective 
Pattern Recognition for the diagnosis of ovarian cancer when 
utilised by an average ultrasound operator assessing adnexal 
lesions	
Study 1A 
 
This study has shown that the accuracy of the IOTA Logistic Regression Model (LR2) 
was similar in the hands of a non-expert operator compared to the findings in the 
original IOTA study. Although the AUCs were not significantly different between our 
study and the two other previous studies conducted by experts, there were some 
differences. The sensitivity was higher in our study than in the original study, but not in 
comparison to the prospective IOTA validation, which was also conducted by experts. 
(Timmerman, 2005; Timmerman, 2010) The specificity in our study was lower than that 
reported in other two previous studies, particularly in comparison to the validation 
study. These differences could be explained by the operator-effect on the performance 
of the model. It has been previously documented that the specificity of ultrasound 
diagnosis is higher when expert operators perform the examinations. (Yazbek, 2008; 
Timmerman, 2000) Ultrasound experts performed the assessment of ovarian tumours 
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during the previous IOTA studies. During data collection, the operators were also able 
to assess tumour characteristics using “pattern recognition”. In many cases the operators 
could have determined the type of ovarian tumour before collecting the data using the 
IOTA protocol. This is a potential source of bias, which could have lead to an 
overestimate of the model specificity. 
 
We considered that with time the experience of our Level II operator would increase, 
which could influence the performance of the IOTA model. Although both the 
sensitivity and specificity of the model were better in the second half of the study, the 
differences were not statistically significant. The Level II operator was under very clear 
instructions not to attempt subjective diagnosis of the nature of ovarian lesions, the aim 
of which was to minimise bias.  
 
Our study had a larger component of malignant tumours; 53.2% (66/124) versus 24% 
(75/312) in the original IOTA study. (Timmerman, 2005) The validation studies also 
had a smaller population of malignant tumours; temporal 30.5% (287/941) and external 
25.6% (255/997). (Timmerman, 2010) The higher prevalence in our study reflects the 
nature of work in a tertiary referral cancer centre with a high proportion of women 
attending with a strong suspicion of ovarian cancer.  In addition, a large proportion of 
women with a presumed benign lesion are managed expectantly, which reduces the 
number of women with benign disease undergoing surgery.  This higher prevalence of 
cancer may have had a positive effect on the positive predictive value, but it should not 
have affected the sensitivity or specificity of the test. 
 
A very high sensitivity of the model, particularly in the non-expert hands, is reassuring 
and it indicates that the LR2 model could be used as a primary test in women with 
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adnexal tumours without fear of missing a significant number of malignant lesions. The 
LR-ve of the model is also high and therefore women with negative results could be 
managed conservatively or by using minimally invasive surgery.  
 
The large number of false positive results in our study was mainly caused by the 
presence of solid areas within 15 of the 18 (83%) incorrectly classified benign lesions. 
In some cases, hyperechoic areas in benign cystic teratomas or precipitated debris in 
ovarian endometriomas were misclassified as solid components within the cyst.  Ascites 
due to other non-malignant medical conditions also contributed to false positive results 
as the model assumes that the adnexal lesion is the cause of the ascites. The positive 
predictive value was 78.1%, which means that more than a fifth of presumed malignant 
lesions were in fact benign. Women with positive results suggestive of cancer would 
therefore require additional tests to check the accuracy of the diagnosis to avoid 
subjecting many women with benign lesions to unnecessary major gynaecological 
staging operations.  
 
Study 1B 
 
In the hands of a level II or non-expert operator, the AUC of both IOTA Logistic 
Regression Models (LR1 and LR2) performed similarly to the previous studies, which 
were conducted by experts. A closer scrutiny of the results showed that, although the 
AUCs did not differ, there were significant differences in both sensitivities and 
specificities between this and the previous studies. Typically, the logistic models tended 
to be more sensitive, but less specific when used by the non-expert in this study. I 
hypothesised that these differences were caused by the ability of the expert operators to 
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use pattern recognition while performing the IOTA logistic regression models. It has 
been demonstrated that the sensitivity of pattern recognition by the expert operator for 
diagnosis of cancer in this study was slightly lower compared with the models, but the 
specificity was much higher. This mirrors the comparisons in the performance of LR1 
(and to some extent LR2) with the original studies. This suggests that the increased 
specificity of the models when tested by the experts could be due to it being performed 
by experts. 
 
I considered whether the experience of the Level II operator would increase during the 
time of the study and therefore influence the performance of the IOTA model and hence 
compared the first half of the study with the second half. Although both the specificity 
and the AUC of the models were better in the second half of the study, the AUCs were 
not significantly different. As part of the study, I as the Level II operator did not attempt 
subjective diagnosis of the nature of the ovarian lesions. The goal was to help to avoid 
bias. 
 
While the prevalence of cancer in our final surgical population was higher at 45.2% as 
compared with 24% (75/312) of the original IOTA study, the overall prevalence of 
cancer in our entire population of women was in fact 23.8%. Many women with benign 
lesions in our population opted for expectant management, which resulted in a relatively 
low proportion of women with benign disease undergoing surgery. Our higher 
proportion of malignant cases also reflects the nature of working in a tertiary referral 
centre. It is important to stress, however, that tertiary referrals accounted only for 31% 
of the total number of women examined by the non-expert operator.  
 
We considered the possibility that prior knowledge that individual patients were high 
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risk could have contributed to the high false positive rate and lower specificity of the 
test. However, this had no effect on the performance of the pattern recognition, which is 
a test more open to bias, and therefore it is unlikely the population characteristics 
influenced the cancer risk assessment using logistic models. 
 
Strength and Limitations 
 
Strengths – 
This study matched the original study exactly, which allowed us to make an accurate 
comparison of use of the model by a level II operator as compared with the original 
study.  
 
Limitations –  
This study did not compare malignant and borderline tumours separately. We had a 
single level II ultrasound operator and this would theoretically reduce the 
generalisability of this study.  
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9.2 Study 2 Discussion – A prospective validation of the IOTA Simple 
Rules for the diagnosis of ovarian cancer 
 
When a level II operator performed the ultrasound scans, the simple rules protocol 
performed acceptably well. The rules were applicable in nearly 80% of women in our 
population, which is a similar percentage when compared with the original and 
validation IOTA studies, and when the rules were applicable the sensitivity was not 
significantly different. The specificity though was less than that in the 2010 validation 
study (p< 0.001) though similar to the original study (p=0.48).  
 
Forty-four percent (44.6%) of our final population had malignant tumours, which may 
have affected our results. This reflects working in a tertiary referral unit but more so it 
reflects the fact that many of the women assessed to have benign tumours by the expert, 
chose not to have a surgical intervention (40% of total population).  The overall 
malignancy rate in the entire population initially assessed was 24%, which is similar to 
the rates in the original (27%) and validation (25%) studies. 
 
The 4 false negative tumours were either unilocular as in the case of the borderline 
tumour and / or had no demonstrable blood flow as was the case in all but the stage III 
tumour. The later tumour demonstrated acoustic shadowing, which caused it to be 
misclassified. These 4 tumours had none of the M features.  
 
The 15 false positives had a range of features, which caused them to be misclassified by 
the simple rules. The actinomycosis, one of the endometriomas and the fibbrothecoma 
appeared to be irregular and solid. The other tumours were either >100mm and irregular 
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multilocular solid, had >4 papillary projections or had a high colour blood flow score. 
None of these patients had ascites present.  
 
Pattern recognition performed by the expert operator was superior to the simple rules in 
cases where the rules were applicable mainly due to significant differences in specificity 
[88.6% vs. 93.2% (P=0.03)].  All ultrasound operators who use simple rules will need to 
determine what to do though for the tumours which cannot be classified by simple rules. 
Assuming malignancy for these will improve sensitivity but at the expense of a 
worsening specificity due to the increased false positive rate.  The overall accuracy 
therefore deteriorates. Utilising an expert instead for this population, appears to be the 
best choice, as the overall accuracy is maintained. As experts are not widely available, 
simple rules provide a good alternative, which should be able to classify 78% of the 
tumours on average.   
 
Strength and Limitations 
 
Strengths – 
The methodology matched the original study allowing an accurate assessment and 
comparison of the performance of the simple rules when performed by a level II versus 
a level III operator. 
 
Limitations –  
Similar to Study 1, we did not compare malignant and borderline tumours separately 
which should be considered for future studies. We had a single level II ultrasound 
operator and this would theoretically reduce the generalisability of this study. 
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9.3 Study 3 Discussion – A prospective evaluation of the IOTA Logistic 
Regression Models (LR1 and LR2) in comparison to Subjective 
Pattern Recognition for the diagnosis of ovarian cancer in the 
outpatient setting using two reference standards 
 
Our study has shown that accuracy of LR1/LR2 for the diagnosis of ovarian cancer in 
the outpatient setting was similar to the previous studies, which were carried out on 
women who were scheduled for surgery. However, if LR1/LR2 had been used as the 
primary diagnostic test to guide the management decisions, rather than the pattern 
recognition, a significantly higher proportion of women would have been referred for 
treatment by gynaecological oncologists because of suspected ovarian cancer.  
 
In previous original and subsequent validation studies the IOTA logistic regression 
models provided accurate diagnosis of ovarian cancer both in hands of expert and non-
expert operators. (Timmerman, 2005; Timmerman, 2010; Nunes, 2012; Nunes, 2013; 
Kaijser, 2014) The models; however, had always been used in population of women 
who all had surgery. In view of that the results could be affected by selection bias and 
they cannot be extrapolated to low risk population majority of whom do not require 
surgical intervention.  The results of previous studies can therefore only be used to help 
to select a surgeon (general or oncological) who should do the operation or the route of 
the surgery (laparoscopic or open). (Campbell, 2012) A more relevant question in 
clinical practice; however, is whether surgery is required at all.  
 
A difficulty in conducting studies on populations of women with adnexal 
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tumours who are managed conservatively is the lack of agreement on the reference 
standard to define the nature of the lesion. In women with presumed benign lesions the 
only way to rule out an ovarian cancer in the absence of histological diagnosis is by 
arranging follow up visits for a certain length of time. The natural history of ovarian 
cancer is unknown and the decisions and about the length and frequency of follow visits 
are pragmatic and based on consensus of opinions, rather than science. Most ovarian 
cancer screening projects adopted the policy of six-monthly or annual visits in women 
with normal ultrasound findings, which is deemed to be sufficiently frequent to detect 
early disease before spreading beyond the ovaries. All women in our study had 
detectable lesions at the time of the initial scan. We therefore postulated that under these 
circumstance a 12 month follow up should be long enough to detect changes in the 
appearance and size of adnexal tumours which would be suggestive of their malignant 
nature.  The absence of such changes was our second reference standard to discriminate 
between benign and malignant lesions.   
 
During follow-up, it is possible that some woman could develop new abnormalities.  
This may erroneously be classified as a prior misdiagnosis rather than the new disease 
that it is. However, this limitation can be overcome.  
There is no single cut-off point before which a cancer diagnosis is a misdiagnosis and 
after which it is a new malignancy. Nonetheless we used 12 months as this point in 
keeping with screening studies that suggest 1 year is sufficient time. (Tailor, 2003; 
Woodward, 2007) Several authors have found that in their studies, women with a prior 
benign-appearing adnexal tumour who subsequently develops an ovarian malignancy, is 
likely to have a borderline tumour or a slow-growing Type I tumour. (Horiuchi, 2003; 
Shuh, 2004; Sharma, 2012; Suh-Bergmann, 2014) 
 
 
247 
All the women in the study were assessed by one of the reference standards: (histology 
and a follow-up ultrasound scan in 12 months or more.  This helped us to reduce the 
incomplete verification bias of including only surgical patients. Bias may though still 
arise if the results of the alternative reference standard are treated identically to the 
results from the preferred reference standard when they may not be identical. This is 
because the two reference standards may be of different quality and it is possible that 
follow up ultrasound scans would be less than100% accurate when compared to 
histology (preferred reference test). This information was considered when performing 
the statistical analysis, but in our study the results were nit different when the 
probability of ultrasound follow up (alternative test) was reduced to 90%. (de Groot, 
2011)  
 
Our results showed that in this population with a 28.0% malignancy rate the LR1 and 
LR2 models had a high sensitivity and a moderate specificity to diagnose ovarian 
cancer. The specificity of LR1 model was significant lower than pattern recognition (P 
< 0.0001) whilst the sensitivity was significantly different (P=0.13). This relatively high 
false positive rate would result on 62% more women being treated for potential ovarian 
cancer. However, four women with false negative diagnosis ovarian cancer (one 
invasive epithelial and three borderline) would receive earlier treatment.  
 
Strength and Limitations 
 
Strengths – 
This study assessed and corrected for the potential bias of analysing only the women 
who had surgery. This is the first study on LR1/LR2 to do this. 
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Limitations –  
The overall intervention rate in our study was relatively high which reflects the nature 
of work in a large clinical centre.  Many women were referred following the diagnosis 
of an adnexal cyst in primary or community care. They often had larger lesions and 
were advised by their GPs that surgery was required even if the lesions were benign.  
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9.4 Study 4 Discussion – A prospective evaluation of the IOTA simple 
rules as a triage tool for the diagnosis of ovarian cancer in the 
outpatient setting using two reference standards 
 
Also see discussion for study 3 (section 9.3) regarding use of follow-up ultrasound 
scans as a second and alternative reference test. 
  
This study showed that simple rules performed better in the outpatient setting than 
IOTA models. In comparison to pattern recognition, there were no significant 
differences in the sensitivity and the specificity making this a useful and accurate tool. 
There are though, a large proportion of women (20%) for whom the rules do not apply 
and therefore who have indeterminate tumours. This poses significant limitations on the 
use of this model within a general gynaecological or ultrasound clinic as a secondary 
test should be readily available for the women for whom SR was unable to give a 
diagnosis. Pattern recognition thus far has proven itself to be the test that is able to do 
this. 
 
There were fewer indeterminate tumours in the population who had expectant 
management (12.2% versus 22.8%) (P=0.0067) because most these tumours were 
benign and easier to classify as benign which makes the tool more useful in this 
population.  
 
These analyses more accurately reflect the real clinical scenario faced in the general 
gynaecology clinic when a test needs to help the gynaecologist to determine whether 
surgery is needed at all and only after that, which type of surgeon should do it (general 
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or oncological) and the route (via laparoscopy or laparotomy).  Simple rules was 
comparable to pattern recognition and was superior to LR1 and LR2. 
 
Strength and Limitations 
 
Strengths – 
This is the first study on simple rules that includes women who had expectant 
management. This assesses and correct for a potential selection bias by only including 
women who had surgery. 
 
Limitations –  
There was single ultrasound operator, which may potentially affect the ability to apply 
the results in every unit.  
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9.5 Study 5 Discussion – Use of the IOTA Simple Rules for the 
diagnosis of ovarian cancer: a Meta-Analysis 
 
This meta-analysis summarizes the currently available evidence concerning the 
accuracy of the simple rules ultrasound tool in the diagnosis of ovarian cancer. It has 
shown that the simple rules performed well overall for the diagnosis of ovarian cancer 
in hands of ultrasound operators of varying levels of expertise, with a pooled sensitivity 
of 0.93 (0.90 to 0.96) (I2 of 32.1%) and a pooled specificity of 0.95 (0.93 to 0.97) (I2 of 
78.1%) when internal and external validation studies were included.  The tool 
demonstrated a good discriminatory capacity in diagnosing ovarian cancer when the 
rules were applicable.  The study with the lowest sensitivity and the study with the 
lowest specificity were those with the smallest sample sizes, which may have affected 
their results. When we only included the external validation studies the sensitivity 
decreased slightly and the specificity increased slightly. Amongst the premenopausal 
women the sensitivity and the overall accuracy was lower when compared with the 
postmenopausal population.  
 
There appeared to be a strong and increasing relationship between the sensitivity and 
the proportion of women diagnosed with ovarian cancer in the study population. There 
was a weaker and decreasing relationship between specificity and the prevalence. 
Overall this suggests that when the rules are applicable, the sensitivity of simple rules 
increases and the specificity decreases with the increasing prevalence of malignancy in 
the study population. Daemen et al also saw this phenomenon and these authors 
reported that the specificity of the test was lower in centres with a higher prevalence, 
and suggested that these centres have more borderline and complex benign cases that 
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are harder to classify. (Daemen, 2011) 
 
A recently published systematic review and meta-analysis included an analysis of 
simple rules. (Kaijser, 2013) They included all tumours unclassifiable by the simple 
rules as malignant and assessed data from 2 studies. (Timmerman, 2010; Sayasneh, 
2013a) They found the same sensitivity as us but a lower specificity in both pre- and 
postmenopausal women. This is likely due to the inclusion of all indeterminately 
assessed tumours in the malignant group. When we did this with our current study, we 
found an increase in sensitivity and a significant fall in specificity.  
 
Strength and Limitations 
 
Strengths – 
This study allows the limitations of the previous study to be overcome by including 
results from a range of units with a range of ultrasound scan abilities and experience. 
This makes the results now better generalisable.  
 
Limitations –  
While the process of literature review and meta-analysis is a practical and useful way of 
generating a more powerful estimate of diagnostic accuracy with less random error than 
the individual studies, it does present some challenges and have some limitations.  
 
Primarily, the heterogeneity of the studies must be addressed because this may affect the 
justification for pooling the data into a single analysis. In this meta-analysis, diversity in 
study quality, nonconformity in study reporting, differences in the study population 
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characteristics and variation in the cancer prevalence in the study populations caused 
heterogeneity. Not all studies were clear on exclusion of pregnant women, which is a 
factor noted in the entire subset of IOTA studies. Possible reasons for exclusion of 
pregnant women are low risk of ovarian malignancy, increased vascularity of all 
tumours in pregnancy and delay in women undergoing surgery.  
 
There were two studies that did not give the age range of their patients or the percentage 
of women who were postmenopausal making it impossible to determine congruity of 
patient characteristics. The prevalence of malignancy ranged from 10% to 44% across 
the studies. We overcame this limitation by assessing for the influence of this 
heterogeneity on the results. The study sizes also demonstrated diversity ranging from 
103 to 1938 women. 
 
Additionally, operator level was not clear in at least one study making assessment of 
influence of operator level not possible. 
 
Summary 
 
The simple rules protocol is easy to use in routine clinical practice and it is an accurate 
test to discriminate between benign and malignant ovarian lesions. The main limitation 
is the inability to apply the test to more than 20% of women who would need to undergo 
additional testing or an ultrasound examination by an expert who is able to use the 
pattern recognition method to determine the nature of the adnexal tumours.   
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9.6 	Study 6 Discussion – A pilot study of comparison of the potential 
intervention rates when asymptomatic postmenopausal women with 
an adnexal tumour were assessed by two management protocols 
 
In this pilot study, we found that none of the women with tumours classified as low risk 
with either protocol were malignant and all the malignancies were classified as being of 
high or intermediate/indeterminate risk. The number of women classified as having 
tumours of indeterminate or high risk was significantly higher using the RCOG/RMI 
protocol as compared to the simple rules protocol, which was predominantly due to 
tumours of intermediate risk. Intervention rates would therefore be over 6 times higher 
using the RCOG/RMI protocol as opposed to using the simple rules based protocol. 
 
Further work was required to determine the risk of delayed diagnosis/missed cancers 
using simple rules, to determine the unnecessary operations done for benign tumours 
and to quantify the actual intervention rates when both protocols are in use in a general 
gynaecology clinic. 
 
Strength and Limitations 
 
Strengths – 
This pilot study was very useful for the next study. It provided data to allow a power 
calculation to be done. The women had both tests conducted allowing each woman to be 
her own control and therefore allowing a direct comparison of how the each test would 
perform on the exact same tumour in each woman. 
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Limitations –  
As the women had both tests performed we were unable to assess what final 
management the women would choose (surgical or expectant) when presented with one 
assessment or the other as neither result could be used. This would therefore need to be 
investigated in the next study, which was a randomised controlled trial. 
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9.7 Study 7 Discussion – Comparison of the use of two ultrasound-
based protocols for the management of asymptomatic post-
menopausal women with adnexal tumours – A randomized 
controlled trial 
 
 
Our study has shown the proportion of postmenopausal women who are offered surgery 
is significantly higher when the RMI/RCOG protocol was used to triage women for 
surgery compared to the novel SR protocol.  The number of women classified as having 
high-risk tumours was the same and the main difference between the protocols was the 
number of women who were classified as having intermediate risk lesions. It is 
reassuring that all malignant lesions (invasive and borderline) were correctly identified 
as requiring intervention and no woman with cancer had unnecessarily delayed 
treatment. 
 
This significant difference in intervention rates is important and it indicates that in many 
postmenopausal women with adnexal tumours who are currently treated surgically in 
the UK, the operation may not be necessary and it could be avoided. Women classified 
as having tumours of intermediate risk are often anxious about the possibility of having 
an aggressive invasive tumour which may have adverse effect of their psychological 
health and social well-being. The cost of surgery is high and avoiding unnecessary 
operations may result is significant savings to health providers and to society as a 
whole. 
 
The aim of our study was to assess differences in the intervention rates 
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between the two protocols based on different diagnostic models rather than to examine 
their accuracy for the diagnosis of ovarian cancer. This work has already been done and 
has shown that both methods are very sensitive in detecting malignant ovarian lesions. 
(Geomini 2009, Nunes 2014) 
 
A relatively large number of women with intermediate risk lesions in the RMI/RCOG 
arm of the study declined surgery, which was a surprising finding. This could be 
partially explained by the counselling of women at the time of the initial scan which 
tends to place emphasis on reassurance and may downplay the risks of the observed 
lesion being malignant.  For many of these women, the assessment of risk changed after 
the results of blood test to measure CA125 became available, typically a couple of days 
later. As all women were asymptomatic, it could have been that their natural inclination 
was to opt for conservative management relying more on the reassuring ultrasound 
findings rather taking into account the results of the blood test.. This trend was absent in 
the SR arm as the women assigned to this protocol were provided with instant 
information on the likely tumour nature based of the ultrasound findings alone.  
 
A relatively large number of women were deemed unfit for surgery which confirms that 
the risks of operating on older women are increased and   reiterates the need to develop 
effective strategies to reduce the number of avoidable procedures in this age group.  
We decided to follow women up for 12 months as there is evidence from literature that 
this is a sufficient time span to detect changes in the morphology and size of the adnexal 
tumours which could indicate their malignant nature.  
 
A study by Horiuchi in 2003 showed that most women who developed ovarian cancer in 
previously detected cysts had either borderline tumours or well-differentiated early 
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stage invasive lesions. These results support conservative approach to care of women 
with benign-looking adnexal lesions on initial ultrasound scans. In contrast women 
diagnosed with aggressive disseminated invasive ovarian cancers typically had no 
detectable precursor lesions on previous imaging. Shih and Kurman also reported 
similar findings in 2004. Similarly, Sharma et al, as part of the United Kingdom 
collaborative trial of ovarian cancer screening (UKCTOCS) trial, found the absolute risk 
of a diagnosis of an epithelial ovarian carcinoma (EOC) within 3 years in asymptomatic 
women with an adnexal tumour to be 1.08% (95% CI: 0.79% to 1.43%) and these were 
primarily borderline and Type I slow growing tumours whereas those who had normal 
ovaries and developed an EOC, were all found to have the more aggressive Type II 
tumours. (Sharma, 2012) 
 
Strengths and Limitations 
 
Strengths – 
The main strength of our study is that this is the first randomised controlled trial looking 
at the use of the RMI/RCOG protocol which is widely used in routine clinical practice 
in the UK and compare it to a novel alternative management strategy. The novel 
diagnostic model had been extensively studied and all the results showed that it was 
suitable for the use in clinical practice. The study was carefully planned and power 
calculation was based on the results of a prospective audit, which had been carried out 
prior to starting the trial.  Although it was not possible to blind women and all clinicians 
to the patient allocation, the pathologist and the surgeons were not aware which 
protocol was used in individual patients. 
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Limitations –  
Our main weakness was that this was a single centre study, which can affect the 
applicability of the results in other units. 
 
We did not blind the recruiting physician once the woman was assigned to an arm of the 
trial which could have influenced their approach to the conduct of ultrasound scan.  We 
also did not blind the patients their trial allocation, which could have influenced their 
compliance with the protocol as they were less likely to follow a new rather than a 
traditional well-tested approach. Our data show; however, that the compliance was less 
with the standard compared to the novel management protocol. Simple rules require 
higher ultrasound skill that RMI which may affect the performance of the test in unit 
with lower ultrasound skills. 
 
In conclusion, our study has shown that the introduction of simple rules in routine 
clinical practice could result in a significant reduction in the number of surgical 
procedures offered to postmenopausal women with incidental diagnoses of adnexal 
cysts on imaging. Further larger studies, including units with different levels of 
ultrasound expertise, are required to explore confirm these findings.   
 
Implications for clinicians or policymakers 
 
This study shows that relatively minor changes in the management protocols for women 
with adnexal tumours could result in significant differences in the number of surgical 
interventions. The diagnosis of suspected ovarian cancer often causes anxiety to women 
and their carers and they are typically urgently referred to gynaecological oncologists in 
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cancer centres. Algorithms based on models with low specificity would therefore cause 
significant pressure on sub-specialist services and further increase the cost of care. 
Further multicentre studies are required to confirm our findings and would facilitate 
development of more effective and rational care for postmenopausal women with 
adnexal tumours.  
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Part X – Conclusions and Further Research 
 
This thesis has tested for the first time and shown that the IOTA logistic regression 
models LR1 and LR2 perform fairly well as a preoperative method, to determine if an 
adnexal tumour is benign or malignant, when utilised by an average ultrasound 
operator. The overall accuracy of the IOTA LR1 and LR2 models was maintained and 
they both demonstrated comparably good sensitivity though significantly poorer 
specificity when compared to when the experts used the models. Although the models’ 
high sensitivity is reassuring the specificity is too low to allow the use of the LR1 and 
LR2 models as a sole test to diagnose ovarian cancer. In all women with diagnosis of 
ovarian cancer using LR1 or LR2 a secondary test should be used to reduce the rate of 
false positive findings. When available, expert operator should by used to re-examine all 
women with suspected cancer to reduce the rate of unnecessary interventions and 
referrals to regional oncology units.  
 
 
This is the first work to assess use of the IOTA LR1 and LR2 models as a triaging test 
for use in the outpatient setting. We reduced incomplete verification bias by including 
all women who had histology and additionally, all women who have follow up 
ultrasound scans over 12 months (delayed cross sectional analysis). This has not been 
done before. It has demonstrated that the IOTA models maintained their high sensitivity 
when used in the outpatient setting.  Specificity was relatively low which indicates that 
a significant proportion of women could be offered unnecessary surgery for suspected 
ovarian cancer. These results have therefore shown that LR1/LR2 can be used in the 
outpatient environment to triage women and determine who needs surgery. The 
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specificities of the models however, are too low to be used as a single tool for triaging 
women for surgery. It will have a lower risk of a delayed malignant diagnosis but a 
higher rate of a malignant misdiagnosis with the associated unnecessary anxiety and 
interventions for suspected cancer. Pattern recognition could be used as a second stage 
test to reduce the number of false positive findings and surgical interventions in this 
population of women. The overall intervention rate in our study was relatively high 
which reflects the nature of work in a large clinical centre.  Further studies are required 
to assess the performance of IOTA models in hands of level 2 sonographers receiving 
direct referrals from primary care and reproductive health care physicians where the risk 
of ovarian cancer would be lower than in our population.  
 
This thesis has confirmed that the preoperative diagnosis of an adnexal tumour made 
using the ‘simple rules’ also performed fairly well when used by an average operator 
and performed similarly to the original data. This suggests that it would be a useful 
screening test. It is fairly simple to use while focussing on the most useful tumour 
characteristics. There is though a large proportion of the population (25% on average) 
for whom the rules would not be applicable and who would need to consider surgery 
(assuming malignancy) or be offered a second test. Referral for examination by an 
expert using pattern recognition was the superior secondary test as opposed to assuming 
malignancy and offering surgery for all those unable to be defined by the simple rules as 
it demonstrated the greatest accuracy and higher specificity.  
 
The meta-analysis of the simple rules included operators of varied experience and has 
confirmed that the simple rules can be used for the preoperative diagnosis of an adnexal 
mass. When the rules were applicable the model performed very well and this was 
particularly the case in postmenopausal women. Indeterminate tumours continued to 
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need a second line test.  
 
Our dataset showed that when the simple rules model was used as a triage test in the 
outpatient setting with two reference tests (histology and follow up ultrasound scans 
over 12 months), it performed very well with a similar sensitivity and specificity as 
pattern recognition. It was also superior to LR1 and LR2. Use of pattern recognition for 
the indeterminate tumours maintained that good performance while assuming 
malignancy significantly reduced the specificity with an increased false positive rate. 
This improvement in performance was demonstrated because women, who do not have 
surgery, have been excluded from all previous studies, whereas we have included them. 
These women who have proven themselves to having benign tumours (delayed cross 
sectional analysis) are less likely to have indeterminate tumours as their tumours are 
more likely to be easily classifiable and described. This test has therefore proven to be a 
very useful and simple model that can be implemented in a general gynaecology clinic 
once it is determined which secondary test would be employed for women in whom the 
rules do not apply. Further work should explore the benefit of the use of other models or 
other tools in this population of women (20%).  
 
The randomised controlled trial included in this thesis has confirmed the importance of 
test that can better discriminate between benign and malignant tumours. The 
RMI/RCOG protocol and the SR –based protocol both detected all the malignancies but 
the RMI/RCOG protocol had a significantly larger proportion of women being offered 
surgery for tumours of intermediate risk. These women ranged from those who should 
be offered surgery by the general gynaecologist to those who should be seen in a local 
cancer unit. Due to the greater sensitivity, specificity and accuracy seen in the 
postmenopausal population compared to the premenopausal population in the meta-
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analysis (Nunes, 2014), changing the policy for postmenopausal women to the SR-
based protocol is likely to benefit women, the NHS and society as a whole. We have 
seen that while women with benign adnexal tumours still have a risk of a future 
malignancy, this malignancy is likely to be borderline or a slow-growing Type I tumour 
which has a high chance of successful treatment. This compares to the women with 
normal ovaries, who if they develop a malignancy, this tumour is more likely to be an 
aggressive Type II EOC. Reducing surgery in asymptomatic women with benign 
tumours has many potential benefits. It would avoid the higher surgical and anaesthetic 
risks that these women face, it would potentially reduce the number of unnecessary 
referrals to regional gynaecological cancer centres, avoiding the congestion of these 
gynaecological oncology clinics and operating lists with benign disease and it could 
allow accelerated streamlined access and treatment for the women with an actual 
malignancy. Future work should concentrate on a financial evaluation of the benefit of 
simple rules in this population. 
 
Finally, this thesis did show that in all the studies, pattern recognition was the superior 
test performed and increased training of expert ultrasound operators who can perform 
pattern recognition would increase the proportion of accurate diagnoses in the future.  
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Appendix 2: RCT Proforma Simple Rules 
RMI RCOG versus ‘Simple Rules’  
‘Simple Rules’ 
Study number _______________   Scan date _______________ 
Symptoms: 
Pain   Pressure symptoms 
Age:   Time since the menopause:    Parity: 
‘Simple Rules’  
  M Rules     B Rules   
M1 Irregular solid tumour   B1 Unilocular   
M2 Ascites present   B2 Solid component largest <7mm   
M3 >/ 4 papilary projections   B3 Acoustic shadows   
M4 
Irreg multiloc - solid 
tumour >/ 100mm   B4 
Smooth multilocular tumour 
<100mm   
M5 Blood flow score 4   B5 No blood flow - score 1   
If one or more M-rules apply in the absence of a B-rule, the mass is classified as 
malignant.  
If one or more B-rules apply in the absence of an M-rule, the mass is classified as 
benign.  
If there are both or neither M and B rules that apply, the mass is unclassified. 
Classified: Benign   Indeterminate   Malignant 
Follow up visit 1:  Unchanged   Changed  How ____________ 
Follow up visit 2:  Unchanged   Changed How ____________ 
Follow up visit 3:  Unchanged   Changed How ____________ 
Proforma Simple Rules Version 1.1 07.04.2011 
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Appendix 3: RCT Proforma RMI/RCOG 
RMI RCOG versus ‘Simple Rules’  
RMI 
Study number _______________   Scan date _______________ 
     
CA125   
Bilateral   
Ascites   
Multolocular   
Solid   
Metastases   
 
RMI: _______________________ 
 
Cyst: Simple Unilateral Unilocular >2 - <5cm, CA125<30, RMI<25:  
              Yes  No      
 
Classified: Benign   Indeterminate   Malignant 
Follow up visit 1:  Unchanged   Changed  How ____________ 
Follow up visit 2:  Unchanged   Changed How ____________ 
Follow up visit 3:  Unchanged   Changed How ____________ 
 
 
Proforma RMI Version 1.1 07.04.2011 
  
